pmcid,methods_materials,definitions_diagnosis_ranges,clusion_criteria,formula,misc
PMC6509938,Patients and methodsStudy participantsThis was a retrospective observational study which was approved by the Institutional Review Board of Taiwan Adventist Hospital.,0,0,0,0
PMC6509938,Participants of this study included 198 volunteers who used to be with sedentary lifestyle at the NEWSTART Exercise Center of Taiwan Adventist Hospital from May 2015 to August 2017.,0,0,0,0
PMC6509938,"Each of them attended an eight-week LM program, which including exercise and diet regimen.",0,0,0,0
PMC6509938,"Individuals who had been treated with antihypertensive, antidiabetic, or antihyperlipidemic agents were excluded.",0,1,0,0
PMC6509938,"Individuals were not enrolled if they were younger than 18 years of age, less than 150 cm in body height, and had acute illness or complications of chronic diseases (such as known heart diseases or anemia with hemoglobin <8.0 g/dL).",0,1,0,0
PMC6509938,All the exclusion criteria could affect intensity and efficiency of the exercises.,0,0,0,0
PMC6509938,Pregnant or breastfeeding women were ineligible as they could affect the changes in body weight.,0,1,0,0
PMC6509938,"In addition, neither of them was a smoker, and who were not allowed to use any weight loss medications/supplements during eight-week LM programs.",0,1,0,0
PMC6509938,All volunteers had provided written consent for participating in the program.,0,0,0,0
PMC6509938,This study was conducted in accordance with the Declaration of Helsinki.,0,0,0,0
PMC6509938,Diet and exercise programAll participants were asked to record a baseline diet and exercise log before intervention.,0,0,0,0
PMC6509938,"Participants chose their own diet throughout the program, although education on the principles of a healthy diet was provided by registered dieticians every week, and participants were encouraged to decrease intake of calories.",0,0,0,0
PMC6509938,"Each participant would do exercise three times per week, every two days, at least 150 mins/week.",0,0,0,0
PMC6509938,The exercise program included jogging or rhythmic aerobic exercises set to beat music (such as SPINNING®).,0,0,0,0
PMC6509938,"During each session, participants were advised to achieve approximately 70% of their maximal heartbeat rate for a minimum of 30 mins.",0,0,0,0
PMC6509938,"Maximum heartbeat rate was estimated from the formula 220–age (years) with a standard deviation of 10–12 beats/min.15Data collectionBefore and after the program, trained staff would measure the participants’ height, weight, and waist circumference (WC) in light clothing without shoes and after emptying the bladder.",0,0,0,0
PMC6509938,Body mass index (BMI) was calculated as weight (in kilograms) divided by squared height (in square meters).,0,0,1,0
PMC6509938,"The body fat percentage (BFP) and body muscle mass (BMM) were measured by the same bioelectrical body composition analyzer (TANITA® BC-418; TANITA Corp., Tokyo, Japan).",0,0,0,1
PMC6509938,"For pre- and post-program laboratory tests, overnight/8-hr blood samples were obtained from the antecubital vein of the arm for measurement of fasting plasma glucose (FPG), serum insulin (FSI), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid (UA), creatinine (Cr), serum glutamate pyruvate transaminase (S-GPT), and hemoglobin (Hb).",0,0,0,0
PMC6509938,Renal function was recorded as estimated glomerular filtration rate (eGFR) using the MDRD (modification of diet in renal disease) study equation.16,0,0,1,1
PMC6509938,"Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as follows: (FSI × FPG)/405, where insulin is expressed in mIU/L and glucose in mg/dL.17Metabolic syndromeMetS was defined according to the National Cholesterol Education Program adult treatment panel III updated guidelines as the presence of three or more of five risk factors: (1) WC >90 cm (men) and >80 cm (women) (ethnic criteria for Asians); (2) Fasting TG \documentclass[12pt]{minimal}
\usepackage{wasysym}
\usepackage[substack]{amsmath}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage[mathscr]{eucal}
\usepackage{mathrsfs}
\DeclareFontFamily{T1}{linotext}{}
\DeclareFontShape{T1}{linotext}{m}{n} {linotext }{}
\DeclareSymbolFont{linotext}{T1}{linotext}{m}{n}
\DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext}
\begin{document}
$$ \ge $$
\end{document}≥ 150 mg/dL; (3) HDL-C <40 mg/dL (men) and <50 mg/dL (women); (4) systolic blood pressure (SBP) ≥130 and/or diastolic blood pressure ≥85 mmHg; and (5) FPG >100 mg/dL.18,19Statistical analysisNumeric values were presented as mean±standard deviation (SD), with categorical values as n (%).",1,0,0,0
PMC6509938,The differences in clinical and laboratory characteristics between MetS and non-MetS groups were analyzed using independent t-tests or Mann-Whitney U tests for parameters withnormal or skewed distributions and analysis of variance for numeric data and Chi-square test for some categorical data.,0,0,0,0
PMC6509938,"The degrees of association among independent variables for baseline HOMA-IR and the improvement of HOMA-IR, including age, gender, BMI, WC, SBP, eGFR, BFP, BMM, TC, TG, LDL-C, HDL-C, UA, and S-GPT were assessed by multiple regression analyses.",0,0,0,0
PMC6509938,A P-value of <0.05 was considered statistically significant.,0,0,0,0
PMC6509938,"Statistical analysis was performed using SPSS statistical software (version 22.0, IBM Corp., Armonk, NY, USA).",0,0,0,0
PMC3920773,"Search methodsThe search strategy (81 terms) was as listed in Table 01 in the meta-analysis by the Cochrane collaboration (1), and we selected the studies based on our objectives.",0,0,0,0
PMC3920773,We focused on RCTs in MEDLINE (1966–October 2012).,0,0,0,0
PMC3920773,"In addition, we searched PubMed for human trials published in English using the search terms “insulin therapy” and “type 2 diabetes.",0,0,0,0
PMC3920773,”,0,0,0,0
PMC4738205,"MethodsSS pens (sanofi-aventis Deutschland GbmH, Frankfurt, Germany) were purchased from a German pharmacy, while FT pens (Novo Nordisk A/S, Bagsvaerd, Denmark) were obtained through an international pharmacy in the United Kingdom.",0,0,0,0
PMC4738205,The pens were shipped under cool conditions (36-46°F) and stored both unopened and while in use as indicated in the Information for Users for each pen type.,0,0,0,0
PMC4738205,An overview of the tested pens and corresponding injection needles is listed in Table 1. Needles were applied according to the manufacturers’ instruction leaflet.,0,0,0,0
PMC4738205,"Table 1.Insulin Pens and Corresponding Needles Included in This Study.Insulin penManufacturerBatchInsulinNeedlesSoloSTARSanofi2F082AGlulisine (Apidra®)BD Micro-Fine (0.25 mm [31G] × 5 mm)FlexTouchNovo NordiskAP51446Aspart (NovoRapid®)NovoFine (0.25 mm [31G] × 6 mm)Dosing accuracy was determined as described previously by Bohnet et al,7 except that the dosing scheme comprised 1 single measurement of each target dose per pen according to ISO 11608-1:2012 requirements.12 Consequently, instead of 30 pens as per the former ISO standard,13 60 pens of each pen type were investigated.",0,0,0,0
PMC4738205,"Furthermore, each target dose was delivered from the front one-third, middle one-third, and rear one-third of the pen cartridge with a corresponding transfer step in between the doses (Figure 1).",0,0,0,0
PMC4738205,Figure 1.Dosing scheme according new ISO 11608-1:2012.,0,0,0,0
PMC4738205,"Target doses of 1 U (minimum), 40 U (middle), and 80 U (maximum) were ejected and measured for each pen.",0,0,0,0
PMC4738205,All measurements were performed by a single investigator to eliminate potential investigator variability.,0,0,0,0
PMC4738205,The individual insulin pens were operated according to each manufacturer’s instruction leaflet.,0,0,0,0
PMC4738205,"The plunger was kept depressed after each dose for 10 seconds and 6 seconds for SS and FT, respectively, to ensure that the entire dialed dose had been expelled.",0,0,0,0
PMC4738205,Each dose was deposited in a beaker containing a 0.5-1 cm layer of liquid paraffin.,0,0,0,0
PMC4738205,"The dose was weighed immediately using an analytical balance (XP205/M, Mettler Toledo AG, Gießen, Germany) with an accuracy of 0.00001 g. The balance was zeroed before each dose of insulin was deposited and weighed.",0,0,0,0
PMC4738205,Weights were corrected for the relative density of each insulin formulation (1.0066 for insulin aspart; 1.0072 for insulin glulisine).,0,0,0,0
PMC4738205,"For each dose application, a new injection needle was used and an air shot included before the injection.",0,0,0,0
PMC4738205,"The arithmetic average of the actual doses was calculated, as well as the standard deviation, the average deviation (percentage) from the target dose, and the statistical tolerance interval.",0,0,0,0
PMC4738205,"The evaluation of dose accuracy was based on the guidelines of the ISO 11608-1:2012,12 allowing a deviation not more than ± 1 U at the 1 U (0-2 U) dosage level, ± 5% (± 2 U) at the 40 U (38-42 U) dosage level, and ± 5% (± 4 U) at the 80 U (76-84 U) dosage level.",0,0,0,0
PMC4738205,"In addition, the calculated statistical tolerance interval for each pen should lay within the specified upper and lower acceptance limits for each target dose by using a 95% confidence interval and probability content of P = .975 for 60 measurements.12",0,0,0,0
PMC4738205,"To compare the dose accuracy of SS and FT, statistical analysis was performed using Student’s t test.",0,0,0,0
PMC4738205,A P value < .05 was considered to be statistically significant.,0,0,0,0
PMC6834837,"METHODSData source and participantsThis study utilized data from the Korea National Health and Nutrition Examination Survey (KNHANES), collected in 2013 to 2015 (IRB no.: 2013-07CON-03-4C and 2013-12EXP-03-5C).",0,0,0,0
PMC6834837,"In male participants over 20 years of age, subjects with free thyroxine (FT4) or thyrotropin (TSH) concentrations outside the reference range, diabetic values of FPG or HbA1c, or a past history of thyroid disease or diabetes were excluded.",0,1,0,0
PMC6834837,"Subjects with no or incomplete data for thyroid hormone, fasting glucose, or HbA1c concentrations were also excluded.",0,1,0,0
PMC6834837,"Following this, 2,399 euthyroid non-diabetic male were enrolled.",0,0,0,0
PMC6834837,All the survey participants gave their written informed consent.,0,0,0,0
PMC6834837,"Measurements of biochemical and clinical parametersSerum TSH, FT4, and thyroperoxidase (TPO) antibody concentrations were measured using electrochemiluminescence immunoassays (Roche Diagnostics, Mannheim, Germany).",0,0,0,0
PMC6834837,"TSH was measured using an E-TSH kit (Roche Diagnostics), for which the reference range was 0.35 to 5.50 mIU/L.",0,0,0,0
PMC6834837,"FT4 was measured using an E-Free T4 kit (Roche Diagnostics), with a reference range of 0.89 to 1.76 ng/mL.",0,0,0,0
PMC6834837,"HbA1c concentration was measured using high-performance liquid chromatography (HLC-723G7; Tosoh, Tokyo, Japan), and serum FPG using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan).",0,0,0,0
PMC6834837,"Impaired fasting glucose (IFG) was defined by a FPG of >100 to 125 mg/dL, and a high-risk HbA1c concentration was defined as a HbA1c of 5.7% to 6.4% [11].",1,0,0,0
PMC6834837,Prediabetes was defined by the presence of IFG or a high-risk HbA1c concentration.,1,0,0,0
PMC6834837,Waist circumference (WC) was measured standing with a soft tape-measure placed midway between the lowest rib and the iliac crest.,0,0,0,1
PMC6834837,"Blood pressure (BP) was measured using a cuff on the right arm attached to a mercury sphygmomanometer (Baumanometer; W. A. Baum, Copiague, NY, USA).",0,0,0,0
PMC6834837,"Serum total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglyceride (TG) were measured using a Hitachi Automatic Analyzer 7600 (Hitachi).",0,0,0,0
PMC6834837,Metabolic syndrome was defined according to the criteria of the American Heart Association [12].,1,0,0,0
PMC6834837,"Urine iodine concentrations were measured in random spot urine samples using inductively coupled plasma mass spectrometry (Perkin Elmer, Waltham, MA, USA).",0,0,0,0
PMC6834837,Demographic and personal medical data were collected using standardized health questionnaires.,0,0,0,0
PMC6834837,"These data included any past history of hypertension (HTN) or hyperlipidemia, family history of diabetes or thyroid disease, history of alcohol consumption, and smoking history.",0,0,0,0
PMC6834837,"Statistical analysesAll continuous data are presented as mean±standard deviation, and all categorical data as numbers and percentages.",0,0,0,0
PMC6834837,The tertiles were compared with regard to baseline characteristics using analysis of variance or chi-square tests.,0,0,0,0
PMC6834837,"Analysis of covariance was used to estimate the mean FPG and HbA1c values for each tertile, after adjustment for multiple variables.",0,0,0,0
PMC6834837,Multivariable logistic regression models were used to estimate the prevalence of prediabetes in each tertile.,0,0,0,0
PMC6834837,"For all statistical tests, P<0.05 was considered to be statistically significant.",0,0,0,0
PMC6834837,"Statistical analysis was performed using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA).",0,0,0,0
PMC5469089,MethodsStudy designThe study was designed as case control study.,0,0,0,0
PMC5469089,"Study populationThe study groups comprised 60 normal-weight women newly diagnosed with PCOS (age 18–37 years) and 60 healthy, no hirsute volunteers (age 18–40 years) with regular and proven ovulatory cycles.",0,0,0,0
PMC5469089,A sample size of 60 patients per group would have provided 80% power using a type 1 error rate of 0.05.,0,0,0,0
PMC5469089,We defined normal weight as BMI between 18.50 and 24.99 kg/m2 according to the World Health Organization criteria.,1,0,0,0
PMC5469089,"PCOS was diagnosed using the Rotterdam criteria comprising the presence of at least two of the following three features: anovulation/menstrual irre- gularity, clinical and/or biochemical signs of hyperandrogenism, or presence of polycystic ovaries after exclusion of other etiologies (7).",1,0,0,0
PMC5469089,Hirsutism was defined as a modified Ferriman–Gallwey score ≥8 (7).,1,0,0,0
PMC5469089,"Exclusion criteria for the study were as follows: (i) a BMI of <18.5 or ≥25 kg/m2, (ii) waist circumference of >88 cm, (iii) any arrhythmia, (iv) smoking or alcohol abuse, (v) drug usage affecting autonomic balance or interfere with hormonal levels, (vi) a systemic disorder affecting autonomic modulation, and (vii) IR or diabetes mellitus.",0,1,0,0
PMC5469089,Written informed consent was obtained from all the subjects prior to inclusion into the study.,0,0,0,0
PMC5469089,"Our study complies with the World Health Organization Declaration of Helsinki and the World Psychiatric Association, Good Clinical Practices, and Good Laboratory Practice rules.",0,0,0,0
PMC5469089,An independent Ethics Committee approved the study protocol.,0,0,0,0
PMC5469089,"Anthropometric measuresAnthropometric measurements including weight, height, waist circumference, and hip circumference were obtained.",0,0,0,0
PMC5469089,The height of the subjects was measured by portable stadiometers.,0,0,0,0
PMC5469089,Body weight was measured by trained healthcare professionals with participants standing without shoes in light indoor clothing using a digital scale.,0,0,0,0
PMC5469089,Waist circumference was measured midway between the lowest border of the rib cage and the upper border of the iliac crest at the end of normal expiration.,0,0,0,1
PMC5469089,Hip circumference was measured at the widest part of the hip at the level of the greater trochanter.,0,0,0,1
PMC5469089,BMI was calculated as the ratio of body weight in kilograms to the square of the height in meters.,0,0,1,0
PMC5469089,AssayMetabolic and hormonal assessments were made between days 2 and 10 of the menstrual cycle or on any day if the woman was amenorrheic.,0,0,0,0
PMC5469089,"After an overnight 12-h fasting, venous blood samples were obtained between 9 and 10 am.",0,0,0,0
PMC5469089,"Serum glucose, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were measured using the Beckman Coulter AU680 analyzer (Beckman Coulter, Miami, FL, USA) based on enzymatic colorimetric met- hods using original assay reagents (Beckman Coulter, Miami, FL, USA).",0,0,0,0
PMC5469089,"Serum hormone levels were measured using the Beckman Coulter UniCel DxI 800 immunoassay analyzer (Beckman Coulter, Miami, FL, USA) by chemiluminescence immunoassay using original assay reagents (Beckman Coulter, Miami, FL, USA).",0,0,0,0
PMC5469089,The insulin level in serum was measured using a radioimmunoassay method.,0,0,0,0
PMC5469089,IR was measured using the homeostatic model assessment (HOMA-IR):fasting insulin (µIU/mL) ´ fasting glucose (mg/dL)/405.,0,0,0,0
PMC5469089,IR was defined as an HOMA-IR score higher than 2.7.HRV analysisThe study was conducted during the follicular phase of the menstrual cycle in control subjects to avoid the influence of ovarian hormones on autonomic function and HRV (8).,1,0,0,0
PMC5469089,"In the PCOS group, the test was conducted during the amenorrheic period (9).",0,0,0,0
PMC5469089,Participants were evaluated in the morning following at least 8 h sleeping and after having a light breakfast free of caffeine-containing beverages.,0,0,0,0
PMC5469089,"To test the change in sympathetic and parasympathetic parameters of HRV, isometric handgrip exercise and controlled breathing was used.",0,0,0,0
PMC5469089,"After an adaptation period for at least 15-min rest in supine position, electrocardiograms were recorded to calculate HRV parameters for the following 3 periods: (1) during rest in supine position for 5 min, (2) during controlled respiration (15 breaths per minute) in supine position for 5 minutes, and (3) during handgrip exercise in sitting position for 5 min by an investigator blinded to the patient’s status.",0,0,0,0
PMC5469089,"Between each 5-minute recording period, it was left for 5 min to prevent the effect of potential rapid changes in the heart rate on HRV analysis.",0,0,0,0
PMC5469089,"Participants performed an isometric handgrip exercise at 25% of their predetermined maximum volunteer capacity in a manner of 45-s contraction and 15-s resting per minute using the Jamar hydraulic hand dynamometer (Sammons Preston, Bolingbrook, IL, USA).",0,0,0,0
PMC5469089,Blood pressure measurements were obtained using a sphygmomanometer after each period.,0,0,0,0
PMC5469089,"Electrocardiographic data were transferred to a computer and digitalized via an analog-to-digital conversion board (Norav Medical Ltd., Yokneam, Israel).",0,0,0,0
PMC5469089,"Both time and frequency domain of HRV analysis were performed using the HRV Software (Norav Medical Ltd., Yokneam, Israel).",0,0,0,0
PMC5469089,"Mean of RR intervals (mean RR), standard deviation of R–R interval (SDNN), and the root mean square of successive R–R interval differences (RMSSD) were measured by assessing time domain parameters.",0,0,0,0
PMC5469089,Time domain parameters generally reflect the total HRV.,0,0,0,0
PMC5469089,"Extremely low values indicate autonomic dysfunction, whereas higher values for these measures could reflect a more healthy autonomic function.",0,0,0,0
PMC5469089,"For the frequency domain parameters, power spectral analysis based on the fast Fourier transformation algorithm was used.",0,0,0,0
PMC5469089,Two components of power spectrum were computed with the following bandwidths: high frequency (HF) (0.15–0.4 Hz) and low frequency (LF) (0.04–0.15 Hz).,0,0,0,0
PMC5469089,"The LF–HF ratio and the normalized unit of LF (LFnu) and HF (HFnu) were also calculated [LFnu=LF/(LF+HF), HFnu=HF/(LF+HF)].",0,0,0,0
PMC5469089,"HF, HFnu, and RMSSD represent the cardiac parasympathetic drive (10).",0,0,0,0
PMC5469089,LF and LFnu represent both sympathetic and vagal influences (10).,0,0,0,0
PMC5469089,The LF–HF ratio depicts the sympathovagal balance (10).,0,0,0,0
PMC5469089,"SDNN reflects slow heart rate fluctuations; thus, it is considered as a marker of overall autonomic modulation.",0,0,0,0
PMC5469089,"Statistical analysisStatistical analysis was performed using SPSS version 22.0 for Windows statistical software (IBM SPSS Statistics, Chicago, IL, USA).",0,0,0,0
PMC5469089,The results for variables were expressed as mean±standard deviation or median with interquartile range (25th and 75th percentiles) for continuous variables.,0,0,0,0
PMC5469089,The diffe- rences between groups were compared using Student’s t-test for normally distributed data and Mann–Whitney U test for non-parametric data.,0,0,0,0
PMC5469089,Pearson’s coefficient of correlation was used to determine correlations between serum testosterone level and HRV indices.,0,0,0,0
PMC5469089,"For comparing repeated variables within groups, two-way repeated measurements analysis of variance (ANOVA) test (2:3 factorial design) was used for normally distributed data and Friedman’s two-way ANOVA test was used for non-parametric data.",0,0,0,0
PMC5469089,"For all analyses, p<0.05 was considered statistically significant.",0,0,0,0
PMC4511300,"Materials and MethodsParticipantsHealthy volunteers aged between 20 and 65 years were recruited, and 94 individuals (48 men and 46 women) were enrolled in the present cross-sectional study.",0,1,0,0
PMC4511300,The examinations were carried out in February 2013.,0,0,0,0
PMC4511300,Written informed consent was obtained from all the participants to use their health records for analysis.,0,0,0,0
PMC4511300,"The present study was approved by the Ethical Committee of Tokai University, and was carried out in accordance with the Declaration of Helsinki.",0,0,0,0
PMC4511300,Anthropometric MeasurementsAll measurements were carried out after overnight fasting.,0,0,0,0
PMC4511300,"Height and weight were measured in the standing position, and BMI was calculated as weight/height2 (kg/m2).",0,0,1,1
PMC4511300,"Waist circumference was assessed at the end of expiration, measuring the minimum circumference at the level of the umbilicus.",0,0,0,1
PMC4511300,Blood pressure (BP) was measured in the sitting position.,0,0,0,0
PMC4511300,Visceral and subcutaneous fat area was measured at the level of the umbilicus in the spine position using computed tomography.,0,0,0,0
PMC4511300,"Bioelectrical impedance analysis (Inbody 720; Biospace Co., Ltd., Tokyo, Japan) was used for evaluating body fat mass, fat-free mass and percentage body fat.",0,0,0,1
PMC4511300,Biochemical MeasurementsFasting serum immunoreactive insulin was measured by chemiluminescent enzyme immunoassay (CLEIA).,0,0,0,1
PMC4511300,Glycated hemoglobin (HbA1c) was determined by the latex agglutination immunoassay.,0,0,0,1
PMC4511300,HOMA-IR was calculated as: fasting plasma glucose (in mg/dL) × insulin (in mU/mL)/40520.,0,0,1,0
PMC4511300,HOMA-IR ≤ 1.6 was considered as non-insulin-resistant according to the definition of the Japan Diabetes Society21.,1,0,0,0
PMC4511300,"Low-density lipoprotein cholesterol (LDL-C) was measured directly, and high-density lipoprotein cholesterol (HDL-C) and triglycerides were determined enzymatically.",0,0,0,1
PMC4511300,Leptin was measured by double antibody radioimmunoassay.,0,0,0,1
PMC4511300,High molecular adiponectin was measured using the CLEIA method.,0,0,0,1
PMC4511300,High-sensitivity C-reactive protein (hsCRP) was measured by turbidimetric immunoassay.,0,0,0,1
PMC4511300,Plasma amino acid concentrations were measured by liquid chromatography/mass spectrometry (LC/MC).,0,0,0,1
PMC4511300,"Of 39 amino acids measured (taurine, aspartic acid, hydroxyproline, threonine, serine, asparagine, glutamic acid, glutamine, sarcosine, α-aminoadipic acid, proline, glycine, alanine, citrulline, α-aminobutyric acid, valine, cysteine, cystathionine, methionine, isoleucine, leucine, tyrosine, phenylalanine, γ-amino β-hydroxybutyric acid, β-alanine, β-amino-iso-butyric acid, γ-aminobutyric acid, monoethanolamine, homocysteine, histidine, 3-methylhistidine, 1-methylhistidine, carnosine, anserine, tryptophan, hydroxylysine, ornithine, lysine, arginine), 20 amino acids were at detectable levels and eligible for analysis.",0,1,0,0
PMC4511300,"Levels of total amino acid (total AA), non-essential amino acid (NEAA), EAA and BCAA were also obtained and used for analysis.",0,0,0,0
PMC4511300,"Statistical AnalysesData are expressed as mean ± SD. SPSS Statistics (version 22.0; SPSS Inc., Chicago, IL, USA) was used for the statistical analyses.",0,0,0,0
PMC4511300,Pearson's correlation coefficient was calculated as a measure of association.,0,0,0,0
PMC4511300,Statistical significance of comparisons between the HOMA-IR ≤ 1.6 group and HOMA-IR > 1.6 group was determined by the chi squared-test or Student's t-test.,0,0,0,0
PMC4511300,"All P-values were two-tailed, and P < 0.05 was considered significant.",0,0,0,0
PMC5331374,"MethodsThirty-four consecutive patients diagnosed with CSX who had normal coronary arteries on angiography, which was performed because ischemic signs were observed on an exercise stress test, were included in the present study.",0,1,0,0
PMC5331374,Forty-one consecutive healthy subjects with normal coronary arteries on angiography that had no ischemic change during an exercise stress test were included as controls.,0,1,0,0
PMC5331374,"The inclusion criteria for the CSX group were typical angina, a positive exercise ECG stress test, and angiographically documented normal coronary arteries.",0,1,0,0
PMC5331374,"The exclusion criteria for the CSX and control groups were as follows: patients who had hypertensive heart disease with left ventricular hypertrophy, valvular heart disease, idiopathic hypertrophic or dilated cardiomyopathy, acute or chronic inflammatory diseases, history of myocarditis and vasculitis, spondyloarthritis, Tietze's syndrome, gastrointestinal tract diseases, diseases of the aorta, hormone replacement therapy, arrhythmias, active hepatobiliary disease, or alcohol consumption.",0,1,0,0
PMC5331374,"All participants signed their informed consent form before attending the study, and the Local Ethics Committee approved the study protocol.",0,0,0,0
PMC5331374,All participants underwent a complete physical examination and routine laboratory analysis before the study.,0,0,0,0
PMC5331374,"Treadmill exercise stress testingAll treadmill exercise tests were conducted according to the Bruce protocol using a T600 Treadmill (Spacelabs Burdick, WI 53531, USA).",0,0,0,1
PMC5331374,"Three ECG leads (V2, V5, and aVF) were continuously monitored during these tests.",0,0,0,0
PMC5331374,A standard 12-lead ECG print was obtained.,0,0,0,0
PMC5331374,Total exercise times were recorded in all cases.,0,0,0,0
PMC5331374,Electrocardiographic recovery was also continuously monitored until the depressed ST-segment returned to baseline levels.,0,0,0,0
PMC5331374,"A positive treadmill test was defined by the occurrence of ischemic ST-segment depression (≥1.0 mm horizontal or downsloping depression at 80 ms from the J point) in at least two contiguous leads (usually II, III, aVF, or V3–6) on ECG during the treadmill exercise test.Cardiac catheterizationCoronary angiography was performed using the Judkins technique in all patients (Philips Medical Systems Integris H 3500 and 5000).",1,0,0,0
PMC5331374,Coronary arteries were classified as normal based on the absence of any luminal irregularity in a visual assessment.,1,0,0,0
PMC5331374,"To exclude the possibility of coronary artery vasospasm, all patients underwent a hyperventilation test during coronary angiography, which was performed by asking the patients to breathe quickly and deeply for 5 min.",0,1,0,0
PMC5331374,"EchocardiographyA transthoracic echocardiographic study was performed using a Philips IE-33 machine with a broadband S5-1 transducer (Philips, Bothell, USA).",0,0,0,1
PMC5331374,"Left atrial (LA), LV end-systolic, and LV end-diastolic diameters were obtained from 2-D images.",0,0,0,1
PMC5331374,LV ejection fraction (LVEF) was determined using Simpson's rule.,0,0,1,0
PMC5331374,Transmitral pulsed-wave Doppler velocities were obtained from the apical 4-chamber view with the sample volume placed just below the mitral leaflet tips.,0,0,0,1
PMC5331374,"We measured early (E) and late (A) wave velocities, E/A ratio, E deceleration time (DT), and isovolumetric relaxation time (IVRT).",0,0,0,1
PMC5331374,"TDI of the mitral annulus was obtained by placing the sample volume at the septal mitral annulus, and peak myocardial systolic (Sm), peak early diastolic (Em), and peak late diastolic (Am) myocardial velocities, as well as E/Em and Em/Am ratios, were measured.",0,0,0,1
PMC5331374,2-D speckle tracking analyses were performed on grayscale images of the left ventricle obtained in the apical 4-chamber views and short-axis mid-ventricular views.,0,0,0,1
PMC5331374,Three consecutive end-expiratory cardiac cycles using high frame rate (≥50 Hz) harmonic imaging in each echocardiographic view were acquired.,0,0,0,1
PMC5331374,"Resultant data were analyzed using 2-D speckle-tracking software (TMQA, Q-lab, Philips).",0,0,0,1
PMC5331374,A single cardiac cycle in which an apical 4-chamber view in the end-diastolic frame was used for analysis.,0,0,0,1
PMC5331374,Septal and lateral references points on the mitral annulus and apical endocardium were manually selected.,0,0,0,1
PMC5331374,"After initialization, the program positioned those references points at equal distances on the endocardial surface of the LV cavity.",0,0,0,0
PMC5331374,"Later, the target area was analyzed automatically via the software according to a 7-segment model.",0,0,0,1
PMC5331374,Visual assessment of the speckle tracking together with manual fine adjustments was performed if necessary.,0,0,0,0
PMC5331374,The software automatically divided the target area into equal segments from which mean longitudinal and circumferential strains were determined.,0,0,0,0
PMC5331374,"Longitudinal strain was measured from the basal septum, mid-septum, apical septum, apex, apicolateral, mid-lateral, and basal lateral wall segments.",0,0,0,1
PMC5331374,"Circumferential strain was measured from the anteroseptal, anterior, anterolateral, inferolateral, inferior, and inferoseptal walls.",0,0,0,1
PMC5331374,"Three-dimensional echocardiographyLVEF was measured using real-time three-dimensional echocardiography (3-DE) by obtaining a matrix-array full-volume dataset (X3, ie33, Philips Medical Systems, MA, USA).",0,0,0,1
PMC5331374,"Using an offline analysis program (Qlab, Philips Medical Systems), conventional 4-chamber, 2-chamber, and short-axis views were derived from this dataset.",0,0,0,0
PMC5331374,"After the selection of two annular and apical reference points, a 3-DE endocardial shell was built using semi-automated contour tracing.",0,0,0,1
PMC5331374,"Statistical analysisAll statistical analyses were performed using SPSS software, version 17.0 (SPSS Inc., Chicago, IL, USA).",0,0,0,0
PMC5331374,"Continuous variables were presented as means±standard deviation (SD), and categorical variables were presented as numbers and percentages.",0,0,0,0
PMC5331374,All data were tested for normality with the Shapiro–Wilk test.,0,0,0,0
PMC5331374,Between-group comparisons of categorical data were achieved with chi-square or Fisher's exact tests.,0,0,0,0
PMC5331374,"Between-group comparisons of parametric and nonparametric continuous data were conducted using unpaired Student's t-test and Mann–Whitney U test, respectively.",0,0,0,0
PMC5331374,A two-tailed p value of <0.05 was considered statistically significant.,0,0,0,0
PMC2858204,ProceduresPatients were stratified based upon arterial toe blood pressure (≤35 mmHg vs. >35 mmHg) before being randomly assigned to either of the treatment arms.,0,0,0,1
PMC2858204,Randomization was done in blocks of 10 using sealed envelopes.,0,0,0,1
PMC2858204,The study was performed in an ambulatory setting.,0,0,0,1
PMC2858204,Treatment sessions were given in a multi-place hyperbaric chamber five days per week for eight weeks (40 treatment sessions).,0,0,0,1
PMC2858204,"The treatment period could be extended to 10 weeks, but the number of treatments was not allowed to exceed 40.",0,0,0,0
PMC2858204,"An HBOT session included a period of compression in air for 5 min, followed by a treatment period at 2.5 atmospheres absolute (ATA) for 85 min, and then a decompression period of 5 min.",1,0,0,0
PMC2858204,Patients from both groups could be treated in the same session as study gases were administered by masks and air or 100% oxygen entered the chamber through separate double-blinded pipes (19).,0,0,0,1
PMC2858204,"Study treatment was given as an adjunct to regular treatment at the multidisciplinary diabetes foot clinic, which included treatment of infection, revascularization, debridement, off-loading, and metabolic control according to high international standards (18).",0,0,0,1
PMC2858204,Investigators did not intervene in the daily routine clinical management of the patients.,0,0,0,0
PMC2858204,Outcomes were measured every first week during the treatment period (first 8–10 weeks) and then at three-month intervals.,0,0,0,1
PMC2858204,"Ulcers were graded using the Wagner classification system and ulcer areas were measured using Visitrak Digital (Smith & Nephew, Hull, England) (20).",1,0,0,0
PMC5574429,Research design and methodsOur study focused on adult patients with the diagnosis of DKA between the years of 2008 and 2015 who were admitted to the inpatient services of Riverside University Health System Medical Center.,0,1,0,0
PMC5574429,"Our hospital is a safety-net hospital that serves the residents of Riverside County, California, with approximately 189 000 outpatient visits, 21 900 inpatient admissions, and 100 000 emergency room visits annually.",0,0,0,0
PMC5574429,Our hospital treated patients with DKA with a hospital-wide protocol that used the conventional one-bag system until 2013 when the treatment approach transitioned to the two-bag system (supplementary appendix 1).,0,0,0,0
PMC5574429,"In our hospital, after initial diagnosis of DKA in the emergency room, the DKA protocol is initiated by ER physicians.",0,0,0,0
PMC5574429,"In our institution, the DKA protocol is a hospital-wide protocol, which is followed in the inpatients units as well as in the emergency room.",0,0,0,0
PMC5574429,Any patient who requires an insulin drip automatically gets admitted to the ICU.,0,0,0,0
PMC5574429,"If there is a delay in getting an ICU bed, the protocol is carried out in the ER.",0,0,0,0
PMC5574429,"In our patient population, except a small group of patients with a diagnosis of mild DKA in the ER who improved on subcutaneous insulin therapy, all other patients were admitted for ICU care.",0,1,0,0
PMC5574429,10.1136/bmjdrc-2017-000395.supp1Supplementary file 1,0,0,0,0
PMC5574429,All adult patients over the age of 18 years with an admitting diagnosis of DKA were retrospectively identified from the medical record searching through ICD-9-CM codes 250.10 (DKA in type 1 diabetes) and 250.11 (DKA in type 2 diabetes) diagnosis.,0,1,0,0
PMC5574429,"Once a list of the patients was gathered, the diagnosis of DKA was verified.",0,0,0,0
PMC5574429,"The following criteria were used to define DKA, a blood glucose ≥250 mg/dL and two of the following three criteria: serum bicarbonate (HCO3) <18 mEq/L; serum beta-hydroxybutyrate (BHB) >3 mmol/L; and pH <7.30.",1,0,0,0
PMC5574429,Patients with a diagnosis of hyperosmolar hyperglycemic state as a final diagnosis in the chart were excluded.,0,1,0,0
PMC5574429,"Ketosis from any other etiology, for example, alcoholic ketoacidosis, starvation ketosis, as a final diagnosis in the chart was excluded.",0,1,0,0
PMC5574429,Our chart review confirmed that there were no pregnant patients on our list eliminating any case of DKA associated with pregnancy.,0,0,0,0
PMC5574429,"During initial chart review, we did not include any patient with DKA who was not started on an insulin drip eliminating cases of DKA treated with a subcutaneous insulin protocol.",0,1,0,0
PMC5574429,We identified 383 patients admitted with DKA that received treatment with either the one-bag system (n=249) or the two-bag system (n=143).,0,0,0,0
PMC5574429,"Data were extracted from individual chart review using a standard data collection instrument that recorded the following information at the time of admission: patient’s age and sex, hemoglobin A1c (HgbA1c), body weight, body mass index (BMI), pH, anion gap, admission blood glucose, comorbidities, HCO3, serum BHB, and the time of initiation and discontinuation of the DKA protocol.",0,0,0,0
PMC5574429,"We also captured changes in anion gap, serum glucose, and bicarbonate level as patients received treatment for DKA.",0,0,0,0
PMC5574429,"Study outcomesDuring the treatment of DKA, hyperglycemia is corrected faster than the ketoacidosis.",0,0,0,0
PMC5574429,"Thus, we chose closure of the anion gap as our primary outcome measure which served as a surrogate for the resolution of DKA.",0,0,0,0
PMC5574429,"Our secondary outcome was time to reach plasma glucose <250 mg/dL, time to reach HCO3 level >18 mmol/L, and hospital length of stay.",0,0,0,0
PMC5574429,"Sample size calculationBecause we could not find any prior study focusing on the timing of the closure of the anion gap addressing our research question, we took a small convenience sample of seven patients who were recently admitted with the diagnosis of DKA.",0,0,0,0
PMC5574429,The average time to close the anion gap was 10.4 hours with an SD of 6.4 hours.,0,0,0,0
PMC5574429,We decided that a 15% difference in time from this average would be considered clinically significant.,0,0,0,0
PMC5574429,"Using an effect size of 0.25, an unpaired two-sided t-test, an alpha of 0.05, a beta of 0.2, and a power of 80%, the calculated sample size was 199 per group.",0,0,0,0
PMC5574429,Data analysisThe descriptive analysis comparing the baseline characteristics of the two cohorts used the two-independent samples t-test for continuous variables and χ2 test for proportions for categorical variables.,0,0,0,0
PMC5574429,"Outcome measures comparing the one-bag versus two-bag protocols used the two independent samples t-test to compare the time to closure of the anion gap (primary outcome measure) and time to reach plasma glucose <250 mg/dL, time to reach HCO3 level >18 mmol/L, and hospital length of stay (secondary outcome measures).",0,0,0,1
PMC5574429,The relationship between the time to closure of the anion gap and admission variables was assessed using the Pearson product–moment correlation.,0,0,0,1
PMC5574429,"To further compare the times to closure of the anion gap between the two protocols while statistically controlling for the effects of admission variables that were not of primary interest, an analysis of covariance (ANCOVA) model was developed using time to closure of the anion gap as the dependent variable, and the following admission variables as covariates: patient’s age, weight, BMI, admission pH and anion gap, BHB, blood urea nitrogen (BUN), serum creatinine, serum blood glucose, HgbA1c, and the Charlson Comorbidity Index.24 A stepwise model selection method was used to determine the significant variables in the ANCOVA model.",0,0,0,0
PMC5574429,Data were entered into a Microsoft Excel spreadsheet and analyzed using SAS V.9.3.,0,0,0,0
PMC5574429,This study was prospectively approved by the Institutional Review Board (IRB) of the Riverside University Health System Medical Center.,0,0,0,0
PMC4023579,"Materials and MethodsStudy PopulationA population‐based prospective study of cardiovascular disease and its risk factors has been underway since 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area on Japan's Kyushu Island.",0,0,0,0
PMC4023579,"The population of the town has been stable for 50 years, and was approximately 8,000 in 2010.",0,0,0,0
PMC4023579,"The age and occupational distributions, and nutritional intake of the population were almost similar to those of Japan as a whole based on data from the national census and nutrition survey15.",0,0,0,0
PMC4023579,"As a part of the study, two cross‐sectional diabetes surveys have been carried out on Hisayama residents in a similar manner in 1988 and 2002.",0,0,0,0
PMC4023579,A detailed description of these surveys was published previously15.,0,0,0,0
PMC4023579,"Briefly, of a total of 3,227 residents in 1988 aged 40–79 years based on the town registry, 2,587 (participation rate, 80.2%) consented to taking part in a comprehensive assessment, including the 75‐g OGTT.",0,0,0,0
PMC4023579,"After excluding 82 subjects who had already had breakfast, 10 who were on insulin therapy and 15 because of complaints of nausea or general fatigue during the ingestion of glucose, a total of 2,480 subjects completed the 75‐g OGTT.",0,1,0,0
PMC4023579,"Among the excluded subjects, 10 who were on insulin therapy for type 2 diabetes, who had been diagnosed by their attending physicians, were included in the analysis; thus, the final 1988 study group comprised 2,490 participants (1,077 men and 1,413 women).",0,1,0,0
PMC4023579,"In 2002, of a total of 3,896 residents aged 40–79 years, 3,000 (participation rate, 77.0%) consented to participating in the examination, and underwent a comprehensive assessment.",0,0,0,0
PMC4023579,"Of these, a total of 2,822 participants completed the OGTT after excluding 46 who had already eaten breakfast, 32 who were on insulin therapy and 100 who refused the OGTT.",0,1,0,0
PMC4023579,"Among the participants who received insulin therapy, two with a clinical diagnosis of type 1 diabetes were excluded, and the remaining 30 subjects who were on insulin therapy were included in the analysis.",0,1,0,0
PMC4023579,"Consequently, 2,852 participants (1,257 men and 1,595 women) made up the final 2002 study group.",0,0,0,0
PMC4023579,"Clinical Evaluation and Laboratory MeasurementsIn both the 1988 and 2002 surveys, clinical evaluation and laboratory measurements were carried out in a similar manner.",0,0,0,0
PMC4023579,"The study participants underwent the OGTT between 08.00 h and 10.30 h after an overnight fast of at least 12 h. Blood for the glucose assay was obtained by venipuncture into tubes containing sodium fluoride at fasting and at 2‐h postload, and was separated into plasma and blood cells within 20 min.",0,0,0,1
PMC4023579,Plasma glucose concentrations were determined by the glucose‐oxidase method.,0,0,0,1
PMC4023579,"Glucose tolerance status was defined by the 1998 World Health Organization criteria17; namely, for normal glucose tolerance, fasting plasma glucose (FPG) <6.1 and 2‐h postload glucose (PG) <7.8; for impaired fasting glycemia (IFG), FPG 6.1–6.9 and 2‐h PG <7.8; for impaired glucose tolerance (IGT), FPG <7.0 and 2‐h PG 7.8–11.0; and for diabetes, FPG ≥7.0 mmol/L or 2‐h PG ≥11.1 mmol/L or both, or the use of antidiabetic medications.",1,0,0,0
PMC4023579,Prediabetes was defined as either IFG or IGT.,1,0,0,0
PMC4023579,Total and high‐density lipoprotein (HDL) cholesterols and triglycerides were determined enzymatically.,0,0,0,1
PMC4023579,"The height and weight were measured with the participant in light clothes without shoes, and the body mass index (BMI; kg/m2) was calculated.",0,0,1,0
PMC4023579,Overall obesity was defined as a BMI ≥25.0 kg/m2.,1,0,0,0
PMC4023579,"Waist circumference was measured at the umbilical level with the participant standing by a trained staff member, and central obesity was defined as a waist circumference ≥90 cm in men and ≥80 cm in women.",1,0,0,1
PMC4023579,"Blood pressure was obtained three times using a mercury sphygmomanometer in 1988 and an automated sphygmomanometer (BP‐203RV III; Colin, Tokyo, Japan) in 2002 with the participant in a sitting position after rest for at least 5 min; the average values were used in the analyses.",0,0,0,1
PMC4023579,"Hypertension was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg or current treatment with antihypertensive agents.",1,0,0,0
PMC4023579,"Each participant completed a self‐administered questionnaire covering medical history, antidiabetic and antihypertensive treatments, alcohol intake, smoking habits, and physical activity.",0,0,0,0
PMC4023579,Alcohol intake and smoking habits were classified as either current use or not.,1,0,0,0
PMC4023579,Participants engaging in sports at least three times per week during their leisure time were defined as the regular exercise group.,1,0,0,0
PMC4023579,"Statistical AnalysisThe sas software package version 9.3 (SAS Institute, Cary, NC, USA) was used to carry out all statistical analyses.",0,0,0,0
PMC4023579,The prevalences of type 2 diabetes and each diabetes‐related factor were adjusted for the age distribution of the world standard population18 by using the direct method with 10‐year age groupings.,0,0,0,1
PMC4023579,The age‐adjusted mean values of diabetes‐related factors were calculated using the analysis of covariance method with age included as a continuous variable.,0,0,1,0
PMC4023579,"The statistical significance of the difference in the prevalence or mean of each factor between the surveys was assessed using the logistic or linear regression model fit by the generalized estimating equations, respectively, to take into account the individuals who participated in the two surveys19.",0,0,0,1
PMC4023579,Serum triglyceride values were transformed into logarithms to improve the skewed distribution.,0,0,0,0
PMC4023579,A value of P < 0.05 was considered statistically significant in all analyses.,0,0,0,0
PMC4023579,"Ethical ConsiderationsThe present study was carried out with the approval of the Kyushu University Institutional Review Board for Clinical Research, and written informed consent was obtained from the participants.",0,0,0,0
PMC4209349,"METHODSFrom November 2012 to March 2013, a total of 77 patients with DPN and 30 normal participants were enrolled at Chonbuk National University Hospital in Korea.",0,1,0,0
PMC4209349,"The demographic information and important medical histories of patients were reviewed by medical records, including age, sex, race, type of diabetes, duration of diabetes, height, body weight, body mass index (BMI), hypertension, hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG).",0,0,0,0
PMC4209349,The participants' medical records were carefully reviewed to exclude subjects with other neurological or autonomic disorders.,0,1,0,0
PMC4209349,A diagnosis of type 2 diabetes was made based on the American Diabetes Association (ADA) guidelines.,1,0,0,0
PMC4209349,"The normal group was made based on patients' medical history, FPG, PPG, and HbA1c levels.",0,1,0,0
PMC4209349,The normal group was not included in the prediabetic range.,0,1,0,0
PMC4209349,"In both groups, patients who had coronary heart disease or renal dysfunction were not included in this study.",0,1,0,0
PMC4209349,"Among the diabetes group, two patients were taking medication with significant anticholinergic properties, antidepressants or β-blockers, which may influence neuropathy.",0,0,0,0
PMC4209349,"Thus, these patients were excluded in this study.",0,0,0,0
PMC4209349,Both the diabetes and normal groups were asked to respond to the SAS scale.,0,0,0,0
PMC4209349,"In addition, patients with DPN underwent cardiac autonomic neurological examinations on the same day.",0,0,0,1
PMC4209349,"Caffeine, smoking and some medications that may affect CAN, and these were discontinued for at least 12 hours prior to performing CAN.",0,0,0,1
PMC4209349,We compared the SAS scale to a series of CAN tests respectively.,0,0,0,0
PMC4209349,These studies were approved by the Institutional Review Board of Chonbuk National University Hospital for research.,0,0,0,0
PMC4209349,The SAS scale consists of 11 items in females and 12 in males (Table 1).,0,0,0,1
PMC4209349,It assessed both the presence of autonomic symptoms and the degree of severity.,0,0,0,0
PMC4209349,Each item was rated using an impact score ranging from 1 (least severe) to 5 (most severe).,0,0,0,1
PMC4209349,"These questions assessed the following autonomic symptom domains: orthostatic, sudomotor, vasomotor, gastrointestinal, urinary, and sexual dysfunction (for males).",0,0,0,0
PMC4209349,It was translated into the Korean language with the consent of the developer of the SAS scale.,0,0,0,0
PMC4209349,The transcript was also retranslated by experts of the English and Korean languages.CAN was diagnosed according to the ADA guidelines [8].,1,0,0,0
PMC4209349,"CAN testing was performed using a devise (DiCAN; Medicore, Seoul, Korea) by one physician.",0,0,0,1
PMC4209349,"They consisted of the valsalva ratio (changes in heart rate during the valsalva maneuver), lying standing heart rate (30/15 ratio), R-R interval variation (maximum-minimum heart rate during expiration and inspiration), postural hypotension (change in systolic blood pressure after standing), and sustained handgrip (increase in diastolic blood pressure after the handgrip exercise).",1,0,0,0
PMC4209349,"All of these tests and their normal values have been used according to ADA recommendations (normal valsalva ratio >1.2, normal lying standing heart rate >1.04, normal R-R interval variation >15 bpm, normal postural hypotension <10 mm Hg, and normal sustained handgrip >16 mm Hg).",1,0,0,0
PMC4209349,These results were reported as either normal or abnormal.,0,0,0,0
PMC4209349,"The existence of CAN was based on the sum of the CAN test score (using Ewing methods).DPN was diagnosed by the clinical score (Michigan Neuropathy Screening Instrument questionnaire), TSS for pain, medical record review, electrophysiology study, or QST.",1,0,1,0
PMC4209349,"QST testing was performed using the device (TSH II; Medoc, Ramat Yishai, Israel).",0,0,0,1
PMC4209349,All participants of the DPN group had small or large fiber neuropathy at the QST examinations.,0,0,0,0
PMC4209349,"The TSS consisted of the frequency and intensity for pain, burning, paresthesia, and numbness.",1,0,0,0
PMC4209349,"All of the statistical analyses were performed using the SPSS version 18 (IBM Co., Armonk, NY, USA).",0,0,0,0
PMC4209349,"Continuous variables were described using the mean±standard error of the mean (SEM), and categorical variables were presented as percentages.",0,0,0,0
PMC4209349,The Mann-Whitney U test was used to compare between groups for variables with a skewed distribution.,0,0,0,0
PMC4209349,The Spearman correlation method was used to evaluate whether there was a significant correlation between variables.,0,0,0,0
PMC4209349,Receiver operating characteristic (ROC) curves were calculated to assess the SAS cutoff value.,0,0,1,0
PMC4209349,P values <0.05 were considered statistically significant for all calculations.,0,0,0,0
PMC5336751,"MethodsStudy designA single center, cross-sectional, retrospective, case-control study was conducted in a rheumatology outpatient clinic of a tertiary referral center.",0,0,0,0
PMC5336751,The study protocol was approved by the Research and Ethics Committees of Gülhane Medical Faculty.,0,0,0,0
PMC5336751,Signed informed consent was obtained from each participant before any study-related procedures were performed.,0,0,0,0
PMC5336751,PatientsA total of 104 subjects were consecutively enrolled in the study.,0,0,0,0
PMC5336751,"Thirty-five (5 females, 14%) of them were healthy controls.",0,0,0,0
PMC5336751,"Sixty-nine patients, of whom 11 (16%) were female, were patients with a diagnosis of FMF according to the Tel-Hashomer criteria (1).",0,0,0,0
PMC5336751,"Patients with other known inflammatory rheumatologic disease, atherosclerotic cardiovascular disease, hypertension and diabetes, those under the age of 18, or those refusing to participate in the study were excluded.",0,1,0,0
PMC5336751,"AssessmentsThe demographic parameters, anthropometric measurements, current presence of any attack, previous attack types, genetic mutations, daily colchicine dose, blood pressures, medications, and laboratory results of the participants were obtained.",0,0,0,0
PMC5336751,"The predominant attack type was recorded as peritonitis, pleuritis, arthritis, febrile myalgia, and erysipelas-like erythema.",0,0,0,0
PMC5336751,"Patients with evidence of any target organ damage from high blood pressure (BP), diabetes mellitus, cardiac disease, thyroid dysfunction, liver disease, renal failure, malignancy, and other chronic, infectious, and inflammatory diseases were excluded.",0,1,0,0
PMC5336751,The patients were rested for 10 min before BP was measured.,0,0,0,0
PMC5336751,The mean of two BP measurements was calculated.,0,0,0,0
PMC5336751,The mean arterial blood pressure was calculated according to the following formula: MAP=DBP+[(SBP–DBP)/3].,0,0,1,0
PMC5336751,"The complete blood count, ESR, renal and hepatic function tests, serum CRP, fibrinogen, electrolytes, serum lipid levels, urine protein, and thyroid hormones of the patient and control groups were recorded.",0,0,0,0
PMC5336751,"FMF patients had collected 24-h urine for protein measurement for routine control, and the results were recorded.",0,0,0,0
PMC5336751,Weight (kg) and height (cm) were obtained and BMI was calculated as body weight/height2 (kg/m2).,0,0,1,0
PMC5336751,Neutrophil/lymphocyte ratios were calculated by dividing the neutrophils by lymphocyte counts.,0,0,1,0
PMC5336751,"Arterial stiffness measurementsThe TensioMed device (TensoMed Ltd., Budapest-Hungary) was used for the measurement of arterial stiffness.",0,0,0,1
PMC5336751,"A rheumatologist examined all of the patients consecutively, and noted their demographic factors, physical findings, laboratory results, and the presence of attack.",0,0,0,0
PMC5336751,"Another physician performed the stiffness measurements, and was blind to the patients’ and controls’ diagnosis, attack-status, and other factors.",0,0,0,0
PMC5336751,"Systolic and diastolic blood pressures, arterial stiffness measurements, pulse wave velocity (PWV), aortic and brachial augmentation indexes (Aixao and Aixbr), central aortic pressure (CAP) analysis, and ankle-brachial index (ABI) measurements were made on the participants.",0,0,0,1
PMC5336751,"PWV, Aixao, Aixbr, and CAP analysisThe TensioMed arteriography measurement device reported the measurement results automatically.",0,0,0,1
PMC5336751,"Measurements were made after a 5-minute rest of the patient, without smoking or taking caffeinated beverages for at least the last 30 minutes.",0,0,0,1
PMC5336751,They were in the sitting position in a reserved quiet room.,0,0,0,1
PMC5336751,The data of the distance between the jugular notch and the symphysis pubis of the patients were measured and recorded.,0,0,0,1
PMC5336751,"During the measurement, an intentional brachial artery occlusion was executed (only 8–20 s) and the blood flow was stopped as a part of the process.",0,0,0,1
PMC5336751,"Ankle-brachial index (ABI) measurementsLower extremity blood pressure was measured with a digital device (Omron Healthcare Co., Ltd, Japan) and entered into the arteriography device interface.",0,0,0,1
PMC5336751,This automatically gave the ankle-brachial index by calculating the division of the lower extremity blood pressure with the upper.Statistical analysesThe SPSS 22.0 statistical package was used for statistical analysis.,0,0,1,0
PMC5336751,"Independent samples t-test, chi-square test, correlation tests, univariate analysis, and linear regression analysis tests were used.",0,0,0,0
PMC5336751,Quantitative variables were expressed as the mean±standard deviation.,0,0,0,0
PMC5336751,The Kolmogorov–Smirnov and Shapiro–Wilkins tests were used to determine the distribution characteristics of variables and Levene’s test was used to determine the equality of variance.,0,0,0,0
PMC5336751,Differences between the groups were studied for significance by the independent samples t-test as appropriate.,0,0,0,0
PMC5336751,Categorical variables were compared by chi-square test.,0,0,0,0
PMC5336751,Pearson and Spearman correlation analysis were used to evaluate the relationships between variables.,0,0,0,0
PMC5336751,Results of the analysis were expressed as a percent for the qualitative variables and as the mean±standard deviation for continuous variables.,0,0,0,0
PMC5336751,"The post hoc power of the study was calculated as 96.5%, when the mean of the stiffness measurements and patient numbers of the study groups were taken into account with an alpha error rate of 0.05.",0,0,0,0
PMC5336751,A two-sided p<0.05 was considered significant.,0,0,0,0
PMC4442134,"MethodsPatientsEligibility criteria included age 18–35 years, diabetes duration >2 years, and glycated hemoglobin (HbA1c) <8.0% (64 mmol/mol).",0,1,0,0
PMC4442134,"In addition, participation required absence of all diabetes-related complications including impaired awareness of hypoglycemia (assessed via the Clarke method17), no medication other than insulin, and participation in regular exercise (a minimum of 30 min aerobic exercise at least three times per week).",0,1,0,0
PMC4442134,"Ten males with type 1 diabetes were recruited ((mean±SEM) age 27±2 years, body mass index 25±0.8 kg/m2, diabetes duration 12±2 years, HbA1c 6.9±0.2% (52.4±2.2 mmol/mol), VO2peak 51.3±2.1 mL/kg/min), all of whom successfully completed the study.",0,0,0,0
PMC4442134,"All were using a basal-bolus regimen comprising glargine (n=8) or detemir (n=2) long-acting insulin, and rapid-acting insulin aspart.",0,0,0,0
PMC4442134,Participants had been stable on their respective insulin regimen for a minimum of 1 year.,0,0,0,0
PMC4442134,"Fifty percent of participants using insulin glargine administered this in the morning, and 50% in the evening.",0,0,0,1
PMC4442134,Both participants using insulin detemir administered this twice daily (morning and evening).,0,0,0,1
PMC4442134,"All were familiar with carbohydrate counting, administering 1.0±0.2 units (IU) of insulin aspart per 10 g of carbohydrate.",0,0,0,1
PMC4442134,Fully informed written consent was obtained from all participants following study approval by the local National Health Service Research Ethics Committee (13/NE/0016; NCT02204839).,0,0,0,0
PMC4442134,"Participants attended the Newcastle National Institute for Health Research Clinical Research Facility exercise laboratory for a preliminary screening visit as described previously in detail,8 before returning to establish peak cardiorespiratory parameters during the completion of an incremental-maximal treadmill running protocol as per the methods of Campbell et al.7
8 Following these two preliminary visits, participants performed two experimental trials in a randomized and counterbalanced fashion, which were separated by 7 days (see online supplementary 1 for a schematic of the experimental design).",0,0,0,1
PMC4442134,"Prelaboratory phaseContinuous glucose monitoringParticipants were fitted with a continuous glucose monitor (CGM; Paradigm Veo, Medtronic Diabetes, Northridge, California, USA) a minimum of 48 h before each experimental arm.",0,0,0,1
PMC4442134,"An Enlite sensor (Medtronic MiniMed, Northridge, California, USA) was inserted into the posterolateral abdominal region to minimize physiological time lags between blood and interstitial glucose,18 with the site of insertion replicated on each visit.",0,0,0,1
PMC4442134,"Although the Paradigm Veo provides real-time glucose profiles as part of an insulin pump facility, participants did not use CSII and continued their usual basal-bolus insulin regimen.",0,0,0,0
PMC4442134,"The CGM was installed with glucose alerts that were set at ≤3.5 and ≥16.0 mmol/L during the pretrial period, but the high glucose alert was discontinued after experimental trials.",0,0,0,0
PMC4442134,"During CGM wear, participants provided a minimum of four daily capillary blood glucose test readings (GlucoMen LX, Menarini, Diagnostics, Berkshire, UK) that were entered into the CGM for calibration purposes.",0,0,0,0
PMC4442134,"Capillary glucose values, not real-time CGM data, were used for self-informed rapid-acting insulin administration.",0,0,0,0
PMC4442134,"Diet and activity replicationParticipants were required to replicate their diet (assessed using weighed dietary recording sheets) and instructed to maintain their normal insulin regimen, with basal dose standardized (dose, injection site, and time of injection) for 24 h before each experimental trial day.",0,0,0,1
PMC4442134,The start of the experimental trial day was considered as the morning sample prior to evening attendance.,0,0,0,1
PMC4442134,"Throughout this time, participants were provided with a pedometer (Omron Healthcare Europe BV, Hoofdorp, the Netherlands) to record total step count.",0,0,0,1
PMC4442134,"Participants were instructed to maintain similar patterns of activity across trials avoiding strenuous activity in the preceding 48 h.Experimental trial dayThe intervention consisted of either maintaining regular basal insulin dose (100%; 34±4 IU), or reducing the total amount of basal insulin dose administered across this day to 80% (ie, a 20% reduction; 27±3 IU).",0,0,0,0
PMC4442134,Basal dose timings were maintained throughout as per each participant's individual regimen.,0,0,0,0
PMC4442134,"On the day after exercise, participants under the 80% condition returned to their usual full basal insulin dose.",0,0,0,0
PMC4442134,"Participants presented to the laboratory on the morning of each main trial at ∼08:00 h for a resting, fasted venous blood sample via venepuncture.",0,0,0,0
PMC4442134,This blood sample defined the start of each experimental arm.,0,0,0,0
PMC4442134,"Participants then consumed a standardized cereal-based breakfast meal (sugar-coated corn flakes, peaches, and semiskimmed milk; 534±27 kcal), before being discharged from the laboratory.",0,0,0,0
PMC4442134,"At ∼13:00 h participants consumed a standardized pasta-based lunch meal (pasta, tomato-based sauce, cheddar cheese, olive oil 951±40 kcal) which was prescribed to them by the research team, before returning for the evening visit at ∼17:00 h. Each meal equated to 1.3 g carbohydrate/kg body mass, so that when combined with meals provided in the laboratory, total carbohydrate intake across the day was calculated to constitute ∼5.0 g carbohydrate/kg body mass.19",1,0,0,0
PMC4442134,"The combined macronutrient content of all meals equated to carbohydrate=77%, fat=12%, and protein=11%.",0,0,0,0
PMC4442134,Patients administered their usual (full/unchanged) rapid-acting insulin dose with both pretrial meals.,0,0,0,0
PMC4442134,"Between morning and evening visits, CGM continued to capture interstitial glucose under free-living conditions.",0,0,0,0
PMC4442134,Participants arrived for the evening laboratory visit at ∼17:00 h.,0,0,0,0
PMC4442134,Individual trial start time was replicated across conditions.,0,0,0,0
PMC4442134,"On arrival at the laboratory, participants assumed a seated and rested position while a 20-gauge cannula (Vasofix, B. Braun, Melsungen AG, Melsungen, Germany) was inserted into the antecubital vein of their non-dominant arm.",0,0,0,1
PMC4442134,"Following a resting blood sample, participants self-administered a 25% (2.0±0.5 IU) dose (ie, a 75% reduction9) of rapid-acting insulin into the abdomen.",0,0,0,0
PMC4442134,"Injection site was standardized across trials by administration at mid-point between the iliac crest and naval.7
8
20
21 With this insulin dose, participants consumed a pre-exercise carbohydrate bolus (sugar-coated corn flakes, peaches, semiskimmed milk; 415±17 kcal) equating to 1.0 g carbohydrate/kg body mass.",0,0,0,0
PMC4442134,"Following this bolus, participants remained rested for 60 min, at which point a second blood sample was drawn immediately before starting 45 min of treadmill (Woodway, Weil am Rhein, Germany) running at a speed calculated to elicit 70% of VO2peak.",0,0,0,0
PMC4442134,"This exercise intensity falls within current recommendations of the American College of Sports Medicine.22 Breath-by-breath respiratory parameters (MetaLyzer 3B, Cortex, Leipzig, Germany) and heart rate (S810, Polar, Kempele, Finland) were continuously recorded during exercise.",0,0,0,0
PMC4442134,"Immediately following exercise, a blood sample was taken, with subsequent samples at 15, 30, and 60 min postexercise.",0,0,0,0
PMC4442134,"In between all blood draws, a stylet (Vasofix Stylet, B. Braun Melsungen AG, Melsungen, Germany) and periodic infusion of saline was used to keep the cannula patent.",0,0,0,0
PMC4442134,"At 60 min postexercise, participants self-administered a rapid-acting insulin dose reduced by 50% (4.0±0.3 IU) into the contralateral abdominal site to the previously administered pre-exercise rapid-acting insulin injection.8",0,0,0,0
PMC4442134,"With this, participants consumed a carbohydrate-based postexercise meal (basmati rice, tomato-based sauce, turkey breast, and an isomaltulose orange flavored drink (10% solution); 402±31 kcal) designed to elicit a low GI (GI=37) response, providing 1.0 g carbohydrate/kg body mass, as per Campbell et al.7 Following this meal, participants were discharged, receiving transport home.",0,0,0,0
PMC4442134,CGM continued to capture overnight interstitial glucose under free-living conditions between evening and morning visits.,0,0,0,0
PMC4442134,"At approximately 180 min following the postexercise meal (240 min postexercise), participants consumed a low GI (GI=38) bedtime snack (Soya and linseed burgen sliced bread, and an isomaltulose orange flavored drink (10% solution); 204±9 kcal), equating to ∼0.4 g carbohydrate/kg body mass, and omitting rapid-acting insulin.7",1,0,0,0
PMC4442134,Participants were contacted before the bedtime snack to ensure compliance.,0,0,0,0
PMC4442134,Participants were required to replicate sleeping patterns as much as possible across trials.,0,0,0,0
PMC4442134,"On the subsequent morning (∼08:00 h), following each main trial, participants returned to the laboratory for a fasting blood sample and were given a standardized breakfast meal (sugar-coated corn flakes, peaches, semiskimmed milk; 415±17 kcal) administering their usual (full/unchanged) rapid-acting insulin dose (8.0±1.0 IU).",1,0,0,0
PMC4442134,"Following consumption of this meal, participants were discharged from the laboratory with monitoring of interstitial glucose via CGM for a further 11 h (ie, 24 h from exercise cessation).",0,0,0,0
PMC4442134,"During this time, participants continued to self-record their diet using the weighed food diaries.",0,0,0,0
PMC4442134,Basal dose over the course of this day was maintained at 100% according to each participant's usual regimen.,0,0,0,0
PMC4442134,"Blood samplingAt each time point, 10 mL of venous whole blood was taken, with 20 µL used for the immediate quantification of blood glucose and lactate (Biosen C-Line, EKF Diagnostic GmbH, London, UK), and 10 µL for hemoglobin and hematocrit (HemoControl, EKF Diagnostic, GmbH) which was used to correct for changes in plasma volume23 before and during exercise.",0,0,0,0
PMC4442134,"The remaining sample was dispensed equally into serum separation and lithium-heparin (Vacuette, Greiner Bio-One GmbH, Kremsmünster, Austria) tubes before being centrifuged for 15 min at 3000 rpm at 4°C and stored at −80°C for retrospective analysis of serum insulin (Invitron Insulin Assay, Invitron, Monmouth, UK), cortisol (Cortisol Parameter Assay Kit, R&D systems, Roche Diagnostics, West Sussex, UK), non-esterified fatty acids (RANBUT, Randox Laboratories, London, UK), β-hydroxybutyrate (RANBUT, Randox Laboratories, London, UK), and plasma glucagon (Glucagon EIA, Sigma-Aldrich, St. Louis, Missouri, USA), epinephrine (CAT ELISA, Eagle Biosciences, London, UK), interleukin 6 (IL-6; Human IL-6 Quantikine ELISA, R&D Systems, Roche Diagnostics, West Sussex, UK), and tumor necrosis factor α (TNF-α; Human TNF-α Quantikine ELISA, R&D Systems, Roche Diagnostics, West Sussex, UK).",0,0,0,0
PMC4442134,The intra-assay coefficient of variation was <10% for all assays.,0,0,0,0
PMC4442134,"Owing to assay cross-reactivity with insulin detemir, only participants treated with insulin glargine were included in serum insulin analysis (n=8).",0,1,0,0
PMC4442134,"Data analysisHypoglycemia was defined as a blood or interstitial glucose concentrations of ≤3.9 mmol/L, and hyperglycemia was defined at ≥8.0 mmol/L.7
8 For interstitial glucose data, a hypoglycemic or hyperglycemic episode was defined as three consecutive readings (totaling 15 min) below each respective glucose threshold.",1,0,0,0
PMC4442134,"CGM data were downloaded after each experimental trial and retrospectively processed/analyzed using CareLink Pro software (Medtronic Diabetes, Northridge, California, USA).",0,0,0,1
PMC4442134,"Complete CGM data were obtained from all participants, with no missing data streams.",0,1,0,0
PMC4442134,The mean absolute difference between interstitial glucose and capillary blood glucose meter readings over both trials was 1.2±1.1 mmol/L.,0,0,0,0
PMC4442134,"Area under the curve was calculated using the methods described by Wolever and Jenkins.24Statistical analysis was performed using PASW Statistics V.18 software (IBM, Armonk, New York, USA) with significance set at p≤0.05.",0,0,1,0
PMC4442134,Interactions of time and condition were examined using repeated measures analysis of variance.,0,0,0,0
PMC4442134,"Where significant p values were identified for interaction effects (time×condition), basal insulin dose was deemed to have influenced the response, and simple main effects analyses were performed.",0,0,0,0
PMC4442134,Significant main effects of time were further investigated using Bonferroni adjusted pairwise comparisons.,0,0,0,0
PMC4442134,"Where relevant, paired samples t tests were conducted.",0,0,0,0
PMC4442134,Data are presented as mean±SEM.,0,0,0,0
PMC5741557,METHODSAnimalsThe Otsuka Long Evans Tokushima Fatty (OLETF) rat is a useful animal model for T2DM with obesity [16].,1,0,0,0
PMC5741557,"At 5 to 6 weeks, the OLETF rat develops obesity, while diabetic symptoms appear at about 24 weeks [17].",0,0,0,0
PMC5741557,"Male OLETF rats and age-matched male Long-Evans Tokushima Otsuka (LETO) rats were supplied by Tokushima Research Institute, Otsuka Pharmaceuticals (Tokushima, Japan).",0,0,0,0
PMC5741557,The rats were individually housed in a standard animal facility with access to standard food and water ad libitum and maintained on a 12-hour light-dark cycle (lights on at 7:00 AM) in a temperature- (22° to 25℃) and humidity- (50% to 60%) controlled colony room.,0,0,0,0
PMC5741557,"All procedures were in accordance with institutional guidelines for animal research at Inha University in Incheon, the Republic of Korea.",0,0,0,0
PMC5741557,"Experimental protocolAt 12 weeks of age, a total of 56 OLETF rats were randomly allocated into four groups: (1) OLETF rats with no treatment (OC, n=14), (2) OLETF rats with rosiglitazone treatment only (OR, n=14), (3) OLETF rats with exercise only (OEx, n=14), and (4) OLETF rats with combined treatment of rosiglitazone and exercise (OREx, n=14).",0,0,0,0
PMC5741557,"LETO rats were used as normal controls (LETO, n=14).",0,0,0,0
PMC5741557,Additional non-treated OLETF rats (n=7) and LETO rats (n=7) were sacrificed at baseline (12 weeks old) for pathologic examination.,0,0,0,0
PMC5741557,"Rosiglitazone maleate (3 mg/kg/day, Avandia; GSK Inc., Philadelphia, PA, USA) was orally administered to OR and OREx once a day, 6 days/week from week 12 as previously described [18] for 12 or 28 weeks.",0,0,0,0
PMC5741557,"The OEx and OREx groups were submitted to a 30 minutes exercise at 15 m/min speed (low-intensity) on a forced exercise wheel system (rat activity cage; JD-A-06; Jungdo B&P, Seoul, Korea) 5 days a week for 12 or 28 weeks.",0,0,0,0
PMC5741557,"After 12 weeks (24 weeks old) and 28 weeks (40 weeks old) of treatment, intraperitoneal glucose tolerance test (IPGTT) was performed for the evaluation of glucose tolerance, and the animals were sacrificed for evaluation of the pancreatic islet cells and molecular analysis.",0,0,0,1
PMC5741557,"Analysis of blood samplesBlood samples were drawn after an overnight fast, and the serum samples were kept at −80℃ for subsequent assays.",0,0,0,0
PMC5741557,"Insulin and leptin levels were determined with enzyme-linked immunosorbent assay (ELISA) kits (Linco Research Inc., St. Charles, MA, USA).",0,0,0,1
PMC5741557,"Adiponectin levels were determined with an ELISA kit (ALPCO Diagnostics, Windham, NH, USA).",0,0,0,1
PMC5741557,"Glucose, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, and free fatty acids were assessed with an automated chemistry analyzer (ADVIA 1650; Bayer, Tokyo, Japan).",0,0,0,1
PMC5741557,"A surrogate index of insulin sensitivity was calculated from fasting blood glucose and plasma insulin concentrations as follows: homeostasis model assessment of insulin resistance (HOMA-IR)=(G0×I0)/22.5, with glucose expressed as mmol/L and insulin expressed as µU/mL [19].",0,0,1,0
PMC5741557,Glucose tolerance testThe IPGTT was performed as described previously [17].,0,0,0,1
PMC5741557,"Blood glucose level was analyzed using a glucometer (One Touch Instrument; Roche, Basel, Swiss).",0,0,0,1
PMC5741557,"Area under the curve (AUC) for glucose was calculated according to the trapezoidal rule from the glucose measurements at baseline, 30, 60, 90, 120, and 180 minutes.",0,0,1,0
PMC5741557,Dual energy X-ray absorptiometryBody composition was measured at 30 weeks of age by dual-energy X-ray absorptiometry (DEXA).,0,0,0,0
PMC5741557,"Before undergoing a whole-body scan, the rats were anaesthetized with Ketamine mixtures (Ketamine 35 mg/kg+Xylazine 3 mg/kg+Acetylpro-mazine 0.75 mg/kg), and then total body mass, bone mineral content, lean body mass, and fat mass were measured in vivo with a QDR 4500A DEXA using small animal analysis software (DEXA; Hologic Inc., Waltham, MA, USA).",0,0,0,1
PMC5741557,The β-cell and islet morphologyImmunocytochemistry was performed as described previously [20].,0,0,0,1
PMC5741557,"For insulin staining, tissue sections were incubated with anti-insulin antibody (1:1,000;",0,0,0,0
PMC5741557,"Biogenex, San Ramon, CA, USA) for 24 hours at 4℃.",0,0,0,0
PMC5741557,In situ hybridization for insulin was carried out on tissue sections.,0,0,0,0
PMC5741557,"After treating with proteinase K, the sections were incubated with alkaline phosphatase-conjugated anti-digoxigenin antibody.",0,0,0,0
PMC5741557,Hybridization signals were revealed by nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate toluidinium.,0,0,0,0
PMC5741557,"For the double immunostaining, tissue sections were treated with mouse anti-rat insulin antibody (1:1,000;",0,0,0,0
PMC5741557,"Biogenex) and rabbit anti-rat glucose transporter 2 (GLUT-2) antibody (1:1,000;",0,0,0,0
PMC5741557,"Alpha Diagnostic International, San Antonio, TX, USA).",0,0,0,0
PMC5741557,"After applying the secondary antibody, fluorescein isothiocyanate (FITC) conjugated anti-mouse and rhodamine conjugated anti-rabbit antibody (Jackson Immuno-Research Lab. Inc., West Grove, PA, USA) were added.",0,0,0,0
PMC5741557,"The tissue sections were observed using a Radiance 2100 confocal microscope (Bio-Rad and Nikon, Tokyo, Japan).",0,0,0,0
PMC5741557,"For morphometric analysis, insulin-positive cells were counted in the entire area of the tissue sections, and β-cell number per unit area (1 µm2) was calculated as reported previously [21].",0,0,0,0
PMC5741557,"To assess islet preservation, the islet destruction ratio (%) was calculated as (the number of destructed islets)/(the total islet number evaluated)×100 (%).",0,0,0,0
PMC5741557,"For each pancreas, two slides were reviewed at 10× magnification and 20 photos without overlap were randomly taken to count the number of islets.",0,0,0,0
PMC5741557,The corresponding islets were examined at 40× magnification to evaluate whether there were signs of destruction.,0,0,0,0
PMC5741557,Destructed islets were defined as having lymphocyte infiltration and a distorted outline disabling clear demarcation of the islet area.,1,0,0,0
PMC5741557,The mean of the islet destruction ratios of the two slides was calculated.,0,0,1,0
PMC5741557,"Image files were analyzed using Quantity One (Bio-Rad, Hercules, CA, USA).Statistical analysisNonparametric tests were performed to compare the metabolic parameters, body weight, and body composition of the LETO, OC, OR, OEx, and OREx groups at each age point, due to the relatively small sample size of each group.",0,0,0,1
PMC5741557,The Mann-Whitney U test was used to compare the glucose tolerance levels and AUCs between LETO and OC groups at the 12-week age point.,0,0,0,0
PMC5741557,"We compared body weight, body composition, glucose metabolic parameters, and AUCs among LETO, OC, OR, OEx, and OREx groups at 24 and 40 weeks using the Kruskal-Wallis test and Tukey method, using ranks for multiple comparisons.",0,0,0,0
PMC5741557,Bonferroni adjustments for multiple tests were additionally carried out to compare body and epididymal fat weight variables.,0,0,0,0
PMC5741557,"SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.",0,0,0,0
PMC5741557,A level of 5% was used for statistical significance.,0,0,0,0
PMC3283829,"METHODSSubjectsFrom October 2008 to July 2009, we retrospectively investigated 35 patients who, based on their medical records, had been diagnosed with diabetic peripheral neuropathy.",0,1,0,0
PMC3283829,All patients had received autonomic and vestibular function tests in Gyeongsang National University Hospital.,0,0,0,0
PMC3283829,"We also investigated age, sex, height, weight, body mass index (BMI), cigarette smoking, alcohol consumption, diabetes type, duration of diabetes, presence of microvascular complications and hypertension in all subjects.",0,0,0,0
PMC3283829,"We excluded patients with diseases that could possibly cause peripheral neuropathy as well as disorders influencing autonomic function such as: 1) severe neuropathy involved with paresis, muscle atrophy, or vibratory/heat sensory dysfunction on at least five areas including bilateral first toes, first metatarsal bones, or dorsa of the feet; 2) peripheral arterial obstructive disease; 3) alcoholic neuropathy or chronic alcohol abuse; 4) drug history potentially related to neuropathy (cisplatin, taxol) or exerting substantial influence on the result of the survey (antidepressants, anticonvulsants, opiates, neuroleptics); 5) neuropathy due to a malignant tumor, Parkinson's disease, epilepsy, multiple sclerosis, spinal stenosis, vitamin B12 deficiency, or leprosy; 6) panhypopituitarism or hypothyroidism; 7) pheochromocytoma; 8) congestive heart failure or amyloidosis; or 9) other severe diseases (cancer, liver cirrhosis, chronic hepatitis, GOT/GPT ≥80 IU/L, serum creatinine ≥3.0 mg/dL, hemodialysis).Diagnosis of diabetic peripheral neuropathWe included patients with abnormal results on a total symptom score questionnaire and neurologic tests (128",0,1,0,0
PMC3283829,"Hz vibration sense test, pin prick test, 10 g monofilament test) [12].",0,1,0,0
PMC3283829,"The following were defined as abnormal:
≥2 points in total symptom score based on questions targeting
pain, burning sensation, dysesthesia, and anesthesia.",1,0,0,0
PMC3283829,"≥10-second discrepancy between subject and tester in a
128-Hz vibration test≤7 incidences of pain perception during a pin-prick test
on the foot≤7 correct responses during a 10 g monofilament test
Diagnosis of diabetic autonomic neuropathyDiabetic autonomic neuropathy was evaluated using tilt and Valsalva tests as well as by monitoring heart rate response to deep breathing (HRDB) using a finometer model-1 (Finapres Medical Systems BV Co., Ltd., Amsterdam, The Netherlands).",1,0,0,0
PMC3283829,"A quantitative sudomotor axon reflex test (QSART) was conducted using QSWEAT (WR Medical Electronics Co., Stillwater, OK, USA).",0,0,0,1
PMC3283829,"The severity of autonomic neuropathy was assessed using a composite autonomic scoring scale (CASS) from 0 to 10, calculated as the cumulative score of sudomotor (0 to 3), cardiovagal (0 to 3) and adrenergic subscores (0 to 4).",1,0,0,1
PMC3283829,"In determining the severity of autonomic neuropathy, scores of 0 to 3, 4 to 6, and 7 to 10 were defined to be mild, moderate and severe, respectively [13].",1,0,0,0
PMC3283829,A CASS score ≥1 confirmed the presence of DAN.The quantitative sudomotor axon reflex test assesses only postganglionic sudomotor function.,1,0,0,0
PMC3283829,"This is a more sensitive test than a sympathetic skin response (SSR), which is associated with polysynaptic reactions.",0,0,0,0
PMC3283829,Evaluation of vestibular functionPatients were given a questionnaire which elicited vertigo symptoms in the outpatient otolaryngology department.,0,0,0,0
PMC3283829,"Patients then underwent examinations including the spontaneous nystagmus test, gaze nystagmus test, positional nystagmus test, head shaking test, Dix-Hallpike test, and the Roll test.",0,0,0,1
PMC3283829,A videonystagmography with caloric test was performed to reflect lateral semicircular canal and superior vestibular nerve functions.,0,0,0,1
PMC3283829,Statistical analysisData are presented as the mean±standard deviation (SD) or median (25th to 75th percentile).,0,0,0,0
PMC3283829,A chi-square with Fisher's exact test or Mann-Whitney U test was used to detect differences between the groups.,0,0,0,0
PMC3283829,Spearman's correlation analysis was used to assess correlations.,0,0,0,0
PMC3283829,"Statistical analysis was performed using PASW version 18.0 software (SPSS Inc., Chicago, IL, USA).",0,0,0,0
PMC3283829,"For all statistical analyses, a P value of less than 0.05 (two-sided) was considered statistically significant.",0,0,0,0
PMC6947713,2METHODS2.1Study subjects and designThe study population (N = 1014) of type 2 diabetes subjects was derived from the Cycloset Safety Trial (CST).,0,0,0,0
PMC6947713,"The study protocol and design for the CST have been previously described in detail.98, 102 Briefly, the CST was a multicenter, placebo‐controlled, double‐blind, parallel‐group safety and efficacy study in outpatient type 2 diabetes subjects recruited from general practice and diabetes clinics across 74 clinical centres in the United States and Puerto Rico.",0,0,0,0
PMC6947713,"Subjects were between the ages of 30 and 80 years and had a body mass index <43 kg/m2, with established type 2 diabetes by ADA 2003 criteria and HbA1c ≤10.0%.",0,1,0,0
PMC6947713,"Subjects with New York Heart Classifications I and II congestive heart failure (CHF) were allowed to participate, as were subjects with a history of myocardial infarction (MI) or coronary revascularization occurring >6 months before enrolment.",0,1,0,0
PMC6947713,"Subjects were required to have maintained a stable diabetes treatment regimen for ≥30 days prior to randomization, consisting of lifestyle interventions of medical nutrition therapy and appropriately prescribed physical activity with or without oral antihyperglycaemic agents (≤2) or insulin either alone or in combination with 1 oral antihyperglycaemic agent.",0,1,0,0
PMC6947713,"Following randomization (2:1 active agent vs placebo), the study drug (B‐QR or placebo) was titrated from an initial starting dose of 1 tablet daily (0.8 mg B‐QR per tablet or matching placebo) by increasing the daily dose by 1 tablet per week until a maximum tolerated daily dose between 2 and 6 tablets once daily (1.6‐4.8 mg B‐QR/day) was achieved.",0,0,0,0
PMC6947713,"The study drug was taken with the morning meal, within 2 hours of waking.",0,0,0,0
PMC6947713,Subjects were required to continue their established antihyperglycaemic treatments during the first 3 months of the study.,0,0,0,1
PMC6947713,"However, the dosages of the oral agents or insulin could be modified as deemed appropriate by the study site investigator.",0,0,0,1
PMC6947713,"After 3 months, alterations in the diabetes treatment regimen were allowed, if deemed necessary by the study site investigator, as long as these changes did not result in a final regimen that exceeded two oral agents or insulin plus one oral agent, exclusive of the study drug.",0,0,0,0
PMC6947713,"Due to the above study design, the prespecified statistical analysis plan for the CST102 had specified that data at 24 weeks of treatment be considered for efficacy analyses and therefore were used to assess B‐QR's effects on dysglycemia and RHR in the present study.",0,0,0,0
PMC6947713,"The study protocol was approved by site‐specific or central institutional review boards, and all subjects provided written informed consent to participate in the study before enrolment.",0,0,0,0
PMC6947713,The study was conducted in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) 2004 guidelines.,0,0,0,0
PMC6947713,This current study and analyses are original and different from any previously reported results from the CST.,0,0,0,0
PMC6947713,"The study population for the present study consisted of all subjects from the CST who completed 24 weeks of study drug treatment with no concomitant hypertension medication changes (to avoid confounding arising from BP and/or heart rate effects from changes in concomitant antihypertensive medications during this period) and no antidiabetes medication changes (since the original CST protocol had allowed for changes in dosages and regimens of antidiabetes medications, to avoid any potential confounding arising from the possibility of such diabetes medication changes affecting RHR or BP changes).",0,1,0,0
PMC6947713,Subjects on insulin therapy were excluded from this population given the limitations of the database in clearly determining insulin dose changes (and hence ensuring that there were no changes in concomitant diabetes therapies) and also more importantly to control for the potential effects of insulin itself and changes in insulin dose on sympathetic activity given that insulin acts centrally to increase SNS activity.,0,1,0,0
PMC6947713,"103, 104 A total of 1014 subjects (642 B‐QR, 372 placebo) meeting the above criteria constituted the study population for this study.",0,0,0,0
PMC6947713,Resting heart rate was derived from 12‐lead electrocardiograms (ECGs) obtained at baseline and at 24 weeks.,0,0,0,0
PMC6947713,"BP and HbA1c measurements were obtained at the baseline and 24‐week study visits.2.2Statistical analysesTo assess the effects of treatment with B‐QR on RHR and if baseline RHR influences this effect and determine if there is a RHR threshold at which the treatment effect might first occur, a 2‐way analysis of variance was performed to test the interaction of treatment arm (B‐QR vs placebo) and baseline RHR subgroup (stratified as RHR <60, 60‐69, 70‐79 and ≥80) as two independent variables/factors and change in RHR from baseline to week 24 as the outcome variable.",0,0,0,0
PMC6947713,The treatment effects within each RHR subgroup were further analysed with t tests.,0,0,0,0
PMC6947713,Paired sample t tests were used to assess within‐treatment group changes and Student's t test for between‐group differences.,0,0,0,0
PMC6947713,"Based on the findings from these initial analyses, that indicated baseline RHR ≥70 as the threshold above which an effect of B‐QR in lowering RHR was evident (Table 2), all further analyses were stratified by a baseline RHR cut‐off of <70 vs ≥70 or ≥80 BPM.In addition to changes in RHR, changes in systolic BP (SBP), diastolic BP (DBP) and mean arterial pressure (MAP) from baseline to 24 weeks were analysed in the study population stratified by baseline RHR < or ≥70 BPM.",1,0,0,0
PMC6947713,"Multivariable linear regression analyses stratified by RHR <70 and ≥70 BPM were performed with change in RHR from baseline to 24 weeks as the outcome variable and treatment with B‐QR vs placebo as a covariate along with age, gender, race, BMI, duration of diabetes, baseline HbA1c, baseline RHR, baseline and changes in SBP and DBP as other covariates included to further evaluate the effect of B‐QR treatment on RHR after controlling for potential effects of these other factors on RHR.Further analyses were then performed to evaluate (a) the relationships between baseline RHR as well as baseline HbA1c and the change in RHR associated with B‐QR therapy (vs placebo) and (b) the relationship between B‐QR's impact on elevated RHR and its glycaemic control effect.",1,0,0,0
PMC6947713,"To evaluate the relationships between baseline RHR, baseline HbA1c and B‐QR's impact on RHR, the changes in RHR with B‐QR vs placebo were analysed in the baseline RHR <70, ≥70, and ≥80 subgroups stratified by baseline HbA1c (baseline HbA1c ≤7, >7 and ≥7.5)",1,0,0,0
PMC6947713,.,0,0,0,0
PMC6947713,"The nature of the relationship between (a) baseline RHR and B‐QR's antidiabetes effect and (b) B‐QR's impact on elevated RHR and its antidiabetes effect each was analysed in those subjects with suboptimal glycaemic control (HbA1c ≥7.5%) at baseline (N = 198:125 B‐QR, 73 placebo) as described below.",1,0,0,0
PMC6947713,"To evaluate if baseline RHR impacts the glycaemic control effects of B‐QR, the change in HbA1c from baseline to week 24 with B‐QR vs placebo was analysed in subjects with baseline HbA1c ≥7.5 stratified by baseline RHR <70, ≥70, and ≥80.",1,0,0,0
PMC6947713,"The relationship between study drug‐induced change in elevated RHR and change in HbA1c was analysed in subjects with baseline HbA1c ≥7.5 and baseline RHR ≥70 using Pearson correlation as well as multivariable linear regression with change in HbA1c from baseline to week 24 as the outcome variable and change in RHR as a covariate along with age, gender, race, baseline HbA1c and other concomitant diabetes medications (metformin, SU and/or TZD, each coded as 0 = no and 1 = yes) as the other variables included in the analysis.",0,0,0,0
PMC6947713,All statistical analyses were performed using SPSS software (Build 1.0.0.1012; IBM Corp).,0,0,0,0
PMC6947713,The significance level was set at P < .05.,0,0,0,0
PMC6947713,Data are presented as mean ± standard error of the mean (SEM) except categorical variables shown as numbers and per cent.,0,0,0,0
PMC2660471,"MethodsNonfasting blood samples, collected longitudinally between February 2001 and January 2006, were analyzed for determination of total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides (TG), and non-HDL cholesterol.",0,0,0,0
PMC2660471,"To exclude lipid abnormalities related to untreated diabetes, samples collected within the first month of diagnosis were excluded.",0,1,0,0
PMC2660471,"In addition, patients on treatment with statins were also excluded from the analysis.",0,1,0,0
PMC2660471,"A total of 2,194 lipid measurements were available from 895 subjects; the mean ± SD number of measurements per patient was 2.5 ± 1.0 and the median 3 (range 1–5).",0,0,0,0
PMC2660471,"A total of 183 subjects had only one measurement, 254 had two measurements, 333 had three measurements, 121 had four measurements, and only 4 subjects had five measurements.",0,0,0,0
PMC5336801,"MethodsStudy subjectsFor this study, cases were selected from patients enrolled in our cardiovascular ward or had visited our cardiovascular clinic who had self-reported ethnic Han origin.",0,1,0,0
PMC5336801,The study recruited 597 consecutive patients with AF formed the case group.,0,0,0,0
PMC5336801,The diagnostic criterion of AF was made by expert cardiologists and according to ACC/AHA/ESC 2006 guidelines for the management of patients with AF (19).,1,0,0,0
PMC5336801,Physical examinations were performed by either a 12-lead electrocardiogram (ECG) or by Holter ECG recordings.,0,0,0,0
PMC5336801,"On the ECG, AF is characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in amplitude, shape, and timing, associated with an irregular, frequently rapid ventricular response.",1,0,0,0
PMC5336801,"According to clinical characteristics, AF can be classified into paroxysmal AF (episodes that generally last 7 days or less), persistent AF (episodes that sustain beyond 7 days), and permanent AF (ongoing long-term episodes, in which cardioversion has failed or has not been attempted).",1,0,0,0
PMC5336801,"AF patients who are under 60 years of age without clinical or echocardiographic evidence of cardiopulmonary disease, including hypertension, were considered as lone AF.",1,0,0,0
PMC5336801,"Patients with other types of cardiac arrhythmias, cardiomyopathies, and valvular disease were excluded from this study.",0,1,0,0
PMC5336801,"We acquired relevant information such as age; gender; and history of hypertension, diabetes, coronary artery disease (CAD), and hyperthyroidism from the medical records.",0,0,0,0
PMC5336801,The remaining 996 patients were assigned to control group on the basis of the ECG or no history of AF.,0,0,0,0
PMC5336801,"Similar to the cases, the controls were selected without consideration of the presence or absence of hypertension, diabetes, coronary artery disease, and hyperthyroidism.",0,1,0,0
PMC5336801,The study protocol was approved by local Ethics Committees and all participants signed consent forms.,0,0,0,0
PMC5336801,"DNA isolation and genotypingBlood samples were drawn from study participants and genomic DNA was extracted from EDTA-preserved whole blood, using the standard phenol-chloroform method (20).",0,0,0,0
PMC5336801,"The SNP was genotyped using the TaqMan allelic discrimination Assay (Applied Biosystems, Inc., USA).",0,0,0,0
PMC5336801,"Genotyping was performed in 25 µL of standard PCR volume containing 1 µL of LC Green dye, 5 pmoL of each primer, 25 ng of genomic DNA, 2.5 µL of 10× PCR buffer with 1.5 mmoL/L MgCl2, 5 mmoL deoxynucleotide triphosphates, and 1 U of Taq polymerase.",0,0,0,0
PMC5336801,Statistical analysisSNP rs17042171 genotypes were tested for Hardy-Weinberg equilibrium among controls using PLINK v1.05.,0,0,0,0
PMC5336801,Continuous variables were presented as mean and standard deviation (SD); normality tests (Kolmogorov-Smirnov) were used.,0,0,0,0
PMC5336801,Categorical variables compared using the χ2 test.,0,0,0,0
PMC5336801,The χ2 test was used to determine deviations of the genotype distribution between two groups.,0,0,0,0
PMC5336801,The Hardy-Weinberg equilibrium of the genotype distribution of polymorphisms in the case and control groups was determined using the χ2 test.,0,0,0,0
PMC5336801,"Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated when we used logistic regression to adjust for covariant factors, including age; gender; and presence or absence of hypertension, diabetes, coronary artery disease, or hyperthyroidism, to assess the strength of the relationship of the genotype distribution of SNPs between the AF and control groups.",0,0,0,0
PMC5336801,The results have statistical significance if p<0.05 or the range of 95% CI did not include unity.,0,0,0,0
PMC5336801,"All statistical analyses were performed using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).",0,0,0,0
PMC4352693,"MethodsDesign overviewPatients with type 1 diabetes were recruited, characterized, and prospectively followed by the Finnish Diabetic Nephropathy (FinnDiane) Study.",0,0,0,0
PMC4352693,"The FinnDiane Study is an ongoing nationwide multicenter survey, founded in 1997 to elucidate genetic and environmental risk factors for diabetic nephropathy in patients with diabetes.",0,0,0,0
PMC4352693,"The study protocol is in accordance with the declaration of Helsinki, and it has been approved by the local ethics committee at each study center.",0,0,0,0
PMC4352693,"During the baseline visit, details on clinical status, including age at diagnosis, insulin therapy, and other medications, as well as presence and severity of diabetic complications are registered by a standardized questionnaire, which is completed by the patient's attending physician based on medical files.",0,0,0,0
PMC4352693,"Fasting blood samples were collected during the baseline visit from the patients for the measurement of glycated hemoglobin (HbA1c), which was determined by standardized assays at each study center.",0,0,0,1
PMC4352693,"After the baseline visit, the patients were followed and re-examined with prospective visits approximately in 3–5-year intervals.",0,0,0,0
PMC4352693,Subsequent urine analyses were conducted for the follow-up of urinary AER for the possible detection of the development and progression of diabetic nephropathy.,0,0,0,0
PMC4352693,Nephropathy data were also collected from the medical records.,0,0,0,0
PMC4352693,Setting and participantsFollow-up started in 1996 and ended at death or at the end of 2009.,0,0,0,0
PMC4352693,"The FinnDiane patient cohort constituted of 4748 patients with type 1 diabetes, of whom 52.7% were males.",0,0,0,0
PMC4352693,"For each patient with diabetes, three non-diabetic control (NCD) subjects who were matched for sex, age, and place of residence in the year of diagnosis of diabetes were selected from the Finnish Public Register Centre.",0,0,0,0
PMC4352693,"After exclusion of individuals who died or moved abroad before 1996, and those who were entitled to special reimbursement of drug cost for diabetes mellitus between 1996 and 2009, the final number of control subjects was 12 954 (51.6% males).",0,1,0,0
PMC4352693,Type 1 diabetes was defined as age at onset <40 years and permanent insulin treatment started within 1 year after the diagnosis of diabetes.,1,0,0,0
PMC4352693,"The severity of diabetic nephropathy was assessed by the AER in at least two of three overnight or 24 h urine collections: normal AER (<20 µg/min or <30 mg/24 h), microalbuminuria (≥20 <200 µg/min or ≥30 <300 mg/24 h), macroalbuminuria (≥200 µg/min or ≥300 µg/24 h), and ESRD (defined as dialysis treatment or kidney transplantation).",1,0,0,0
PMC4352693,"Urinary samples were not collected, if the patients had fever or female patients were menstruating.",0,1,0,0
PMC4352693,"The time point for detection of nephropathy progression was defined as the year when the AER, in subsequent urine samples collected during scheduled prospective visits or measured in conjunction with hospital visits, had in at least two of three samples increased to the following stage of nephropathy, that is, microalbuminuria or macroalbuminuria, or for ESRD the date of the first dialysis or kidney transplant.",1,0,0,0
PMC4352693,The AER was not available at baseline for 579 patients.,0,0,0,0
PMC4352693,The final number of patients with confirmed AER was therefore 4169.,0,0,0,0
PMC4352693,"Altogether, there were 2664 patients with normal AER, 544 with microalbuminuria, 625 with macroalbuminuria, 85 with dialysis, and 251 with kidney transplantation at the baseline visit.",0,0,0,0
PMC4352693,"During the follow-up time, 8.2% of the patients with normoalbuminuria, 18.2% with microalbuminuria, and 39.4% with macroalbuminuria progressed to a higher level of albuminuria or ESRD.",0,0,0,0
PMC4352693,"Of the patients on dialysis, 27.1% underwent kidney transplantation during the follow-up.",0,0,0,0
PMC4352693,"Estimated glomercular filtration rates (eGFR), calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, were used in the analyses as a complementary method for diabetic kidney disease progression.",0,0,1,0
PMC4352693,"When the analyses were conducted by eGFR, those patients with unknown AER could also be included.",0,0,0,0
PMC4352693,"Instead, the patients with ESRD were excluded.",0,1,0,0
PMC4352693,"Data sources and outcomesInformation on hospitalizations due to bacterial infections and on antimicrobial drug prescription purchases for each participant was drawn from two nationwide registries: the Finnish Hospital Discharge Register, which includes the diagnoses of all in-hospital treatment periods, and the Finnish National Drug Prescription Register, which includes all of the antibiotics purchased from pharmacies outside hospitals.",0,0,0,0
PMC4352693,"Infections treated in hospitals were classified according to their most common etiology as bacterial, viral, fungal, or as unspecified infections, using the primary and secondary diagnoses from the Hospital Discharge Register, according to the WHO International Classification of Diseases (ICD) 10th revision.",1,0,0,0
PMC4352693,The specific types and sites of the hospital-treated infections are more closely specified in online supplementary table S1.,0,0,0,0
PMC4352693,The risk of infections in outpatients was assessed by acquiring information on the annual outpatient prescription purchase frequencies of antibiotics.,0,0,0,1
PMC4352693,Antibiotics were identified using the WHO Anatomical Therapeutic Chemical (ATC) Classification System as drugs with an ATC code beginning with J01.,0,0,0,1
PMC4352693,"Since comorbidities may have an effect on the risk of infections, common comorbidities were identified from the Hospital Discharge Register, the Drug Prescription Register, and the Drug Reimbursement Register for patients with diabetes and NDCs.",0,0,0,1
PMC4352693,"These comorbidities included hypertension, cardiovascular disease (CVD including ischemic heart disease and stroke), atherosclerosis, cancers, mental disorders, neurological diseases, alcoholism, autoimmune diseases such as rheumatoid arthritis, and respiratory disease (asthma and obstructive pulmonary disease) as they belong to the most common diseases in adults.",1,0,0,0
PMC4352693,"The codes indicating certain diseases are available in online supplementary table S2.In a subanalysis, the number of antibiotic purchases was compared between patients who had retained a normal AER during the whole follow-up period (n=2445) with their respective sex-matched and age-matched NDCs (n=6560) to separate between the impact of nephropathy and other possible effects of diabetes on antibiotic purchases.",0,1,0,0
PMC4352693,"In order to study more closely the association between glycemic control and bacterial infections in patients with diabetes, we examined the impact of the baseline HbA1c on the total number of antibiotic purchases made within a 3-year period: 1 year before the baseline visit, during the examination year, and 1 year after the baseline visit.",0,0,0,1
PMC4352693,"The baseline HbA1c values were categorized into five groups: <7%, 7–7.9%, 8–8.9%, 9–9.9%, and ≥10%.",1,0,0,0
PMC4352693,Results are presented as incidence rate ratios (RRs) with 95% CIs with the lowest value as reference.,0,0,0,0
PMC4352693,"The analyses were conducted separately in patients with normal AER, and in patients with microalbuminuria or macroalbuminuria.",0,0,0,0
PMC4352693,Patients with unknown nephropathy status were excluded from these analyses.,0,1,0,0
PMC4352693,"Finally, the potential association between bacterial infections and the development of diabetic nephropathy was studied in a subset of patients with diabetes who developed microalbuminuria during our follow-up period (n=219).",0,1,0,0
PMC4352693,"The annual number of antibiotic purchases was counted from up to 4 years before, and 3 years after, the year of the diagnosis of incident microalbuminuria.",0,0,0,1
PMC4352693,"For each of the patients, we assigned sex, age, and diabetes duration (±2 years) matched controls with diabetes who had retained a normal AER (n=874) during the whole follow-up period.",0,0,0,0
PMC4352693,"For these controls, the number of antibiotic purchases was counted for the same years as their corresponding patients with incident microalbuminuria.",0,0,0,0
PMC4352693,Statistical analysisThe cumulative number of hospitalizations due to infections and the number of antibiotic purchases were calculated for each individual annually from 1996 until death or the end of the year 2009.,0,0,0,0
PMC4352693,"In case of no hospitalization or antibiotic purchase, the outcome was set to zero.",0,0,0,0
PMC4352693,"When the analyses were conducted according to nephropathy groups, the follow-up started from the baseline visit.",0,0,0,0
PMC4352693,The patients contributed the data during each year to the corresponding nephropathy group.,0,0,0,0
PMC4352693,"Since there were only a few baseline visits in the years 1996 and 1997 in each nephropathy group, these results are shown between 1998 and 2009.",0,0,0,0
PMC4352693,The count data were highly skewed with excess zeros.,0,0,0,0
PMC4352693,"Thus, zero-inflated Poisson (ZIP) models were fitted to the data using the SAS NLMIXED procedure,21 which takes into account the excess of zeros.",0,0,0,1
PMC4352693,"Since one person may have had multiple events, subject-specific random effects were incorporated into the models.",0,0,0,0
PMC4352693,"When the outcomes between the patients with and without diabetes were compared, the predictors were calendar year of the event and comorbidities.",0,0,0,0
PMC4352693,"When the analyses were conducted separately for these groups, the age in the year 1996 and sex were included as covariates.",0,0,0,0
PMC4352693,"In the analyses according to nephropathy groups, the covariates were age and duration of diabetes at baseline visit, sex, calendar year, HbA1c, eGFR (not in the patients with ESRD), smoking status, and comorbidities.",0,0,0,0
PMC4352693,The RRs of hospitalization rates or antibiotic purchases and the 95% CIs as well as predicted values were derived from the final ZIP models.,0,0,0,0
PMC4352693,"Statistical analysis was performed using the Statistical Analysis System (SAS) software (SAS 9.3, Cary, North Carolina, USA).",0,0,0,0
PMC5505541,"MethodsMultiple PubMed-indexed searches were performed using the following keywords in different combinations: intrauterine growth restriction (IUGR), small for gestational age (SGA), prematurity, hypertension, metabolic syndrome, insulin resistance, diabetes mellitus, epigenetics, and obesity.",0,0,0,0
PMC5505541,The articles were narrowed down based on relevance to the topic.,0,0,0,0
PMC5505541,Original studies were included.,0,1,0,0
PMC5505541,Additional references were incorporated after relevant references were taken from review articles.,0,1,0,0
PMC5505541,"In our review, IUGR was defined as an intrauterine growth restriction during the later trimesters.",1,0,0,0
PMC5505541,SGA was defined as infants with a birth weight below the 10th percentile for gestational age.,1,0,0,0
PMC5505541,"A newborn can be IUGR, SGA, both, or neither.",0,0,0,0
PMC5505541,"Newborns who are IUGR but not SGA may have originally developed in utero along a normal percentile in the first trimester but had growth restriction during later trimesters, remaining greater than the 10th percentile and thus IUGR but not SGA.",0,0,0,0
PMC5505541,"One can also be constitutionally small, due to genetically small parents, but can have normal growth and cannot be considered IUGR.8",0,0,0,0
PMC5505541,"The classification of infants according to birth weight, gestational age, and growth restriction is essential for outcome studies.",0,0,0,0
PMC5505541,"Low birth weight (LBW) infants (<2,500 g) have a 5–30 times higher mortality rate in the perinatal period compared to their appropriate for gestational age (AGA) counterparts.9",1,0,0,0
PMC5505541,"In a study by Campbell et al,10 infants with severe SGA (defined as birth weight <3rd percentile) were associated with maternal smoking during pregnancy with an odds ratio (OR) of 5.3, preeclampsia (OR 4.6), threatened preterm labor (OR 3.9), and primiparity (OR 2.4).",1,0,0,0
PMC5505541,Infants with moderate SGA (birth weight 3rd to 10th percentile) were associated with primiparity (OR 1.9) and prepregnancy underweight (OR 2.4).,1,0,0,0
PMC5505541,These results led the authors to the conclusion that the severe and moderate SGA infants represent two different cohorts of infants.,0,0,0,0
PMC5505541,"Severe SGA infants consist mainly of IUGR infants, while moderate SGA infants are a heterogeneous group of IUGR infants and constitutionally small infants.10",0,0,0,0
PMC5399738,Materials and MethodsDUAL I extension and DUAL II study overviewsThis post hoc analysis used data from the DUAL I extension and DUAL II trials in patients with T2D; detailed trial designs and methods were reported previously.,0,0,0,0
PMC5399738,"13–15 Briefly, DUAL I was a 26-week trial14 with an extension to 52 weeks15 comparing IDegLira with IDeg or liraglutide in insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs; in this case being metformin with or without pioglitazone).",0,0,0,0
PMC5399738,"Throughout this article, when referring to DUAL I, results from the full 52-week trial are reported.",0,0,0,0
PMC5399738,"In DUAL II, IDegLira was compared with IDeg for 26 weeks in patients who were previously uncontrolled on 20 to 40 U of basal insulin plus metformin, with or without sulfonylureas or glinides; these latter two classes were discontinued at randomization.13",0,1,0,0
PMC5399738,"In DUAL II, IDeg was limited to a maximum dose of 50 U so that the contribution of the liraglutide component of IDegLira could be evaluated at equivalent insulin doses.",0,0,0,0
PMC5399738,The trial protocols were approved by independent ethics committees or institutional review boards at all participating institutions and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.,0,0,0,0
PMC5399738,"18,19",0,0,0,0
PMC5399738,Written informed consent from all patients was obtained before enrollment.,0,0,0,0
PMC5399738,"The baseline characteristics of the patients in the two trials are summarized in the Supplementary Tables S1 and S2 (Supplementary Data are available online at www.liebertpub.com/dia).SMBG profilesSMBG levels were assessed in the DUAL I extension and DUAL II trials using hand-held glucose meters (Abbott Diabetes Care, Alameda) calibrated to display plasma equivalent values of capillary whole blood glucose measurements.",0,0,0,0
PMC5399738,SMBG levels were recorded in the diary in the following sequence of time points: (1) just before breakfast; (2) 90 min after the start of breakfast; (3) just before lunch; (4) 90 min after the start of lunch; (5) just before dinner; (6) 90 min after the start of dinner; (7) at bedtime; (8) at 4 am; and (9) just before breakfast the following day.,0,0,0,1
PMC5399738,These nine-point profiles were completed within 1 week before site visits on a day when the subject did not anticipate unusual strenuous exercise.,0,0,0,0
PMC5399738,"The 90-min postprandial interval was selected as the mid-point in the 1–2 h timeframe recommended for assessing postprandial plasma glucose targets, and in an effort to provide a closer reflection of postprandial peak than the common 2-h postprandial interval.4,20",0,0,0,1
PMC5399738,"In addition, fasting prebreakfast SMBG was measured daily for both IDeg and IDegLira treated patients (the two study arms that included dose titration), and 3 days a week for liraglutide-treated patients (as per study protocol).",0,0,0,1
PMC5399738,"Interpreting nine-point SMBG profilesWe assessed the proportions of patients treated with IDegLira, IDeg, or liraglutide, who achieved SMBG values (plasma equivalent values) from the nine-point profile within recommended capillary plasma glucose target ranges at baseline and end-of-trial (EOT).4,21",0,0,0,0
PMC5399738,"The preprandial (before breakfast, lunch, dinner, and breakfast the following day) target was achieved if SMBG was ≥3.9 and ≤7.2 mmol/L at all four assessments.",1,0,0,0
PMC5399738,21,0,0,0,0
PMC5399738,The postprandial (90 min after all three meals) target was SMBG <9.0 mmol/L at all three assessments.4,1,0,0,0
PMC5399738,"Patients were considered to have the entire nine-point profile within target range if SMBG was ≥3.9 and <9.0 mmol/L at all nine assessments (all pre- and postprandial time points, before bedtime and 4 am).We also assessed the range of SMBG values in the nine-point profile (the difference between the minimum and maximum SMBG values recorded) for each individual patient, at baseline and at EOT.",1,0,0,0
PMC5399738,"The difference in range from baseline to EOT was determined for each patient, and the change in range was compared across treatments arms.",0,0,0,0
PMC5399738,"Analysis of parameters determined from the nine-point profiles was based on the full analysis set (FAS; all randomized subjects), with the last observation carried forward (LOCF) method of imputation for all subjects with a full nine-point profile at baseline.",0,0,0,0
PMC5399738,"Continuous endpoints were analyzed using an analysis of covariance (ANCOVA) model with treatment, region, sub-study, baseline HbA1c stratum (≤8.3% [≤67 mmol/mol], >8.3% [>67 mmol/mol]), and previous OAD treatment as fixed effects, and the baseline value of the parameter included as a covariate.",0,0,0,1
PMC5399738,"Binary endpoints were analyzed using logistic regression with treatment, region, baseline HbA1c stratum (≤8.3% [≤67 mmol/mol], >8.3% [>67 mmol/mol]), and previous OAD treatment as fixed effects.",0,0,0,1
PMC5399738,"Day-to-day variability with prebreakfast SMBG valuesThe coefficient of variation (CV, defined as the SD of the measurements as a percentage of the mean) of prebreakfast SMBG was calculated for each patient during the maintenance period of treatment to assess day-to-day variability.",0,0,0,1
PMC5399738,"The maintenance period was defined as week 16 (inclusive) onward, and covered 38 visits over 37 weeks in DUAL I (weeks 16–52; includes regular and follow-up visits in week 27), and 11 visits over 11 weeks in DUAL II (weeks 16–26).",1,0,0,0
PMC5399738,The CV of the individual prebreakfast SMBG values during the maintenance period was log-transformed before analysis.,0,0,1,0
PMC5399738,"Data were analyzed using an ANCOVA model with treatment, region, sub-study, baseline HbA1c stratum (≤8.3% [≤67 mmol/mol], >8.3% [>67 mmol/mol]), and previous OAD treatment as fixed effects.",0,0,0,0
PMC5399738,"Continuous glucose monitoringCGM was used to characterize interstitial glucose (IG) excursions over a 24-h period encompassing all three main meals, at baseline and at week 52, in the DUAL I extension sub-study of 260 patients.",0,0,0,1
PMC5399738,"Subjects wore the CGM device (iPro1 and iPro2 [Europe and Australia], Medtronic International, Tolochenaz, Switzerland) for a minimum of 72 h for each recording, performed 3–4 days immediately before site visits.",0,0,0,1
PMC5399738,"IG measurements were recorded every 5 min during each 72-h period and calibration of CGM devices was completed, using SMBG values (methods described previously), four times per day as per the manufacturer's instructions.",0,0,0,1
PMC5399738,"Subjects were instructed to maintain diet, OAD dose, and investigational product treatment dose during the 72-h period.",0,0,0,1
PMC5399738,Subjects recorded meal times and dates in diaries during CGM; meal times were confirmed by cross-checking against rises in IG on the CGM profile.,0,0,0,1
PMC5399738,"Successfully uploaded CGM data were blind-reviewed and quality checked for missing information, such as meal times.",0,0,0,0
PMC5399738,CGM data were not collected in the DUAL II study.,0,1,0,0
PMC5399738,"We assessed the following CGM parameters: mean IG; IG fluctuation (adjusted integrated absolute distance from the mean profile, that is, flatness of IG profile; Formula S1); mean amplitude of glycemic excursions (MAGE); low blood glucose index (LBGI); high blood glucose index (HBGI); postprandial IG increment across all meals (90 min after the start of each meal—in line with the postprandial time point used for the nine-point SMBG profiles); time spent with IG >3.9 mmol/L and ≤9.0 mmol/L, as a measure of the time that glucose profile was within range; duration and episodes (number of times the profile goes below the threshold after having been either above or missing) of IG <3.1 and <3.9 mmol/L, including during the nocturnal period (00:01–05:59); day-to-day IG variability (SD of daily [24 h] mean IG); and day-to-day variability of fasting IG (SD of daily fasting IG, 20 min before breakfast).",0,0,0,0
PMC5399738,Objective decision rules were used to handle incomplete CGM data.,0,0,0,0
PMC5399738,"If there was no valid sensor value 5 min before, or 85 to 95 min after, the start of a meal, the meal increment was considered missing.",0,0,0,0
PMC5399738,"If this total interval included a 30 min continuous period without sensor values, the meal was considered missing.",0,0,0,0
PMC5399738,"For incomplete profiles, mean IG and IG fluctuation were derived from periods with available data.",0,0,0,0
PMC5399738,"All CGM parameters, except for episodes of IG <3.1 and <3.9 mmol/L, were analyzed based on observed data using an ANCOVA model with treatment, region, baseline HbA1c stratum (≤8.3% [≤67 mmol/mol], >8.3% [>67 mmol/mol]); and previous OAD treatment as fixed effects, and baseline values of parameters included as covariates for mean IG and postprandial IG increment.",0,1,0,0
PMC5399738,The SD of daily mean and daily fasting IG was log-transformed before analysis.,0,0,0,0
PMC5399738,"Analysis of the episodes of IG <3.1 mmol/L and <3.9 mmol/L was based on observed data using a negative binomial regression model with a log link and the logarithm of the profile duration as offset, and treatment, region, baseline HbA1c stratum (≤8.3% [≤67 mmol/mol], >8.3% [>67 mmol/mol]) and previous OAD treatment as fixed effects.",0,0,0,0
PMC5248930,MethodsThis was an intervention study with three parallel groups.,0,0,0,0
PMC5248930,"The study protocol was divided into two phases: in the first (phase I), lasting 16 weeks, the first of the two RT groups performed a moderate-intensity RT and the second group a high-intensity RT, and the aerobic training (AT) group performed AP; in the second phase (phase II), lasting 6 weeks, all the three groups performed AP.",0,0,0,0
PMC5248930,"At the end of the intervention, a 12-week post-intervention follow-up was made.",0,0,0,0
PMC5248930,"Anthropometric measures, body composition and fitness parameters were assessed at baseline, after phase I and phase II and after follow-up period (Figure 1).",0,0,0,1
PMC5248930,"Forty-five overweight adolescents of both genders were enrolled in the study, but only 41 completed all phases of the study.",0,0,0,0
PMC5248930,"The eligibility requirements were age ≥ 12 and ≤ 15 years, sedentary lifestyle, percentage of body fat ≥ 25% for male and ≥ 30% for female and body mass index (BMI) > 85th percentile, in comparison with the representative data of adolescents of the same age,14,15 and a valid medical certificate.",0,1,0,0
PMC5248930,"The exclusion criteria were: recent history of injury, presence of metabolic syndrome, cardiovascular diseases and low adherence to the training sessions (absences > 20%).",0,1,0,0
PMC5248930,The flowchart of the study is reported in Figure 2.The Ethics Committee of University of Molise reviewed and approved this study.,0,0,0,0
PMC5248930,"A written informed consent was obtained from all participants and their parents before the participants were recruited for the study, in accordance with the principles outlined in the Declaration of Helsinki.",0,0,0,0
PMC5248930,All data obtained for the study were anonymized.,0,0,0,0
PMC5248930,"After the baseline assessment, the participants were randomly divided into three groups: moderate-resistance training (MRT), high-resistance training (HRT) and AT.",0,0,0,0
PMC5248930,"They were randomized into groups of six, with two subjects randomly assigned to each group according to a sequence of computer-generated random numbers (SPSS version 20.0; IBM, Armonk, NY, USA).",0,0,0,0
PMC5248930,This procedure was designed to obtain groups of equal sizes and to avoid selection bias.,0,0,0,0
PMC5248930,"During phase I, the MRT group performed the RT at isotonic machines with an intensity of 13-repetition maximum (13-RM), three sessions per week.",0,0,0,0
PMC5248930,"The HRT performed the same exercises protocol with the same modality of MRT group, but with higher intensity (9-repetition maximum, 9-RM).",0,0,0,0
PMC5248930,"The number of sets and repetitions was not modified during phase I, but the loads were modified in accordance with the strength improvement reached by the participants in order to assure an intensity of 9-RM and 13-RM.",0,0,0,0
PMC5248930,"At baseline, the 9-RM and the 13-RM intensities, respectively used in HRT and MRT, were assessed during the familiarization sessions, and in the following weeks, the 9-RM and the 13-RM intensities were assessed every 3 weeks during the session of training.",0,0,0,0
PMC5248930,"For the interpretation of the strength improvement, 1-RM was also indirectly estimated using the Brzycki submaximal method.16",0,0,1,0
PMC5248930,This indirect evaluation was used in order to ensure the safety of the participants.,0,0,0,0
PMC5248930,"The AT group performed AP, three sessions per week, at 45–50% of heart rate reserve, using cycle-ergometers and treadmills.",0,0,0,1
PMC5248930,"The duration of each session was progressively increased from 25 minutes up to 40 minutes, adding 5 minutes every following session, with 10 minutes of warm-up and cool-down.",0,0,0,1
PMC5248930,"During phase II, all the three groups performed AP with the same modalities of the AT group in phase I.The physical activity was supervised by three professional personal trainers appointed for each group (the ratio of personal trainer and participants was at least 1:5) in order to assure the safety of the participants, the correct execution of the exercises and the adherence to the protocols.",0,0,0,0
PMC5248930,"The heart rate was monitored using Polar Team 2 system (Polar Electro Oy, Kempele, Finland).",0,0,0,1
PMC5248930,"All the participants performed two preliminary sessions to get familiarized with the correct use of isotonic machines and ergometers and to assess the RT loads (13-RM and 9-RM).At the end of the intervention, the participants were exhorted to continue the physical activity, and after 12 weeks, they were reassessed (follow-up).",0,0,0,0
PMC5248930,A questionnaire was administered in order to investigate if they had an active daily life and continued their physical activity program.,0,0,0,0
PMC5248930,"Based on the results of the questionnaire, the participants were classified into two categories: positive continuer (POS-CO) consisting of the participants who continued the physical activities, and negative continuer (NEG-CO) consisting of those who did did not continue the physical activity properly, after the end of the intervention.",1,0,0,0
PMC5248930,The follow-up assessment aimed to evaluate if the three groups had long-term benefits on anthropometric measures and body composition in comparison with their starting condition (baseline evaluation) and the condition achieved at the end of the intervention (phase II evaluation).,0,0,0,0
PMC5248930,"Anthropometric and body composition evaluationHeight, weight, BMI, waist circumference and waist–hip ratio were measured in order to evaluate macroscopic changes in the body measures.",0,0,1,0
PMC5248930,Internationally acceptable cut-off points for waist circumference were used in this study.,0,0,0,0
PMC5248930,17,0,0,0,0
PMC5248930,Body composition was assessed using skinfold measurements.,0,0,0,1
PMC5248930,The skinfolds were measured on the right side of the body and recorded to the nearest 0.1 mm.,0,0,0,1
PMC5248930,"The measurements were taken in triplicate by the same investigator, and the average of the three measurements was used in the data analysis.",0,0,0,1
PMC5248930,"A skinfold caliper was used to measure biceps, triceps and subscapular and supra-iliac skinfolds.",0,0,0,1
PMC5248930,The measures obtained (in millimeters) were included in the Johnston et al18 equation in order to obtain the body density of the participants.,0,0,0,0
PMC5248930,"The body density was therefore used to calculate their percentage of fat mass (%FM) using the equation of Weststrate and Deurenberg,19 specific for adolescent population.",0,0,1,0
PMC5248930,A study of Rodríguez et al20 calculated that the predicted %FM assessed with this procedure has an absolute error of 5.92% in female and 3.90% in male subjects compared with the measurement obtained with the dual-energy X-ray absorptiometry.,0,0,1,0
PMC5248930,The FFM (in kilograms) of the participants was also calculated in order to evaluate modification in their lean body mass.,0,0,1,0
PMC5248930,"Physical assessmentPhysical assessment was carried out using the specific tests of the Eurofit Test Battery for flexibility,21 agility, resistance and balance, and the Queens College Step Test for aerobic fitness.",0,0,0,0
PMC5248930,22,0,0,0,0
PMC5248930,All the tests were performed between 9 and 12 am.,0,0,0,1
PMC5248930,The Queens College Step Test is used for estimating maximal oxygen uptake.,0,0,0,1
PMC5248930,"The protocol consisted of stepping up and down on a platform of 41.3 cm, at a rate of 22 and 24 steps per minute (for females and males, respectively), for 3 minutes.",0,0,0,0
PMC5248930,"The participants stopped the test after the third minute, and their heart rate was measured as beats per minute (bpm) after 20 seconds of recovery.",0,0,0,0
PMC5248930,"The heart rate was assessed using a Polar A300 heart rate monitor, with H7 heart rate sensor.",0,0,1,0
PMC5248930,"The estimation of maximum oxygen consumption (VO2max) was made using one of the two following equations according to the gender: for males, VO2max (mL·kg−1·min−1) = 111.33 – (0.42 × bpm); for females, VO2max (mL·kg−1·min−1) = 65.81 – (0.1847 × bpm).23 The Sit and Reach Test was performed to measure the flexibility of the lower back and hamstring muscles.",0,0,1,0
PMC5248930,"24 The Abdominal Curl Test, an endurance strength test for abdominal muscles, was used to record the total number of curl-ups performed by each participant in 60 seconds.",0,0,1,0
PMC5248930,25,0,0,0,0
PMC5248930,The Flamingo Balance Test assessed the ability to balance on a single-leg-standing position.,0,0,0,1
PMC5248930,The total number of times of loss of balance in 60 seconds was recorded.,0,0,0,1
PMC5248930,"26 The Shuttle Test assessed anaerobic power, speed and agility.",0,0,0,1
PMC5248930,The total time taken to consecutively run 10 times the distance of 5 m between two markers was recorded.,0,0,0,1
PMC5248930,24,0,0,0,0
PMC5368454,"MethodsIn this study, we assessed homocysteine levels in normotensive children of hypertensive adult parents to determine whether there is any change prior to the onset of hypertension.",0,0,0,0
PMC5368454,A total of 79 normotensive children of essential hypertensive parents who were followed up at the cardiology department and 72 healthy children of normotensive parents who presented to the department of pediatrics at our clinic with complaints such as nonspecific chest pain and innocent murmur were included in the study.,0,1,0,0
PMC5368454,"Consent for the study protocol was attained from the Ethical Committee of Eskişehir Osmangazi University Medical School (consent number April 4, 2013/03).",0,0,0,0
PMC5368454,"Detailed medical, personal, and family histories were recorded.",0,0,0,0
PMC5368454,Children who had chronic disease or anemia and those using medication were excluded from the study.,0,1,0,0
PMC5368454,"Physical examination was completed, and children with normal findings were included.",0,1,0,0
PMC5368454,"Complete blood count and low-density lipoprotein (LDL), TG, total cholesterol (TC), folic acid, vitamin B12, and homocysteine levels were noted.",0,0,0,0
PMC5368454,Children of parents who were diagnosed with essential hypertension and followed-up at the cardiology department with the use of regular antihypertensives were included in the study.,0,1,0,0
PMC5368454,We considered that the parents had no cardiovascular or other chronic disease.,0,0,0,0
PMC5368454,"Height was measured using a calibrated scale, and height was determined with a standard height scale while the child was in an upright position without wearing shoes.",0,0,0,1
PMC5368454,Body mass index (BMI) was calculated as weight (kg)/height (m2).,0,0,1,0
PMC5368454,"Blood pressure was measured 3 times with a mercury sphygmomanometer using an appropriate cuffs while in the seated position after 10 min of rest, and the mean blood pressure was noted.",0,0,0,1
PMC5368454,Blood samples were collected from the antecubital vein following 12-h fasting.,0,0,0,1
PMC5368454,"Serum homocysteine and vitamin B12 levels were measured with the chemiluminescent method by IMMULITE 2000 (Siemens Healthcare Diagnostics AG, Erlangen, Germany) using a SIEMENS homocysteine kit.",0,0,0,1
PMC5368454,Venous blood samples were drawn into BD Vacutainer Z tubes (2 mL) for analysis of folic acid levels.,0,0,0,0
PMC5368454,The analysis was performed in the hematology department using a HITACHI E170 modular device on the basis of Roche Diagnostic criteria.,0,0,0,1
PMC5368454,"For TC, TG, high-density lipoprotein (HDL), and LDL analysis, following 12-h fasting, 5-mL venous blood samples were drawn into standard biochemical tubes.",0,0,0,0
PMC5368454,"The analysis was performed in the biochemistry department with the enzymatic colorimetric method using a Roche modular device (Mainheim, Germany) on the basis of Roche Diagnostic criteria.",0,0,0,1
PMC5368454,"Statistical analysisData were statistically analyzed using SPSS 13.0 (SPSS Inc., Chicago, Illinois, USA).",0,0,0,0
PMC5368454,The Shapiro–Wilk test was performed to evaluate the consistency of variables with normal distribution.,0,0,0,0
PMC5368454,Variables with normal distribution were analyzed using the independent samples t-test and the results were expressed as mean±standard deviation (SD).,0,0,0,0
PMC5368454,"The Mann–Whitney U test was performed for variables with non-normal distribution, and the results were expressed as median and percentile values (25%- 75%).",0,0,0,0
PMC5368454,The Pearson chi-square test was employed for cross-table analysis.,0,0,0,0
PMC5368454,"To demonstrate the power and type (positive or negative) of the relationship between the variables, Spearman correlation analysis was performed for variables with non-normal distributions.",0,0,0,0
PMC5368454,A value of p<0.05 was considered statistically significant for all tests.,0,0,0,0
PMC4869671,"MethodsWe performed an observational and cross-sectional study of employees of a government bank network in Vitória, Espírito Santo; anthropometric, hemodynamic, and biochemical variables were analyzed.",0,0,0,0
PMC4869671,"The study was approved by the Research Ethics Committee (number 059/08) of the Center for Health Sciences, Federal University of Espirito Santo.",0,0,0,0
PMC4869671,Written informed consent was obtained from all of the participants.,0,0,0,0
PMC4869671,"Data were collected during 2008 and 2009, from employees of a state-owned banking network located in southeastern Brazil, who were aged between 20 and 60 years.",0,1,0,0
PMC4869671,"Employees answered a questionnaire of investigative questions, and blood pressure data, anthropometric measurements, and blood samples were collected for subsequent biochemical analyses.",0,0,0,0
PMC4869671,Trained researchers conducted the entire study procedure.,0,0,0,0
PMC4869671,"Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using a OMRON 742H digital® (OMRON Healthcare Inc, Shanghai, People’s Republic of China) following the protocol of the Joint National Committee on Prevention (2003).",0,0,0,1
PMC4869671,Blood pressure was classified according to the VI Guidelines on Hypertension.14,1,0,0,0
PMC4869671,"Waist circumference was measured at the natural waist using a metal inextensible tape (Sanny®; American Medical do Brasil, Ltda, São Bernardo do Campo, Brazil).15Biochemical tests were performed in an accredited network reference laboratory using the COBAS E601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) to measure glucose levels, high-density lipoprotein cholesterol (HDL-c), triglycerides (TAG), and CRP.",0,0,0,1
PMC4869671,"Blood samples were obtained by venipuncture in patients who fasted for 12 hours, and approximately 10 mL of blood was collected into tubes without anticoagulants (ie, dry tube).16Data collection in the initial group revealed an MS prevalence of 17.2% (n=86, 95%).12",0,0,0,1
PMC4869671,"The presence of MS was classified according to the NCEP/ATP III, which identifies the presence of MS when at least three of the following criteria are present: central obesity, measured as a waist circumference (PC) >102 cm for men and >88 cm in women; SBP/DBP ≥130/85 mmHg; fasting blood glucose ≥110 mg/dL; TAG ≥150 mg/dL; and HDL-c <40 mg/dL for men and <50 mg/dL for women.",1,0,0,0
PMC4869671,17,0,0,0,0
PMC4869671,"The use of medication for regulation of blood pressure, and of lipids and blood glucose levels should also be considered in the diagnosis of MS.6",1,0,0,0
PMC4869671,"This methodology is recommended by the I Brazilian Guidelines for Diagnosis and Treatment of Metabolic Syndrome.1Patients who reported having an infection did not have their blood collected initially, but the collection was extended by 2 weeks until the infection was cured.",0,0,0,0
PMC4869671,"Patients with colds, flu, emphysema, bronchitis, arthritis, or CRP values above 10 mg/dL were excluded from the study.",0,1,0,0
PMC4869671,The latter patients may indicate transient changes in CRP levels because of an infection and/or an acute inflammatory condition.6,0,0,0,0
PMC4869671,"Therefore, data were initially collected from 521 bank employees.",0,0,0,0
PMC4869671,"Fifty-eight of these employees were excluded because they had a chronic infection, 26 employees had CRP values >10 mg/dL and 25 employees did not undergo evaluations of biochemical and anthropometric tests that allowed their classification according to the criteria for MS, for a total of 412 employees with valid data.",0,1,0,0
PMC4869671,"The us-CRP classification was assigned for altered us-CRP values >1 mg/dL, and adequate CRP was assigned for values ≤",1,0,0,0
PMC4869671,"1 mg/dL, according to the Centers for Disease Control and the American Heart Association (Atlanta, USA, 2003).",1,0,0,0
PMC4869671,"Controls exhibited the following classifications, which were also recommended by the American Heart Association: low risk <1 mg/dL; medium risk: 1–3 mg/dL; and high risk: >3–10 mg/dL.18The Kolmogorov–Smirnov normality test was initially applied to determine parametric and nonparametric variables.",1,0,0,0
PMC4869671,The us-CRP values underwent logarithmic transformation to reduce the asymmetry of the distribution using the natural logarithm of us-CRP and the Pearson correlation coefficient.,0,0,1,0
PMC4869671,We used frequency and measures of central tendency to characterize the sample.,0,0,0,1
PMC4869671,We used the mean ± standard deviation for symmetric distributions and median and inter-quartile ranges for asymmetric distributions.,0,0,0,0
PMC4869671,Comparisons of different categories were performed using the chi-square test (χ2).,0,0,0,0
PMC4869671,"Student’s t-test was used for parametric variables, and the Mann–Whitney U test was used for nonparametric variables.",0,0,0,0
PMC4869671,"In all cases, P-values <0.05 were considered significant.",0,0,0,0
PMC4869671,"The statistical package SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL, USA) was used for all analyses.",0,0,0,0
PMC6167305,"MethodsStudy DesignThis systematic review was conducted following the Cochrane Handbook for Systematic Reviews of Interventions and reported according the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [18, 19].",0,0,0,0
PMC6167305,"The review protocol was registered in March 2016, in the international prospective register of systematic reviews (PROSPERO: CRD42016032674) (Online Appendix 1).Data",0,0,0,0
PMC6167305,"Sources and SearchesA medical information specialist (JL) performed a systematic search in OVID MEDLINE (including Epub Ahead of Print, In-Process & Other Non-Indexed Citations), OVID EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 27 April 2018 to identify RCTs on effects of prenatal exposure to OADs on the offspring.",0,0,0,0
PMC6167305,To this end we searched for controlled terms (i.e. MeSH) and free text terms for (1) OADs including metformin and (2) prenatal exposure (or pregnancy and offspring/child) combined with (3) a search filter adapted from the Cochrane Collaboration to identify RCTs [20].,0,0,0,0
PMC6167305,No language or date restrictions were applied.,0,0,0,0
PMC6167305,ClinicalTrials.gov was searched to potentially identify trial results that were not reported elsewhere.,0,0,0,0
PMC6167305,We cross-checked the reference lists and the articles citing the identified relevant papers to find additional publications including grey literature.,0,0,0,0
PMC6167305,Finally we searched for systematic reviews to ensure that no systematic review with a similar research question was recently published.,0,0,0,0
PMC6167305,"The complete search strategies are presented in Online Appendix 2.Study SelectionRCTs that reported on post-neonatal health effects in offspring and compared maternal treatment with an OAD with no treatment, placebo, an alternative OAD or insulin during pregnancy were considered eligible for inclusion for this systematic review.",0,1,0,0
PMC6167305,"Non-RCT design studies, animal studies, studies in an incorrect population, studies that did not report on outcomes in offspring and studies only reporting on neonatal outcomes were excluded from this systematic review.",0,1,0,0
PMC6167305,"Two authors (VW, WvW) independently screened all potential articles and conference abstracts on title and abstract using COVIDENCE [21].",0,0,0,0
PMC6167305,Disagreements were resolved by discussion or consulting a third author (RP).,0,0,0,0
PMC6167305,"Two authors (VW, WvW) independently screened the full text of all remaining articles to determine the final selection.",0,0,0,0
PMC6167305,"Data Extraction and Quality AssessmentUsing a standardised data extraction form (Online Appendix 3), two authors (VW, WvW) independently performed data extraction.",0,0,0,0
PMC6167305,"If data was not presented in the original publication in a way that would allow aggregation or if relevant outcomes were not reported at all, authors of the articles were contacted by e-mail.",0,0,0,0
PMC6167305,The Cochrane Collaboration’s tool for assessing risk of bias was used to assess the methodological quality of the included studies [22].,0,0,0,1
PMC6167305,Discrepancies in data extraction and quality assessment were solved by discussion and consulting a third author (RP).,0,0,0,0
PMC6167305,"Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the strength of the body of evidence for all outcomes that are included in meta-analysis [23].",0,0,0,1
PMC6167305,Data,0,0,0,0
PMC6167305,Synthesis and AnalysisReported outcomes of similar domains were combined in summary tables (Online Appendix 4).,0,0,0,0
PMC6167305,Outcomes that were reported by multiple studies were included in random-effects meta-analyses using the Inverse Variance method in Review Manager (RevMan 5.3) [24].,0,0,0,1
PMC6167305,"Meta-analyses in which more than two studies could be included are presented in the results, including sensitivity analyses for treatment indication.",0,0,0,0
PMC6167305,Outcomes reported at the same age were presented as unadjusted mean values and 95% confidence intervals (CI).,0,0,0,0
PMC6167305,Outcomes reported at different ages were presented as standardised mean differences and 95% CI.,0,0,0,0
PMC6167305,Heterogeneity was evaluated using the I2 statistic.,0,0,0,0
PMC6167305,"If the same study population was used to report on similar outcomes at the same age in multiple follow-up studies, the study with the largest number of participants was used to report on overlapping outcomes.",0,0,0,0
PMC6167305,"If the same outcome was reported at different ages, the study with the largest number of participants was included in the meta-analysis to increase statistical power to find differences between the treatment groups.",0,1,0,0
PMC6167305,"In case of discrepancy between the reported p values in the original articles and our own analyses, the p values calculated using Review Manager were reported in this systematic review.",0,1,0,0
PMC5574450,MethodsStudy design and sampleAn online survey of PCPs linked with utilization data from EMRs of patients treated by each surveyed PCP was conducted.,0,0,0,0
PMC5574450,Data sourceQuintilesIMS’ proprietary EMR database was used to recruit PCPs for the online survey.,0,0,0,0
PMC5574450,"Eligible PCPs were participants in the Medical Quality Improvement Consortium (MQIC), a network of ambulatory care providers that had previously expressed an interest in research activities.",0,1,0,0
PMC5574450,"The MQIC network comprised over 650 member institutions, including over 39, 000 providers and over 37 million patient lives, with over 17 million patients regularly using services.",0,0,0,0
PMC5574450,Patient-level data from the surveyed PCPs (linked by National Provider Identified (NPI) numbers) were then extracted from the EMR database.,0,0,0,0
PMC5574450,"Patient-level de-identified and Health Insurance Portability and Accountability Act (HIPAA) compliant records provided researchers with demographics, vital signs, medical diagnoses, diagnostic tests/results, procedures, insurance information, and prescription details in a longitudinal patient medical record.",0,0,0,0
PMC5574450,Survey respondent selection and recruitmentThe study was approved by New England International Review Board.,0,0,0,0
PMC5574450,The PCPs NPI numbers were identified and used to obtain contact details from the publicly available Center  for Medicare and Medicaid Services (CMS) NPI Registry Data or MQIC Sites’ Points of Contact.,0,0,0,0
PMC5574450,The PCPs were sent invitations to participate in the survey through emails or US mail.,0,0,0,0
PMC5574450,"Identified PCPs were provided with a description of the study, survey instructions, and a web-based link to an online survey portal.",0,0,0,0
PMC5574450,Electronically signed informed consent was collected before proceeding with the survey.,0,0,0,0
PMC5574450,The intent to perform concordance between PCPs’ responses and evidence from EMR was not disclosed to participants as it may have biased the results of the study; this was noted in the Institutional Review Board (IRB) submission.,0,0,0,0
PMC5574450,Only PCPs with at least 3 years of experience and providing care for adults (≥18 years) were allowed to participate in the survey.,0,1,0,0
PMC5574450,Surveyed PCPs’ patient selection and follow-upEMR data for all patients associated with each surveyed PCP were extracted.,0,0,0,0
PMC5574450,"Study patients who met the following inclusion criteria were included in the study: (1) aged >
18 years who had 4 or more years of activity with the surveyed physician between January 2009 and September 2014, with at least one office visit in those 4 years; (2) eligible for diabetes screening tests based on ADA or 2008 USPSTF criteria between January 2010 and September 2011 (see online supplementary table S2 for details on screening guideline criteria applied to EMR database); and (3) having at least one activity in the year before they were observed to be eligible for diabetes screening.",0,1,0,0
PMC5574450,"The time frame to observe patient’s screening eligibility was January 2010 through September 2011, to ensure a subsequent 3-year time interval to observe receipt of the diabetes screening test (guidelines recommend screening every 3 years).",0,0,0,1
PMC5574450,This approach captured some patients who already had conditions making them eligible for screening (prevalent) as well as those who became eligible after study entry (incident).,0,0,0,0
PMC5574450,Patients with any of the following criteria were excluded: (1) evidence of pregnancy or gestational or type 1 diabetes during study period; and (2) diagnosis of pre-diabetes or diabetes or use of antidiabetic medications in the 1-year baseline.,0,1,0,0
PMC5574450,The patients eligible for screening were followed for 3 years to examine if they received diabetes screening test.,0,0,0,0
PMC5574450,"The types of screening test included fasting or random plasma glucose test, oral glucose tolerance test, and HbA1C test.",0,0,0,0
PMC5574450,"Study measuresSurvey measuresThe following areas were covered by the physician survey: (1) demographics and practice characteristics, (2) preferred screening test, (3) factors contributing to their decision to screen (i.e., clinical experience, screening guidelines, prompts from EMR or other), (4) which guidelines they most often use (i.e., USPSTF, ADA or other), and how often they use these guidelines (i.e., 100%, ≥70%, ≥50% or <50% of the time), and (5) attitude toward USPSTF and ADA individual criteria.",0,0,0,0
PMC5574450,"The PCPs were asked to select response options on a scale from 0 to 10, with 0 being ‘Not at all likely’ and 10 being ‘Extremely likely,’ which was used to measure likelihood to screen patients with the following characteristics: (A) USPSTF criteria: blood pressure ≥135/80/80 mm Hg; (B) ADA criteria: patients 18–45 years old, overweight/obese (body mass index ≥25 kg/m2) and having additional risk factors (listed in online supplementary table S1).",0,1,0,0
PMC5574450,The physicians were also asked to report how often they recommend diet and lifestyle coaching or provide referral to DPP and DSME/DSMS (diabetes self-management support).,0,0,0,0
PMC5574450,Physicians who reported that their treatment varies by severity level in patients newly diagnosed with type 2 diabetes were asked to report treatment approaches by severity.,0,0,0,0
PMC5574450,"EMR-based physician level concordance measuresTo assess alignment between self-reported use of ADA/USPSTF guidelines and evidence from EMR, the following measure was calculated for each physician:
pi,k′= No. of patients receiving screening under guideline kNo. of patients eligible for screening under guideline k",0,0,1,0
PMC5574450,"The index i represents individual physician, and the k represents different screening guidelines.",0,0,0,0
PMC5574450,"In order to estimate concordance between the physician’s self-reported and actual adherence to guidelines, the answers from the survey (use of USPSTF/ADA either 100%, ≥70%, ≥50%, or <50% of the time) were compared with p′i,k.",0,0,0,0
PMC5574450,"Additionally, a series of measures were calculated to measure concordance with respect to self-reported likelihood to screen patients with individual USPSTF/ADA criteria as shown below:
pi,j= No. of patients receiving screening under criteria jNo. of patients eligible for screening under criteria j",0,0,0,0
PMC5574450,The index j represents the different screening criteria.,0,0,0,0
PMC5574450,"Each survey question scale related to screening criteria was assumed to represent a percentage between 0% and 100%, which was compared with pi,j to estimate concordance (see details in the Statistical analyses section).",0,0,0,0
PMC5574450,Two of the survey criteria (physical inactivity and history of gestational diabetes or given birth to baby >9 lb) were not compared due to unavailability of information in EMR.Statistical analysesSurvey measures were summarized in a descriptive manner (counts (percentages) or means (SD)).,0,0,0,0
PMC5574450,Multivariable logistic regression models were used to assess whether adherence to USPSTF and ADA screening guidelines (self-reported guidelines they most often use) differed by specific physician and practice characteristics.,0,0,0,0
PMC5574450,"For the concordance analysis, physicians were categorized as: (1) concordant (following screening guidelines) (e.g., they say they frequently follow guidelines and the evidence from the EMR supports this), (2) concordant (but not following guidelines) (e.g., they say they less frequently follow guidelines and the evidence from the EMR supports this), (3) non-concordant (e.g., they say they frequently follow guidelines and the evidence from EMR does not support this), and (4) flagged (e.g., they say they do not follow guidelines or less frequently use guidelines and the evidence from EMR suggests that they actually do follow guidelines (had higher screening rates)).",1,0,0,0
PMC5574450,"To divide physicians into the above four categories for measuring adherence to USPSTF/ADA, a cut-off value of 50% was used (i.e., if a physician reported they use USPSTF guidelines ≥50% of the time and if ≥50% of their USPSTF eligible patients (pi,k′) received screening test, they were categorized as concordant).",1,0,0,0
PMC5574450,"For measuring concordance with respect to individual criteria, a cut-off value of self-reported response ≥50% (likelihood to screen) and percentage of patients screened ≥50% (pi,j) was used to define concordant.",1,0,0,0
PMC5013384,"Research design and methodsThe CARDIA study is a prospective, multicenter, longitudinal cohort study designed to investigate coronary heart disease risk factors in young adults.",0,0,0,0
PMC5013384,"Participants were recruited from four US study centers (Minneapolis, Minnesota; Chicago, Illinois; Birmingham, Alabama; and Oakland, California) with recruitment balanced by age, race, sex, and education level.",0,0,0,0
PMC5013384,A total of 5115 black and white women and men aged 18–30 years were enrolled in 1985–1986.,0,0,0,0
PMC5013384,"Study visits were at year 0 (Y0) and again at years 2, 5, 7, 10, 15, 20, and 25 after enrollment.",0,0,0,0
PMC5013384,"Retention rates were 91%, 86%, 81%, 79%, 74%, 72%, and 72% of the surviving cohort at each visit, respectively.",0,0,0,0
PMC5013384,Additional details of the CARDIA study methods have been published elsewhere.,0,0,0,0
PMC5013384,21,0,0,0,0
PMC5013384,"All study procedures were approved by the institutional review board from each study center, and all participants provided written informed consent for study participation.",0,0,0,0
PMC5013384,"For the purposes of this analysis, only data from Y0 and year 25 (Y25) were included.",0,1,0,0
PMC5013384,"Participants were excluded if they had diabetes or pre-diabetes at Y0 (n=138), if they did not have fitness or dietary intake data available at Y0 (n=67; n=64 did not have fitness data and n=4 did not have dietary intake data), or if their diabetes status at Y25 was unknown (n=1552).",0,1,0,0
PMC5013384,This yielded 3358 participants for this analysis.,0,0,0,0
PMC5013384,"Fitness assessmentFitness was assessed by symptom-limited, graded treadmill exercise duration at Y0.",0,0,0,1
PMC5013384,"This was measured using a modified Balke protocol, consisting of nine stages of progressively increasing difficulty (2 min each, maximum of 18 min total).22 Fitness data are presented as total duration of treadmill exercise before a participant stopped exercise due to symptoms, in seconds.",0,0,0,1
PMC5013384,Longer duration indicates higher cardiorespiratory fitness.,0,0,0,0
PMC5013384,Physical activity assessmentPhysical activity data over the prior year were collected at the Y0 visit.,0,0,0,0
PMC5013384,"Data were self-reported by study participants and were collected by an interviewer-administered questionnaire.23 Data were measured in exercise units, with 300 exercise units approximately equal to 150 min of moderate physical activity per week.",0,0,0,1
PMC5013384,24Diet assessmentThe CARDIA dietary history questionnaire was administered at Y0 by trained interviewers.25,0,0,0,1
PMC5013384,"The questionnaire was designed specifically for the CARDIA study, and dietary intake obtained was for the month prior to the interview.",0,0,0,0
PMC5013384,25,0,0,0,0
PMC5013384,"The reliability and validity of the diet history method were evaluated and found to be acceptable, although the results were found to be less reliable in black participants.",0,0,0,0
PMC5013384,26We developed a diet score that characterized a modified Mediterranean dietary pattern.,0,0,0,0
PMC5013384,"Our diet score was developed a priori and was adapted from a previously published Mediterranean diet score1
27 for use in an American young adult population.",0,0,0,0
PMC5013384,A similarly adapted score has been used in the CARDIA cohort to characterize a Mediterranean-like dietary pattern.28,0,0,0,0
PMC5013384,We refer to our diet score as the Americanized Mediterranean diet score (AmMedDiet score).,0,0,0,0
PMC5013384,"To calculate the AmMedDiet score, sex-specific median intake was determined for 15 food groups created from the individual foods reported by CARDIA participants.",0,0,1,0
PMC5013384,"We assigned one point for intake at or above the sex-specific median, and zero points for intake below the median, for food groups representative of an Americanized Mediterranean diet (vegetables, legumes, fruit and nuts, fish and seafood, whole grains, eggs, milk, and beneficial fat ratio).",0,0,0,0
PMC5013384,"Beneficial fat intake was estimated by the sum of MUFA plus polyunsaturated fatty acids (PUFA), divided by saturated fatty acids (SFA) ((MUFA+PUFA)/SFA ratio), as previously described.",0,0,1,0
PMC5013384,28,0,0,0,0
PMC5013384,"This differs from the estimate of beneficial fat intake in the originally published Mediterranean diet score, which used the MUFA/SFA ratio.1",0,0,1,0
PMC5013384,"This change was necessary because unlike in a Greek population, olive oil was not typically consumed in the American diet during 1985–1986 and most beneficial fat intake was from other sources.",0,0,0,0
PMC5013384,"Also, although high dairy consumption is traditionally not considered a part of the Mediterranean diet, we positively scored high dairy intake in our AmMedDiet score because of previous data associating dairy consumption with lower odds of insulin resistance and type 2 diabetes, including in the CARDIA cohort.",0,0,0,0
PMC5013384,29,0,0,0,0
PMC5013384,"In the traditional Mediterranean diet, dairy intake is mostly from high fat products such as cheese and yogurt,1 which differs from the dairy consumption pattern of the CARDIA cohort in the USA in 1985–1986.29",0,0,0,0
PMC5013384,"The final difference between our score and the previously published Mediterranean diet score1 is the addition of separate categories for snacks, sweets, beverages, potatoes, eggs, and refined grains in our score, added to be inclusive of all food groups represented in the CARDIA dietary intake data set.",0,0,0,0
PMC5013384,"In our score, zero points were assigned for intake at or above the sex-specific median, and one point was assigned for intake below the median, for food groups not consistent with an Americanized Mediterranean diet (meat and poultry, refined grains, potatoes, snacks, sweets, and beverages).",0,0,0,0
PMC5013384,"Alcohol intake was also included in the score, with moderate alcohol intake scored positively.",0,0,0,0
PMC5013384,"One point was given for daily alcohol intake of 10–50 g for men and 5–25 g for women, and zero points were given for consumption below or above these ranges.",1,0,0,0
PMC5013384,"Thus, our diet score ranged from 0 (least similar to an Americanized Mediterranean dietary intake pattern) to 15 (most similar to an Americanized Mediterranean dietary intake pattern).",0,0,0,0
PMC5013384,Definition of pre-diabetes and diabetesBlood was drawn at study visits according to a standard protocol.21,0,0,0,0
PMC5013384,"Serum glucose concentrations were measured using the hexokinase method at Linco Research (St Charles, Missouri, USA).",0,0,0,1
PMC5013384,"Hemoglobin A1c (HgbA1c) was determined at the University of Minnesota (Minneapolis, Minnesota, USA) using the Tosoh G7 high-performance liquid chromatography instrument.",0,0,0,1
PMC5013384,Medications were self-reported at each study visit.,0,0,0,0
PMC5013384,"Pre-diabetes was defined by one of the following features at the Y25 visit: fasting glucose of 100–125 mg/dL, 2-hour glucose during a 75 g oral glucose tolerance test of 140–199 mg/dL, or HgbA1c of 5.7–6.4% (39–46 mmol/mol).",1,0,0,0
PMC5013384,"Diabetes was defined by one of the following features at the Y25 visit: fasting glucose ≥126 mg/dL, self-reported use of medications for the treatment of diabetes mellitus, 2-hour glucose during the oral glucose tolerance test of ≥200 mg/dL, or HgbA1c ≥6.5% (48 mmol/mol).",1,0,0,0
PMC5013384,Incidence of pre-diabetes or diabetes at Y25 was the primary outcome.,0,0,0,0
PMC5013384,"Models and statistical analysisPolytomous logistic regression analyses were used to examine the association of Y0 fitness measured by treadmill duration, Y0 AmMedDiet score, and incidence of pre-diabetes or incidence of diabetes at Y25.",0,0,0,1
PMC5013384,This modeling approach was selected to allow pre-diabetes and diabetes to be considered in the same model.,0,0,0,0
PMC5013384,We first tested the models with ordinal logistic regression to assess the proportional odds assumption whether the associations of Y0 treadmill duration and Y0 AmMedDiet score were statistically significantly the same for pre-diabetes compared to normal glycemia and diabetes compared to normal glycemia.,0,0,0,1
PMC5013384,"Since the proportional odds assumption was rejected, we ran the same models using polytomous logistic regression, presenting separate ORs for incident pre-diabetes and incident diabetes at Y25.We developed three polytomous logistic regression models.",0,0,0,0
PMC5013384,The first included the Y0 AmMedDiet score and was designed to test the relationship between Y0 diet and odds of pre-diabetes or diabetes at Y25.,0,0,0,0
PMC5013384,The second model included Y0 cardiorespiratory fitness measured by treadmill duration and was designed to test the relationship between Y0 fitness and odds of pre-diabetes or diabetes at Y25.,0,0,0,0
PMC5013384,"The third model included the Y0 AmMedDiet score and Y0 treadmill duration, with the purpose of analyzing diet and fitness simultaneously in the same model to look for a joint reduction in odds of pre-diabetes or diabetes at Y25.",0,0,0,0
PMC5013384,"All models were adjusted for age, sex, race, field center, body mass index (BMI), education (highest year of school completed), smoking (current/former/never), caloric intake (kcal/day), and self-reported physical activity.",0,0,0,0
PMC5013384,All covariate data used for adjustment were from Y0.,0,0,0,0
PMC5013384,"The interaction between AmMedDiet score and treadmill duration was not statistically significant once the third model was adjusted for covariates, indicating that there was not a joint reduction in odds of pre-diabetes or diabetes when diet and fitness were analyzed in the same model (p-value of type III test for the interaction between the AmMedDiet score and treadmill duration was 0.11).",0,0,0,0
PMC5013384,"For this reason, the interaction term was not included in the adjusted version of this model.",0,0,0,0
PMC5013384,The interaction between the AmMedDiet score and treadmill duration was also statistically nonsignificant when modeled in tertiles.,0,0,0,0
PMC5013384,"Statistical analyses were performed using Statistical Analysis Software (V.9.3, SAS Institute, Cary, North Carolina, USA).",0,0,0,0
PMC5911519,"METHODSStudy designA total 542 patients (study group [AMI+, n=208] from cardiology division and control group [AMI−, n=334] from endocrinology division) were enrolled in this study from March to December 2014.",0,0,0,0
PMC5911519,"We excluded some patients who were under clinical situations that might directly influence the ED (secondary erythrocytosis [n=1], under chemotherapy due to malignancy [n=1], type 1 diabetes mellitus [T1DM; n=1], under regular hemodialysis [n=2], hepatic failure [n=1]).",0,1,0,0
PMC5911519,All patients were classified into two groups according to the presence of an AMI (AMI+) and those without it (AMI−).,0,0,0,0
PMC5911519,"Of AMI+, subjects without history of T2DM (n=128) were excluded.",0,1,0,0
PMC5911519,"Of AMI−, if any history of IHD or previous coronary intervention such as coronary balloon angioplasty and/or a coronary stent implantation, was present, they (n=116) were also excluded due to clarify the hemorheologic effect on newly developed IHD (77 patients in AMI+ and 118 patients in AMI−) (Fig. 1).",0,1,0,0
PMC5911519,Institutional Review Board (IRB 2014-01-494) approved this study from Yeungnam University Medical Center and written informed consent was acquired from all patients.,0,0,0,0
PMC5911519,"Diabetes was diagnosed by demonstrating any one of the following: fasting plasma glucose level ≥126 mg/dL, plasma glucose at 2 hours after oral glucose load ≥200 mg/dL, and random plasma glucose ≥200 mg/dL with classic hyperglycemic symptoms.",1,0,0,0
PMC5911519,"Classification of T1DM and T2DM was based on integration of clinical symptoms, insulin antibody, absolute insulin deficiency, and family history [9].",1,0,0,0
PMC5911519,"An MI was defined as the presence of at least two of the following: anginal pain, elevation of the creatine kinase concentration greater than three times the upper limit of normal, and/or electrocardiographic changes suggesting an MI [10].",1,0,0,0
PMC5911519,A blood sample was taken during the first visit to the endocrinology outpatient department in the cases of AMI−.,0,0,0,0
PMC5911519,"In the cases of AMI+, the laboratory examinations of the blood samples were performed anytime within 3 days prior to invasive coronary intervention procedures after being admitted to the intensive care unit or emergency department.",0,0,0,0
PMC5911519,"In case of individual situation which early coronary intervention was needed to be done, blood sample was taken just before coronary intervention.",0,0,0,0
PMC5911519,We implanted second generation drug-eluting stents in all patients classified as being in the AMI+.,0,0,0,0
PMC5911519,The hemorheologic parameters were analyzed by routine laboratory assays.,0,0,0,0
PMC5911519,"The ED, which was quantified by an elongation index (EI; measured at a constant shear stress of 3 pascal [Pa] %), and the CSS were measured by a microfluidic ektacytometer (Rheoscan-D®; Rheo-Meditech, Seoul, Korea) using a disposable kit [11], and the other hemorheologic parameters were compared between the two groups.",0,0,0,1
PMC5911519,"The EI was calculated from the dimensions of the major (L) and minor (W) axes of an ellipsoid at 3 Pa, EI=[L−W]/[L+W]; this is expressed as a percentage (Fig. 2).",0,0,1,0
PMC5911519,"The homeostatic model assessment of insulin resistance (HOMA-IR), as a marker of insulin resistance, was calculated using the following formula: HOMA-IR=fasting plasma insulin (µU/mL)×fasting plasma glucose (mg/dL)/405; and the homeostatic model assessment of β-cell function (HOMA-β), which means the function of the β-cells of the pancreas, was calculated as the fasting plasma insulin (µU/mL)×360/(fasting glucose [mg/dL]−63) [12].",0,0,1,0
PMC5911519,"The current medications at the time of the blood sampling were also analyzed because some medications, releasing nitric oxide (NO) or modulating the bioactivity of NO, could influence the value of the EI by increasing the NO concentration in the blood [1314].",0,0,0,0
PMC5911519,The structural and functional echocardiographic parameters including the left ventricular ejection fraction (LVEF) were measured by transthoracic echocardiography during hospitalization.,0,0,0,1
PMC5911519,StatisticsThe results are reported as the mean±standard deviation for numerical variables and as frequencies and percentages for categorical variables.,0,0,0,0
PMC5911519,The independent t-test was used to compare the group continuous variables and the chi-square test or Fisher exact test was used to compare the categorical variables.,0,0,0,0
PMC5911519,"A multivariate linear regression analysis was used to demonstrate any significant factors determining the EI and CSS (variable were as follows; sex, age, hypertension, history of cerebrovascular accident, smoking, body mass index, systolic blood pressure, pharmacologic status, LVEF, E/E′ ratio, white blood cell, hemoglobin, red cell distribution width, mean corpuscular volume, mean corpuscular hemoglobin concentration, platelet count, high-sensitivity C-reactive protein, total protein, aspartate transaminase, alanine transaminase, estimated glomerular filtration rate [GFR], glycosylated hemoglobin [HbA1c], total cholesterol, cystatin C, and insulin resistance/sensitivity indices).",0,0,0,0
PMC5911519,"IBM SPSS version 19.0 (IBM Co., Armonk, NY, USA) was used for the statistical analysis and statistical significance was accepted for P<0.05.",0,0,0,0
PMC4838665,"Research design and methodsStudy populationThe study included 1014 participants with T1DM (372 males, 642 females) who were diagnosed before the age of 30 years from 1961 to 1999, and attended a tertiary diabetes care clinic—the diabetes center of Tokyo Women's Medical University (TWMU)—consecutively from 1961 to 1999.",0,1,0,0
PMC4838665,"To test the hypothesis of whether the year of T1DM diagnosis was associated with incidence of ESRD, patients were divided into two groups by the median of the number of participants, that is, diagnosis of T1DM from 1961 to 1984 (group A, n=529) and from 1985 to 1999 (group B, n=485).",0,1,0,0
PMC4838665,"Those with T1DM who did not continue their visits for more than 1 year (n=263) were not included, because these patients only visited, at most, once or twice for the purpose of specialist consultation.",0,1,0,0
PMC4838665,"Patients who already had ESRD, developed ESRD within the 1 year after the registry (n=18), or developed ESRD due to non-diabetic renal disease (n=3), were excluded.",0,1,0,0
PMC4838665,"There was a systematic reconstruction in the TWMU, in which participants with T1DM who visited the Department of Pediatrics before 1987 were included in the records of the diabetes center and those after 1988 were not included.",0,1,0,0
PMC4838665,"T1DM was diagnosed in accordance with the Japan Diabetes Society (JDS) criteria, as previously reported.7",1,0,0,0
PMC4838665,"In brief, T1DM was defined as being prone to ketosis with acute onset and requiring insulin therapy within 1 year of diagnosis.",1,0,0,0
PMC4838665,Two or more physicians belonging to the JDS classified the disease type.,0,0,0,0
PMC4838665,"Assessments of serum C-peptide and antiglutamic acid decarboxylase (GAD) antibody levels were performed after these tests became available, to help support the diagnosis of T1DM; however, the patients who were GAD antibody-positive, but did not require insulin therapy for more than 1 year, were excluded in the present study, from a clinical point of view.",0,1,0,0
PMC4838665,The study was performed in accordance with the tenets of the Helsinki Declaration II.MeasurementsBlood pressure (BP) was measured at each visit by sphygmomanometer with an appropriate-sized cuff in the sitting position after resting for more than 5 min.,0,0,0,0
PMC4838665,"Glycated haemoglobin (HbA1c) was measured by the mini-column method (Isolab (Quik-Sep), Akron, Ohio, USA) in 1980–1981, by the glycospec method (Abbott (ABA-200), North Chicago, Illinois, USA) in 1982 and by the high performance liquid chromatography method (HPLC; HA8120, HA8121, HA8131, HA8150, HA8160, HA8180: ARKRAY, formerly Kyoto Daiichi Kagaku, Kyoto, Japan) from 1983 to date.",0,0,0,0
PMC4838665,"The values gathered using the mini-column method (x1) and the glycospec method (x2) were converted to HPLC (y) values using the formula (y)=((x1)+0.302)/1.179 (r=0.990), (y)=((x2)+2.151)/1.332 (r=0.855), and all values were expressed asHbA1c values (as % and mmol/mol) certified by the American National Glycohemoglobin Standardization Program.",0,0,0,0
PMC4838665,"Patients visited the clinic monthly or bimonthly, and the average values of BP and HbA1c of each year were used for analysis.",0,0,0,0
PMC4838665,"Urinary protein was measured by Albustix (Miles-Sankyo, Tokyo), and proteinuria was defined as three of four consecutive tests being positive in the absence of menstruation, urinary tract infection or other known non-diabetic renal disease.",1,0,0,1
PMC4838665,Diabetic retinopathy was diagnosed after pupillary dilation by ophthalmologists.,0,0,0,0
PMC4838665,"Cardiovascular disease included coronary artery disease, ischemic stroke, and peripheral artery disease.",1,0,0,0
PMC4838665,"Usage of renin angiotensin system inhibitor (RASI) or statin at baseline and follow-up, and current smoking at follow-up, were obtained through the patient records.",0,0,0,0
PMC4838665,"Follow-upESRD was defined by the initiation of renal replacement therapy, that is, hemodialysis, peritoneal dialysis or kidney transplantation, or death from diabetic kidney disease due to refusal or no access to dialysis.",1,0,0,0
PMC4838665,"The time was calculated from the date of registration at the diabetes center until either the date of ESRD, death or the end of observation (December, 2010).",0,0,1,0
PMC4838665,"For participants who were censored, the final date of visit, being alive and free of ESRD, was used for analysis.",0,0,0,1
PMC4838665,"For patients who moved to other cities/hospitals (n=89), a questionnaire was sent to the doctor who took care of the patient.",0,0,0,0
PMC4838665,Statistical analysisData are expressed as the mean±SD unless otherwise stated.,0,0,0,0
PMC4838665,"The year of T1DM diagnosis was analyzed both categorically (two groups, A and B), and as a continuous variable (per year).",0,0,0,0
PMC4838665,"For comparisons between two groups, the unpaired Student's t test for continuous variables and χ2 test for categorical variables were used.",0,0,0,0
PMC4838665,"The incidence density was presented as the number per 1000 person-years, based on the ratio of the observed number of patients experiencing the event (cases) to the total person-years of exposure (at risk).",0,0,0,0
PMC4838665,"For patients who developed an event (ESRD or death), the contribution of person-years was accumulated until the year of onset of the event.",0,0,0,0
PMC4838665,Those who remained free from an event contributed to person-years until the end of follow-up (December 2010).,0,0,0,0
PMC4838665,Those who had no ESRD and who discontinued visits contributed to person-years until the last clinic visit.,0,0,0,0
PMC4838665,"A comparison of the incidence with the rate ratio (RR) was performed using the χ2 test, and the normal approximation after log-transformation was used for the calculation of CIs.",0,0,0,0
PMC4838665,"The cumulative incidence was plotted using the Kaplan-Meier method with the log-rank test statistic, according to years after registration, duration of T1DM, and postpubertal duration of T1DM (from 11 to9 years in males and females, respectively).",0,0,0,0
PMC4838665,Univariate and multivariate Cox regression analyses were used to compute the HRs and 95% CI to assess the effects of covariates on the onset of ESRD.,0,0,0,0
PMC4838665,"The year of T1DM diagnosis (group A and B), gender, baseline age and duration of diabetes, were used as covariates in model A, and baseline proteinuria and retinopathy were added to model B1.",0,0,0,0
PMC4838665,Model B1 was modified to model B2 by replacing the categorical group for year of T1DM diagnosis (A and B) with year of T1DM diagnosis as a continuous variable.,0,0,0,0
PMC4838665,"Time-dependent Cox regression analyses were applied to model C1, including annual mean HbA1c and systolic BP as time-dependent variables and model C2 used year of T1DM diagnosis as a continuous variable.",0,0,0,0
PMC4838665,"For patients who were registered before 1980, the first measured value of HbA1c in 1980 was used as the baseline value of HbA1c because the HbA1c was not available before 1980.",0,0,0,0
PMC4838665,"To explore the cross effects of HbA1c and systolic BP as time-dependent variables on incident ESRD, time-dependent Cox regression analysis was used, adjusted by the continuous variable of year of T1DM diagnosis, gender and baseline status of age, duration, proteinuria and retinopathy as covariates.",0,0,0,0
PMC4838665,"For this analysis, patients were divided into high/low groups of HbA1c and systolic BP by the median values of HbA1c and systolic BP obtained from the entire follow-up period, and the group with low HbA1c and low systolic BP was used as a reference.",0,0,0,0
PMC4838665,"All statistical analyses were performed using SAS software, V.9.4 (SAS Institute, Inc, Cary, North Carolina, USA).",0,0,0,0
PMC5324888,MethodsStudy designA total of 330 patients were included in this study after the study protocol was approved by local Ethics Committee of our hospital.,0,0,0,0
PMC5324888,We retrospectively analyzed the electronic patient data recording system of our hospital for the patients between January 2011 and June 2015.,0,0,0,0
PMC5324888,"A total of 330 patients were included in the study, including 110 patients with isolated CAE, 110 with obstructive CAD without CAE, and 110 with NCA.Inclusion and exclusion criteriaBased on clinical indications such as abnormal stress test results, dobutamine stress echo, positive treadmill tests, and myocardial perfusion scintigraphy or typical chest pain, a coronary angiography was performed to investigate ischemic heart disease.",0,0,0,0
PMC5324888,All of the patients were clinically stable.,0,0,0,0
PMC5324888,Patients with an acute coronary syndrome defined as STEMI or non-STEMI were excluded from the study.,0,1,0,0
PMC5324888,"We also excluded patients with left ventricular systolic dysfunction [left ventricular ejection fraction (LVEF) <40%]; malignancy; and liver, kidney, or other acute or chronic inflammatory diseases, as well as patients who had undergone percutaneous coronary intervention and coronary artery bypass grafting before.",0,1,0,0
PMC5324888,"Data collectionThe standard Judkins technique and 6-Fr catheters (Expo; Boston Scientific Corporation, Natick, Massachusetts, USA) were used to perform baseline angiography via the femoral artery, and Siemens Axiom Sensis XP (Munich, Germany) device was used.",0,0,0,0
PMC5324888,The vessel diameter was calculated quantitatively in case of conflicts about CAE.,0,0,0,0
PMC5324888,CAE was defined based on the criteria used in the Coronary Artery Surgery Study (17).,1,0,0,0
PMC5324888,"According to the angiographic definition used in that study, segmental ectasia was considered when the diameter of the ectatic segment was ≥1.5 times that of the adjacent normal segment.",1,0,0,0
PMC5324888,"When an identifiable normal adjacent segment could not be found, the mean diameter of the corresponding coronary segment in the control group was used as the normal value (1).",1,0,0,0
PMC5324888,"CAE without coronary artery stenosis was considered as isolated CAE, and the severity of isolated CAE was determined according to the Markis classification (3).",1,0,0,0
PMC5324888,"In decreasing order of severity, diffuse ectasia of two or three vessels was classified as type 1, diffuse disease in one vessel and localized disease in another vessel as type 2, diffuse ectasia of only one vessel as type 3, and localized segmental ectasia as type 4. More than 50% of the diameter at one or more major epicardial arteries without CAE was considered as obstructive CAD.Arterial hypertension was considered in patients with repeated blood pressure measurements >140/90 mm",1,0,0,0
PMC5324888,Hg or current use of antihypertensive drugs.,1,0,0,0
PMC5324888,"Diabetes mellitus was defined as fasting plasma glucose levels ≥126 mg/dL on multiple measurements, or current use of anti-diabetic medications.",1,0,0,0
PMC5324888,Hyperlipidemia was considered as a total serum cholesterol level >200 mg/dL or the use of a lipid-lowering medication.,1,0,0,0
PMC5324888,Family history of CAD was considered in case of history of CAD or sudden cardiac death in a first-degree relative before the age of 55 years for men and 65 years for women.,1,0,0,0
PMC5324888,Peripheral venous blood samples of the patients were obtained on their admission to the inpatient ward.,0,0,0,0
PMC5324888,"An automated blood cell counter (Beckman Coulter analyzer, California, USA) was used for measuring complete blood count parameters.",0,0,0,1
PMC5324888,"The levels of the following blood biochemistry parameters were measured: creatinine, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total bilirubin.",0,0,0,1
PMC5324888,"C-reactive protein (CRP) measurement was done before the coronary angiography with nephelometric method, using an automatized analyzer (Beckman Coulter analyzer).",0,0,0,1
PMC5324888,"PLR was calculated as the ratio of platelet count to lymphocyte count, obtained from the same blood sample.",0,0,1,0
PMC5324888,"Transthoracic echocardiography was performed in all patients, and LVEF was calculated using Simpson’s method.",0,0,1,0
PMC5324888,"Statistical analysisSPSS 22.0 statistical package program (SPSS Inc., Chicago, IL, USA) was used to analyze data.",0,0,0,0
PMC5324888,Kolmogorov–Smirnov test was used to analyze the distribution pattern of the variables.,0,0,0,0
PMC5324888,"Normally distributed numerical variables were presented as mean±standard deviation, and non-normally distributed variables as median and interquartile range.",0,0,0,0
PMC5324888,Categorical variables were presented as the number (percentage).,0,0,0,0
PMC5324888,"Group means of the continuous variables were compared with Student’s t-test, Mann–Whitney U test with/without Bonferroni correction, ANOVA, or Kruskal–Wallis test, where appropriate.",0,0,0,0
PMC5324888,A logistic regression analysis was performed to determine the independent predictors of presence and severity of isolated CAE.,0,0,0,0
PMC5324888,Variables that had an unadjusted p value of <0.10 in logistic regression analysis were identified as potential risk markers and then included in the full model.,0,0,0,0
PMC5324888,We made likelihood ratio tests in the reduced model using multivariate logistic regression analysis to eliminate potential risk markers.,0,0,0,0
PMC5324888,A p value of <0.05 was considered statistically significant with a confidence interval of 95%.,0,0,0,0
PMC5324888,Receiver-operating characteristic (ROC) curve analysis was performed to determine the cut-off value of PLR for predicting CAE.,0,0,0,0
PMC5368484,"MethodsStudy populationBetween January 2013 and July 2013, 151 sequential patients (mean age: 62.8±10.4 years) who were admitted to the Adana Numune Training and Research Hospital Cardiology Department outpatient clinic with newly diagnosed essential hypertension (without evidence of secondary causes of hypertension) were included the study.",0,1,0,0
PMC5368484,"All patients in this study lived in the Çukurova region (average latitude 23 meters), located in the southern part of Turkey.",0,0,0,0
PMC5368484,Hypertensive patients had three clinic blood pressure measurements (>140/90 mm Hg) taken at 1-week intervals in the absence of any previous antihypertensive treatment to exclude the pharmacological effects on hemodynamic or ventricular hypertrophy and function.,0,0,0,1
PMC5368484,None of the patients was taking calcium or vitamin D supplements.,0,1,0,0
PMC5368484,"The patients were divided into two groups according to serum 25 (OH) D level: vitamin D-non-deficient group (vitamin D≥20.00 ng/mL, n=53) and vitamin D-deficient group (vitamin D<20.00 ng/mL, n=98).",0,0,0,0
PMC5368484,"Exclusion criteria were malignant HT (high blood pressure with acute impairment of one or more organ systems), evidence of secondary HT (diabetic nephropathy, polycystic kidney disease, renovascular hypertension, Cushing syndrome, thyroid diseases, hyperparathyroidism, coarctation of the aorta, obesity etc.), diabetes mellitus, systolic heart failure (left ventricle ejection fraction (LVEF) <55%), positive history or clinical signs of ischemic heart disease, cerebrovascular disease, valve disease, atrial fibrillation, smoking, receiving any drugs (lithium, NSAİD, prednisolone, etc.), moderate and severe renal insufficiency (eGFR formulated by MDRD <60 mL/min/1.73 m2), evidence of hypercalcemia (normal range: 9-10.5 mg/dL or 2.2-2.6 mmol/L), severe hepatic dysfunction, and major non-cardiovascular diseases, such as autoimmune disease, cancer, and systemic inflammatory conditions.",0,1,0,0
PMC5368484,"The institutional Ethics Committee approved the study, and written informed consent for participation in the study was obtained from all individuals.",0,0,0,0
PMC5368484,Blood pressure measurements used in this study were taken with a mercury sphygmomanometer.,0,0,0,1
PMC5368484,Body mass index (BMI) was computed as weight divided by height squared (kg/m2).,0,0,1,0
PMC5368484,The body surface area of all subjects was computed [BSA (m2) = [height (cm) x weight (kg)]/3600]½Blood samplesBlood samples were drawn in the morning after a 20-min rest following a fasting period of 12 hours.,0,0,1,0
PMC5368484,Blood samples and echocardiographic examinations were performed on the same day in all patients.,0,0,0,1
PMC5368484,"Glucose, creatinine, triglyceride, and total and high-density lipoprotein (HDL)-cholesterol levels were measured for each patient.",0,0,0,1
PMC5368484,The low-density lipoprotein (LDL) value was calculated with Friedewald’s formula.,0,0,1,0
PMC5368484,"High-sensitivity C-reactive protein (hs-CRP) was measured using a BN2 nephe-lometer (Scil Diagnostics GmbH, Viernheim, Germany).",0,0,0,1
PMC5368484,"Serum calcium (8.2-10.2 mg/dL) and parathyroid hormone levels (15-65 pg/mL) were measured on a Cobas c501 analyzer (Roche Diagnostics, Japan).",0,0,0,1
PMC5368484,Serum and plasma from EDTA and citrate blood were separated by centrifugation and stored as aliquots at -40°C.,0,0,0,0
PMC5368484,"The level of serum 25 (OH) D was measured by using a direct competitive chemiluminescent immunoassay (Elecsys; Roche Diagnostics, Mannheim, Germany).",0,0,0,1
PMC5368484,We measured vit-D level two times and averaged them in all patients.,0,0,0,1
PMC5368484,"Intra- and inter-assay coefficients of variation (CVs) were below 4.3% and 7.2%, respectively.",0,0,0,0
PMC5368484,We also recorded the dates of the 25-hydroxyvitamin D measurements and categorized them into 2 seasons: winter (Jan-Mar) and spring-summer (April-July).,0,0,0,0
PMC5368484,"In this study, 20 ng/mL 25-hydroxyvitamin D was used as a cut-off for vitamin D sufficiency according to the recommendations from the WHO and, more recently, the Institute of Medicine (12, 13).",1,0,0,0
PMC5368484,EchocardiographyTransthoracic echocardiographic examination was performed in the left lateral position.,0,0,0,1
PMC5368484,"Standard 2-dimensional and Doppler echocardiographies were performed using a commercially available echocardiography machine (Vivid 7R GE Medical System, Horten, Norway).",0,0,0,1
PMC5368484,"LV end-diastolic diameter (LVDd), LV end-systolic diameter, and left atrial (LA) diameter were measured according to established standards of the American Society of Echocardiography (14).",0,0,0,1
PMC5368484,LVEF was calculated by Simpson’s method (14).,0,0,1,0
PMC5368484,All measurements were calculated from an average of 5 consecutive cardiac cycles.,0,0,0,1
PMC5368484,LV mass (LVM) was calculated according to the Devereux formula (15): LVM=1:04 [(LVDd+IVSth+PWT)3-(LVDdH-13.6.,0,0,1,0
PMC5368484,"Thereafter, LV mass index (LVMI) was obtained by the following formula: LVM/body surface area (g/m2) (13).",0,0,1,0
PMC5368484,"Intra- and inter-assay CV were below 4.8% and 6.5%, respectively.",0,0,0,0
PMC5368484,Relative wall thickness (RWT) was measured at end-diastole as the ratio of (2xPWT)/LVEDD.Tissue,0,0,0,1
PMC5368484,Doppler measurements and calculation of the tissue Doppler-derived myocardial performance indexThe tissue Doppler (TD) of the mitral annulus movement was obtained from the apical 4-chamber view.,0,0,1,0
PMC5368484,A 2-mm sample volume was placed sequentially at the lateral and septal annular sites.,0,0,0,1
PMC5368484,Pulse wave tissue Doppler was performed with a 2-mm sample volume placed at the lateral and septal corner of the mitral annulus from the apical 4-chamber view.,0,0,0,1
PMC5368484,Filters were set to exclude high-frequency signals and gain minimized.,0,0,0,0
PMC5368484,Doppler ultrasound scanning intervals were measured from the mitral annular velocity intervals.,0,0,0,0
PMC5368484,The isovolumetric relaxation time (IVRT) was measured from the onset of closure of the aortic valve until the onset of opening of the mitral valve.,0,0,0,1
PMC5368484,The isovolumetric contraction time (ICT) was measured from the onset of closure of the mitral valve until the onset of the opening of the aortic.,0,0,0,1
PMC5368484,The ejection time (ET) was calculated from the opening until the closure of the aortic valve (10).,0,0,0,0
PMC5368484,All parameters were measured from the same cardiac cycle.,0,0,0,1
PMC5368484,Tissue Doppler measurements were calculated from an average of 5 consecutive cardiac cycles.,0,0,0,0
PMC5368484,The TD-derived MPI value was calculated by adding ICT and IVRT and dividing the sum by the ET: (ICT + IVRT)/ET (10).,0,0,1,0
PMC5368484,"We used the averages of the septal and lateral annulus of the mitral ICT, IVRT, and ET for calculating the MPI.",0,0,0,0
PMC5368484,The method of MPI is shown in Figure 1.,0,0,0,0
PMC5368484,"The intra-assay CV was less than 5%, and the inter-assay CV less than 6% for measurements of the MPI.Figure 1Representation of measurements of Doppler time intervals for the calculation of MPI (according to Tei et al.16).",0,0,0,0
PMC5368484,"MPI is calculated by the formula [(ICT + IRT)/ET]ET - ejection time; ICT - isovolumic contraction time; IRT - isovolumic relaxation timeStatistical analysesAll analyses were conducted using SPSS 17.0 (SPSS for Windows 17.0, Chicago, IL, USA).",0,0,1,0
PMC5368484,"Continuous variables were expressed as mean±SD, and categorical variables were expressed as percentages.",0,0,0,0
PMC5368484,Analysis of normality was performed with the Kolmogorov-Smirnov test.,0,0,0,0
PMC5368484,Comparison of categorical variables between the groups was performed using the chi-square (χ2) test.,0,0,0,0
PMC5368484,Independent-samples t-test was used in the analysis of continuous variables.,0,0,0,0
PMC5368484,Non-normally distributed variables (hs-CRP and triglyceride) were compared with Mann-Whitney U test.,0,0,0,0
PMC5368484,"The correlations between 25 (OH) D and laboratory, hemodynamic, and echocardiographic parameters were assessed by Pearson correlation analysis.",0,0,0,0
PMC5368484,"Multivariate, stepwise linear regression analysis was performed to identify the independent associations of serum 25 (OH) D. All significant parameters in the univariate analysis were selected in the multivariate analysis.",0,0,0,0
PMC5368484,"To avoid overfitting and collinearity in assessing the multivariate model, independent variables were tested for intercorrelation.",0,0,0,0
PMC5368484,Collinearity between variables was excluded before modeling.,0,0,0,0
PMC5368484,"Finally, MPI, LDL, LVMI, LVID, Cr, and parathyroid hormone levels were selected in the multivariate model.",0,0,0,0
PMC5368484,A p <0.05 was considered statistically significant.,0,0,0,0
PMC3661839,"Statistical methodsAnalyses were performed on data collected at baseline (n = 699), month 6 (n = 596), and month 24 (n = 403), which were the major outcome data collection visits including DXA.",0,0,0,0
PMC3661839,"Only data collected prior to the occurrence of the primary outcome (failure to maintain glycemic control) were included since management with insulin, which was started after treatment failure, is known to change measures of body composition.",0,0,0,0
PMC3661839,A mixed effects repeated measures analysis that appropriately accounted for the longitudinal data structure was used to analyze change from baseline.,0,0,0,0
PMC3661839,The method used all data available for each participant at time points prior to treatment failure.,0,0,0,0
PMC3661839,"The model included treatment, visit, and treatment-by-visit interaction, with the value of the outcome at baseline as a covariate.",0,0,0,0
PMC3661839,Models of bone mineral content (BMC) and bone mineral density (BMD) also adjusted for height and age at the time of visit.,0,0,0,0
PMC3661839,"If the treatment-by-visit interaction was significant, we examined pairwise treatment differences at 6 and 24 months.",0,0,0,0
PMC3661839,Model-adjusted means (least squares means [LSmeans]) and SEs of the change from baseline are reported in the tables and the graphs.,0,0,0,0
PMC3661839,"Subgroup differences across treatments were modeled, including an interaction term for treatment by sex or treatment by race/ethnicity.",0,0,0,0
PMC3661839,"Results are given for the three categories of race/ethnicity with acceptable sample size (non-Hispanic black [NHB], Hispanic [H], and non-Hispanic white [NHW]).",0,0,0,0
PMC3661839,The relationships between change from baseline insulin sensitivity (1/fasting insulin in μU/mL) or HbA1c and measures of body composition included the baseline value of either insulin sensitivity or HbA1c as a covariate.,0,0,0,0
PMC3661839,"All analyses were considered exploratory, with statistical significance defined as P < 0.05 and no adjustment for multiple testing; the study was powered for the primary study outcome only.",0,0,0,0
PMC3661839,"The Statistical Analysis Software package (SAS, version 9.2, 2008; SAS Institute Inc., Cary, NC) was used for all analyses.",0,0,0,0
PMC4212578,"MethodsPatientsTREAT (ClinicalTrials.gov registration number NCT00093015) was a prospective, randomized, double-blind, placebo-controlled trial of darbepoetin alfa for the treatment of anemia in 4038 patients with type 2 diabetes mellitus, impaired renal function (eGFR 20–60 mL/min/1.73 m2 by MDRD), hemoglobin ≤11.0 g/dL, and transferrin saturation ≥15%.",0,1,0,0
PMC4212578,"Exclusion criteria included uncontrolled hypertension, previous kidney transplantation or scheduled receipt of a kidney transplant from a living related donor, current use of intravenous antibiotics, chemotherapy or radiation therapy, cancer (except basal-cell or squamous-cell carcinoma of the skin), HIV infection, active bleeding, or pregnancy.",0,1,0,0
PMC4212578,"In addition, patients who had a CV event, major surgery, grand mal seizure, or had received an erythropoetic stimulating agent within 12 weeks prior to randomization were also ineligible.",0,1,0,0
PMC4212578,"The primary endpoints for the study were time to the composite outcome of death or CV event (non-fatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and time to the composite outcome of death or ESRD.",1,0,0,0
PMC4212578,"All endpoints, including ESRD, were adjudicated by a clinical endpoints committee masked to treatment assignment.",0,0,0,0
PMC4212578,"ESRD was defined as the initiation of dialysis (sustained for at least 30 days), initiation of dialysis with death within 30 days, a physician's recommendation to initiate dialysis with documented subject refusal, or renal transplant.",1,0,0,0
PMC4212578,"The detailed study design, entry criteria and main results have been previously described.",0,0,0,0
PMC4212578,"10
11For this analysis, all 4038 TREAT participants were included, and all gave written informed consent for participation in the primary trial.",0,1,0,0
PMC4212578,"At screening, investigators were asked to answer checkbox questions about retinopathy in each eye—whether or not there was retinopathy and, if so, to check all that applied of: background/preproliferative, macular edema, proliferative or laser treatment.",0,0,0,0
PMC4212578,"Questions regarding the baseline presence of a history of diabetic neuropathy, erectile dysfunction, foot ulcer, and amputation were also part of the screening evaluation performed by the site investigator.",0,0,0,0
PMC4212578,"Measurements of serum BUN (blood urea nitrogen), creatinine, albumin, and potassium were obtained at baseline and eGFR was determined using the four-variable MDRD equation.12",0,0,0,0
PMC4212578,Baseline proteinuria was assessed by spot urine protein/creatinine ratio measurements at baseline.,0,0,0,1
PMC4212578,All samples were analyzed by a central laboratory.,0,0,0,0
PMC4212578,"In a subgroup of the first 1000 randomized patients, troponin T (TnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured in a single batch from baseline serum samples.13
14Statistical analysisBaseline characteristics were stratified by a history of retinopathy and laser therapy.",0,0,0,1
PMC4212578,Categorical variables were compared using χ2 tests and continuous variables were compared using the Wilcoxon rank-sum test.,0,0,0,0
PMC4212578,"All tests were two sided, and a p value <0.05 was considered statistically significant.",0,0,0,0
PMC4212578,"At baseline, the univariate association between any degree of retinopathy or laser treated retinopathy and the CV composite endpoint, death, CV death, myocardial infarction, stroke, congestive heart failure, ESRD, as well as the composite of all-cause mortality or ESRD was analyzed in Cox proportional hazards regression models.",1,0,0,0
PMC4212578,The assumption of proportionality for the Cox analysis was tested and the criteria were met.,0,0,0,0
PMC4212578,Multivariable proportional hazards models were constructed for ESRD and the renal and CV composite outcomes.,0,0,0,0
PMC4212578,"The initial model was adjusted for the baseline demographics of age, sex and race.",0,0,0,0
PMC4212578,The first model was nested in the second which also adjusted for proteinuria.,0,0,0,0
PMC4212578,The third model additionally adjusted for baseline eGFR.,0,0,0,0
PMC4212578,Model 4 adjusted for systolic blood pressure and a history of hypertension.,0,0,0,0
PMC4212578,"Model 5 adjusted for glycemic control, known duration of diabetes, and insulin use and the final model included all prior covariates in addition to all baseline characteristics that were significantly different between patients with and without retinopathy.",0,0,0,0
PMC4212578,All variables collected in the baseline case report form were eligible for use in this analysis unless they were missing for >150 patients.,0,1,0,0
PMC4212578,"After the exclusion of missing data, 3894 patients were available for this analysis.",0,0,0,0
PMC4212578,"Stata/SE V.12.1 (StataCorp, College Station, Texas, USA) was used for all analysis.",0,0,0,0
PMC5331352,"MethodsGerman patients from the University Hospital of Aachen, Germany, treated between 1997 and 2012 with DCPs because of symptomatic bradycardia (SSS, high-grade atrioventricular block) for an average period of 5 years were included in this retrospective single-center study.",0,1,0,0
PMC5331352,"They presented with clinical symptoms and signs of HF, a high ventricular pacing percentage (>90%), and a decrease in LVEF (Table 1).",0,1,0,0
PMC5331352,"Patients with a recently diagnosed reduced LVEF and clear reasons for this impaired LVEF, such as the progression of coronary heart disease or a new relevant valvular heart disease, were excluded from the study.",0,1,0,0
PMC5331352,All patients included in the analysis had RV leads positioned in the RV apex.,0,0,0,0
PMC5331352,DCPs were programmed to DDD pacing mode with a lower rate of 60 beats per min (bpm) and with a physiological atrioventricular delay.,0,0,0,0
PMC5331352,"All patients underwent a thorough cardiovascular examination, as well as a transthoracic echocardiography (TTE) and coronary angiography, to rule out the progression of or new onset of a heart disease leading to HF.",0,0,0,0
PMC5331352,Coronary artery disease was ruled out in 10 patients.,0,0,0,0
PMC5331352,Twelve of 22 patients had a history of coronary artery disease (Table 1) and angiographically showed no progress.,0,0,0,0
PMC5331352,A relevant valvular heart disease as a cause of HF was excluded by echocardiography in all patients.,0,0,0,0
PMC5331352,"In all patients, the reprogramming of the pacemaker device in an attempt to reduce the RVP percentage was not possible due to an intrinsic ventricular rhythm lower than 30 bpm.",0,0,0,0
PMC5331352,"All patients were optimized on guideline-based HF medication comprising angiotensin-converting enzyme inhibitors (ACE-inhibitor), beta-blockers, diuretics, and mineralocorticoid receptor antagonists.",0,0,0,0
PMC5331352,All 22 patients had well-controlled arterial hypertension with normotensive blood pressure (<135/85 mm Hg) during the hospital stay.,1,0,0,0
PMC5331352,This was also confirmed in the daily conducted routine blood pressure measurements.,0,0,0,0
PMC5331352,DCPs were then upgraded to biventricular devices with the implantation of an LV lead.,0,0,0,0
PMC5331352,"In addition, 15 of the 22 patients were upgraded to a CRT-defibrillator device.",0,0,0,0
PMC5331352,The CRT pacemaker devices were programmed with standard monitor zones for the detection of ventricular arrhythmias (>170 bpm).,0,0,0,0
PMC5331352,"Table 1Baseline characteristicsNumber of patients22Sex, male/female13/9Age, years (average, SD)71±11LVEF, % (average, SD)37±7Ventricular pacing percentage, % (average, SD)90±14Sick Sinus Syndrome1/22Brady-tachy",0,0,0,0
PMC5331352,"Syndrome11/223rd degree atrioventricular block10/22Atrial fibrillation13/22Coronary heart disease12/22Arterial hypertension22/22Valvular heart disease5/22Diabetes mellitus5/22Renal impairment8/22Beta-blocker22/22ACE-inhibitor22/22Diuretics22/22Mineralocorticoid receptor antagonist22/22Statin22/22Age, LVEF, and ventricular pacing percentage were expressed as mean±standard deviation.",0,0,0,0
PMC5331352,"SD- standard deviationFollow-upAll patients were followed-up at 1, 6, and 12 months after the CRT implant.",0,0,0,1
PMC5331352,"At each follow-up, clinical examination, TTE, 12-lead ECG, and device interrogation were performed.",0,0,0,0
PMC5331352,"In addition, NT-pro brain natriuretic peptide (BNP) levels were assessed to evaluate the severity of HF.Statistical analysisContinuous variables were expressed as mean±standard deviation.",0,0,0,0
PMC5331352,LVEF was analyzed with a two-sided t-test after testing with the Shapiro–Wilk method for normal distribution.,0,0,0,0
PMC5331352,A p-value of <0.05 was considered to be statistically significant.,0,0,0,0
PMC5331352,QRS duration and BNP levels were analyzed with the unpaired t-test due to abnormal distribution.,0,0,0,0
PMC6254592,Statistical methodsBaseline characteristics are provided for liraglutide initiators and “all comparators” combined.,0,0,0,0
PMC6254592,"Because of the complexity of drug use patterns, several methods were used to separately quantify risks associated with starting liraglutide, being on liraglutide currently, and cumulative exposure.",0,0,0,0
PMC6254592,"As the primary analysis, an analog to intention-to-treat (ITT) analysis of randomized trials was applied to quantify the risk associated with starting treatment, attributing all follow-up time to the initial exposure cohort.",0,0,0,0
PMC6254592,"Incidence rates (BC cases per 100,000 person-years) were estimated as the number of patients with BC divided by the person-years of follow-up.",0,0,0,0
PMC6254592,Poisson regression models were used to estimate incidence rate ratios (RRs) and 95% CIs for liraglutide vs each comparator group.,0,0,0,0
PMC6254592,"Generalized estimating equations (GEEs) were used to account for the paired nature of the data created by matching, except in cases when data were too sparse to support the GEE estimation.",0,0,0,0
PMC6254592,24,0,0,0,0
PMC6254592,"In a latency analysis, person-time and BC cases from the first year of each patient’s follow-up were excluded to focus on the probable period of any liraglutide effect on BC.A time-on-drug (TOD) analysis was performed to evaluate the effect of recency of use of liraglutide.",0,1,0,0
PMC6254592,"The dispensing date and days’ supply (ie, a pharmacist-estimated number of days that a prescription is expected to last if taken according to the prescribing instructions) were used to categorize each person-day of follow-up into “current”, “recent”, and “past” use, for each study drug.",0,0,0,0
PMC6254592,“Current” use included the day after the dispensing date up through the end of the days’ supply.,0,0,0,0
PMC6254592,A 31-day grace period was added to the end of days’ supply to allow for variable adherence.,0,0,0,0
PMC6254592,“Current” use continued as long as new refill dispensings were observed before the grace period ended.,0,0,0,0
PMC6254592,"Once the grace period expired, it was assumed the patient discontinued that drug.",0,0,0,0
PMC6254592,The next 31 days (person-time occurring between 32 and 62 days after “current” use) were considered as “recent” use.,0,0,0,0
PMC6254592,"Person-time occurring after “recent” use was categorized as “past” use and persisted unless the patient re-started the same treatment, thereby re-entering the “current” use category.",0,0,0,0
PMC6254592,"Because many patients switched and added AD therapies regularly, patients in matched pairs may have had use of both liraglutide and a comparator during follow-up.",0,0,0,0
PMC6254592,"If BC was diagnosed while the patient was currently on liraglutide and had past use of the comparator, for example, the BC case and corresponding person-time were included in the incidence estimate for “current” liraglutide use and “past” comparator use.",0,0,0,0
PMC6254592,"When patients had concurrent use of both drugs in the comparison, cases and person-time were included in “current” use for both drugs.",0,0,0,0
PMC6254592,"Poisson regression was used to estimate the RRs and 95% CIs for “current”, “recent”, and “past” use of liraglutide vs the same “current-recent-past” category for comparators, adjusted by the logit of the PS to address confounding.",0,0,0,0
PMC6254592,An additional TOD analysis quantified patients’ cumulative time on liraglutide from cohort entry and compared the associated rate of BC within time unexposed to liraglutide (which was generally exposed to other ADs).,0,0,0,0
PMC6254592,"For patients who initiated one of the other study drugs and later initiated liraglutide, cumulative exposure to liraglutide began at the time of that dispensing and subsequent person-time was no longer considered “liraglutide unexposed”.",0,0,0,0
PMC6254592,"RRs were estimated using Poisson regression modeling within categories of cumulative time (<6 months, 6–18 months, and >18 months) relative to all “liraglutide unexposed” time, and models were adjusted for the logit of the PS.",0,0,0,0
PMC6254592,The potential for surveillance bias was considered by comparing frequency of mammography during follow-up for each exposure group.,0,0,0,0
PMC6254592,The timing of BC diagnosis relative to cohort entry was examined for each of the seven matched cohorts.,0,0,0,0
PMC6254592,"In addition, the distribution of cases by age group was examined, relative to the distribution of patients overall.",0,0,0,0
PMC5336859,"MethodsStudy populationSeventy patients, aged 18 years or older, were admitted to participating centers (Eskişehir Osmangazi University, Cardiology Department, Eskişehir, Turkey; Ufuk University, Cardiology Department, Ankara, Turkey; Kilis State Hospital, Cardiology Clinic, Kilis, Turkey; Türkiye Yüksek İhtisas Hospital, Cardiology Clinic, Ankara, Turkey; and Cumhuriyet University, Cardiology Department, Sivas, Turkey) and hospitalized with the diagnosis of acutely decompensated HF defined as a rapid onset or progressive deterioration in the symptoms and signs of congestion and/or low cardiac output (e.g., increasing breathlessness, orthopnea, jugular venous distension, peripheral edema, weight gain, pulmonary crepitations, tachycardia, cold extremities, and hypotension), which were considered to be due to a precipitant or trigger (e.g., an arrhythmia, discontinuation of diuretic treatment, non-adherence to diet/drug therapy, and uncontrolled hypertension), New York Heart Association functional class III-IV, and left ventricular ejection fraction (LVEF) <35% as measured by transthoracic echocardiography were included in this multicenter study.",1,0,0,0
PMC5336859,"ACS defined by progressive angina or chest pain at rest or new ECG changes and/or serial increase in cardiac troponin levels, recent percutaneous coronary interventions (PCI), cardiogenic shock, hypertrophic cardiomyopathy, severe valvular heart disease, severe renal failure, chronic obstructive pulmonary disease, pregnancy, hypo/hyperthyroidism, recent infection history, and abnormal albumin levels (<3.5 g/dL and >5.5 g/dL) were the exclusion criteria.",0,1,0,0
PMC5336859,"A single serum specimen was also collected from aged-matched 32 apparently healthy individuals (mean age 68±7 years, 20 males and 12 female) as a control reference population.",0,0,0,0
PMC5336859,"The control group must also have met the exclusion criteria and was similar with the main study population in terms of age (68±7 vs. 66±10 years, p=0.302), gender (62.5% vs. 70% males, p=0.370), and serum albumin levels (4.0±0.2 mg/dL vs. 3.8±0.6 mg/dL, p=0.270).",0,0,0,0
PMC5336859,"Study design and protocolThe present study was a multicenter, prospective study conducted in the cardiology department of five hospitals from four different cities (14).",0,0,0,0
PMC5336859,"The study protocol was approved by the institutional Ethics Committee, and the study was performed in accordance with the guidelines of the Declaration of Helsinki.",0,0,0,0
PMC5336859,All patients gave written informed consent before enrollment.,0,0,0,0
PMC5336859,"After hospital admission, all patients were treated with guidelines-recommended medical therapy for acute HF including oxygen, intravenous diuretic, and vasodilator therapy on top of their background oral medication such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, or mineralocorticoid receptor antagonists.",0,0,0,0
PMC5336859,"The patients’ background therapy, including beta-blockers, was continued during the hospital stay if tolerated.",0,0,0,0
PMC5336859,Digoxin was used for rate control in the presence of atrial fibrillation.,0,0,0,0
PMC5336859,"In addition, patients who did not respond to optimal pharmacological therapy as evidenced by persistent dyspnea or congestion, those with clinical evidence of organ hypoperfusion such as worsening renal or liver functions as evidenced by oliguria, increase in creatinine and liver transaminase levels, and evidence of elevated cardiac filling pressures received inotropic therapy.",0,0,0,0
PMC5336859,The decision of inotropic support and type of inotropic agent was left at the discretion of the physician.,0,0,0,0
PMC5336859,"Among all patients, 29 were treated with standard HF therapy with oxygen, diuretics, vasodilators (standard therapy group); 18 received an additional 24 h infusion of levosimendan with a loading dose of 6-12 pg/kg over 10 min followed by a continuous infusion of 0.1-0.2 pg/kg/min (levosimendan group), and 23 received dobutamine with a continuous infusion of 5-10 pg/kg/min for 24 h in addition to the standard HF therapy (dobutamine group).",0,0,0,1
PMC5336859,"The serum concentrations of IMA were measured from blood samples collected after diagnosis and before the initiation of HF therapy, and additionally, a second specimen was collected after 24-48 h of the initiation of HF therapy.",0,0,0,0
PMC5336859,Baseline demographic data and medications were documented in all subjects (Table 1).,0,0,0,0
PMC5336859,"N-terminal pro-brain natriuretic peptide (NT-proBNP), hemoglobin, serum potassium, sodium, creatinine, blood urea nitrogen (BUN), albumin, and cardiac troponin-I (cTnI) levels were measured during admission and after 24-48 h of the initiation of HF therapy.",0,0,0,1
PMC5336859,"Also, LVEF and systolic pulmonary arterial pressure (sPAP) were obtained from transthoracic echocardiography.",0,0,0,1
PMC5336859,"In addition to the IMA levels, changes in other laboratory variables were also analyzed.",0,0,0,0
PMC5336859,"Table 1Patient demographics on admissionStudy population (n=70)Age, years66±10Male gender, n49 (70%)Diabetes, n28 (40%)Hypertension, n52 (74%)Hyperlipidemia, n40 (57%)Smoker, n22 (31%)Ischemic heart failure, n62 (88%)Medication ACEI/ARB, n52 (74%) Beta blocker, n49 (70%) MRA, n29 (42%) Diuretic, n39 (56%) Digoxin, n26 (37%)ACEI - angiotensin converting enzyme inhibitor; ARB - angiotensin receptor blocker; MRA - mineralocorticoid receptor antagonistIMA measurementBlood samples for the measurement of the IMA level were centrifuged within 1 h of collection for 15 min at 3000 rpm.",0,0,0,0
PMC5336859,The serum specimens were frozen at -70°C on site before being sent for central lab analysis to determine the IMA concentration.,0,0,0,0
PMC5336859,"The IMA concentrations were measured by the albumin cobalt binding colorimetric assay by the addition of a known amount of cobalt to the serum specimen and by further measurement of the unbound cobalt by colorimetric assay using dithiothreitol, as previously described by Bar-Or et al. (15)",0,0,0,1
PMC5336859,"The analysis in the Human Humalyzer 2000 spectrophotometer (Human Diagnostics, Weisbaden, Germany) were performed at 470 nm, and the results were given in absorbance units (AU).Statistical analysisThe statistical analysis was performed using the Statistical Package for Social Sciences software 20.0 (IBM SPSS 20, SPSS Inc, Chicago, USA), Medcalc 11.3.0 (MedCalc 11.3-MedCalc",0,0,0,1
PMC5336859,"Software bvba, Mariakerke, Belgium).",0,0,0,0
PMC5336859,The variables were expressed as mean±standard deviation and median (25-75 percentiles).,0,0,0,0
PMC5336859,Data were tested for normal distribution with the Shapiro-Wilks test.,0,0,0,0
PMC5336859,Independent and paired sample t-tests were used for the analysis of normally distributed variables.,0,0,0,0
PMC5336859,Mann-Whitney U test and Wilcoxon signed-rank test were used for the analysis of non-normally distributed variables.,0,0,0,0
PMC5336859,The diagnostic performance of IMA was assessed by receiver operating characteristic (ROC) curve analysis.,0,0,0,0
PMC5336859,"From the ROC curve, the optimum diagnostic cutoff point for the present study population was chosen to maximize clinical sensitivity and specificity.",0,0,0,0
PMC5336859,Categorical data were presented as frequencies and percentages.,0,0,0,0
PMC5336859,p-values <0.05 were considered to be statistically significant.,0,0,0,0
PMC6398811,Research design and methodsStudy populationParticipants for this study were drawn from the Selenium Trial (NIH Clinical Trials.gov number NCT00078897).,0,0,0,0
PMC6398811,"The Selenium Trial has been described in detail previously.3 16 Briefly, this was a double-blind, placebo-controlled trial where participants were randomized to receive either 200 µg/day of Se as selenized yeast or placebo to assess the effect of Se on the development of metachronous (ie, new or ‘recurrent’) colorectal adenomas.",0,0,0,0
PMC6398811,"Participants in the trial were men and women between the ages of 40 and 80 years recruited from endoscopy clinics in Arizona, Colorado, Texas, and New York, with one or more colorectal adenomas of diameter ≥3 mm.",0,1,0,0
PMC6398811,All trial participants were required to have undergone total colonoscopy and complete removal of all colorectal adenomas within the 6 months before registration.,0,0,0,0
PMC6398811,"Management of study data and biospecimens was conducted at the University of Arizona Cancer Center (Tucson, Arizona, USA).16
A total of 400 participants were selected for a substudy using HOMA2 assessments.",0,0,0,0
PMC6398811,"Participants were identified based on the availability of a baseline fasting blood draw, as well as a postintervention fasting blood draw within 6 months of intervention completion.",0,1,0,0
PMC6398811,"Exclusion criteria included having taken celecoxib before this arm of the original protocol of the Selenium Trial was discontinued as directed by the Food and Drug Administration,3 16 and not having a fasting blood draw both preintervention and postintervention.",0,1,0,0
PMC6398811,"A stratified random sample of available individuals was then selected from the eligible participants, based on year of randomization, leaving 195 from the placebo group and 205 from the Se treatment group for inclusion in the present analyses.",0,0,0,0
PMC6398811,"Of these participants, results for HOMA2 assessments were available for 188 participants in the placebo group and 201 in the Se group.",0,0,0,0
PMC6398811,"Based on a two-sample t-test, a sample size of 389 allows us to obtain a power of 81% detecting an effect size of 0.29 Cohen’s d for changes in HOMA parameters between the placebo and Se groups at a significance level of 5%.17",0,0,0,0
PMC6398811,"For the modified OGTT (mOGTT) study, a convenience sample of 175 participants was selected.",0,0,0,0
PMC6398811,All participants who remained on the trial near the end of follow-up were approached and asked if they would like to take part in the mOGTT substudy.,0,0,0,0
PMC6398811,"Individuals who agreed to participate were then scheduled for the test, including 96 participants in the placebo group and 79 from the intervention group.",0,0,0,0
PMC6398811,The conduct of the trial was in accordance with requirements of the local IRB at each study site.,0,0,0,0
PMC6398811,"Exposure and outcome assessmentTo assess the primary endpoints of β-cell function (HOMA2-%β) and insulin sensitivity (HOMA2-%S), we used the University of Oxford Diabetes Trials Unit HOMA2 calculator Application Programming Interface downloaded from http://www.dtu.ox.ac.uk/homacalculator/index.php.",0,0,0,0
PMC6398811,Fasting blood draws from participants at the end of the Selenium Trial were obtained.,0,0,0,0
PMC6398811,18,0,0,0,0
PMC6398811,"As described above, a total of 400 participants were selected from the Se intervention and placebo groups to ascertain if there were differences between them for insulin sensitivity and β-cell function.",0,0,0,0
PMC6398811,"For plasma glucose concentrations, blood was drawn into a tiger top tube at each of the time points, processed and shipped directly to a commercial laboratory (Sonora Quest, Tempe, Arizona, USA).",0,0,0,0
PMC6398811,"Assessment of plasma insulin concentrations at each time point were determined in the laboratory of Dr Lawrence Mandarino at Arizona State University (Tempe, Arizona, USA) using immunoassays Alpco Immunoassays (Salem, New Hampshire, USA).",0,0,0,0
PMC6398811,"Each sample from an individual was run in the same assay batch to avoid laboratory drift, along with five internal reference standards included in each batch.",0,0,0,0
PMC6398811,"The coefficients of variation for glucose and insulin were less than 5%.While HOMA2 measures are an efficient strategy for assessing insulin resistance in large epidemiological studies, they are unable to capture dynamic changes in insulin secretion and do not directly address functionality.",0,0,0,0
PMC6398811,19,0,0,0,0
PMC6398811,"We therefore selected a subset of the clinical trial participants for assessment using the mOGTT method of Cobelli et al.19 20 Briefly, an 8-sample, 3-hour mOGTT was performed for each participant.",0,0,0,0
PMC6398811,"The test was commenced after an overnight fast with 75 g oral dose of glucose, followed by intravenous blood draws at 0, 10, 20, 30, 60, 90, 120 and 180 min.",0,0,0,1
PMC6398811,Glucose concentrations were measured as described above.,0,0,0,0
PMC6398811,Measurement of plasma,0,0,0,0
PMC6398811,"Se concentrations were performed with the AAnalyst 600 atomic absorption spectrometer (Perkin-Elmer, Norwalk, Connecticut, USA) with a THGA graphite furnace with Zeeman background correction and a Se electrodeless discharge lamp.",0,0,0,1
PMC6398811,Each participant’s samples were diluted with matrix modifiers containing 0.01% nickel nitrate hexahydrate and 0.0043% magnesium nitrate hexahydrate in 0.4% nitric acid and 0.2% triton X-100.,0,0,0,1
PMC6398811,Calibration standards were prepared using the method of additions.,0,0,0,0
PMC6398811,"Known standards were included for every 10 samples, and each sample was run in triplicate.",0,0,0,1
PMC6398811,"Collection of sociodemographic, dietary and medical history data was performed using self-administered questionnaires on randomization to the Selenium Trial.",0,0,0,0
PMC6398811,The Arizona Food Frequency Questionnaire was employed for dietary data ascertainment and has been described in detail elsewhere.,0,0,0,0
PMC6398811,"21
Statistical analysesMeans, SD and other summary statistics for the overall population and by Se and placebo group were calculated using standard statistical methods.",0,0,0,0
PMC6398811,Univariate comparisons by treatment used t-tests or analysis of variance for normally distributed variables.,0,0,0,0
PMC6398811,"For non-normally distributed variables, univariate comparisons used non-parametric methods.",0,0,0,0
PMC6398811,"Outcome variables, HOMA2-%β and HOMA2-%S were calculated using the HOMA2 API Oxford University 2004 as described above.",0,0,1,0
PMC6398811,"Change in outcome variables, HOMA2-%β and HOMA2-%S was calculated by subtracting pre-measurements from post-measurements.",0,0,1,0
PMC6398811,Outcome difference variables were log transformed to achieve normality if necessary.,0,0,0,0
PMC6398811,"Difference variables were modeled using linear regression on Se/placebo group and adjusting for baseline HOMA2 measurements, age, and gender.",0,0,0,0
PMC6398811,OGTT was log transformed and then analyzed using a linear mixed model approach controlling for correlations between multiple observations per participant.,0,0,0,0
PMC6398811,All analysis were performed using Stata V.15.0.,0,0,0,0
PMC4360821,"MethodsPatientsOur study population consisted of patients with type 2 diabetes who were admitted to the Tokyo Medical and Dental University Hospital for the purpose of glycemic control and/or evaluation of diabetic complications during the period from July 1, 2012 to August 31, 2014.",0,1,0,0
PMC4360821,Patients were eligible if they were aged ≥20 years.,0,1,0,0
PMC4360821,"Patients with type 1 diabetes, those with severe renal impairment (estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2 or undergoing renal replacement therapy), pregnant women, and those with infectious or malignant diseases were excluded.",0,1,0,0
PMC4360821,Type 2 diabetes was diagnosed according to the criteria of the Japan Diabetes Society (JDS).19Clinical and biochemical analysesStandardized questionnaires were used to obtain information on smoking and medication.,1,0,0,0
PMC4360821,Smoking history was classified as either current smoker or non-smoker.,0,1,0,0
PMC4360821,Glycated hemoglobin (HbA1c) was measured by the latex agglutination method.,0,0,0,1
PMC4360821,HbA1c levels were expressed in accordance with the National Glycohemoglobin Standardization Programs recommended by the Japanese Diabetes Society.19,0,0,0,1
PMC4360821,"Urinary albumin and creatinine excretion were measured by the turbidimetric immunoassay and enzymatic method, respectively, in a single 24 h urine collection.",0,0,0,1
PMC4360821,"GFR was estimated using the following equation for the Japanese, as proposed by the Japanese Society of Nephrology;20 GFR=194×SCr−1.094×age−0.287 ((if female)×0.739), where SCr stands for serum creatinine in mg/dL, measured by an enzymatic method.",0,0,1,0
PMC4360821,BMI was calculated as weight divided by the square of height (kg/m2).,0,0,1,0
PMC4360821,"Visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by a dual bioelectrical impedance analyzer (DUALSCAN, Omron Healthcare Co., Kyoto, Japan).",0,0,0,1
PMC4360821,"Previous studies demonstrated a good correlation between VFA measured by a dual bioelectrical impedance analyzer and that measured by an abdominal CT.21
22 According to the definition of obesity and visceral fat obesity in Japan,23 we used cut points of 25 kg/m2 in BMI for obesity and of 100 cm2 in VFA for visceral fat obesity.",0,0,0,1
PMC4360821,"We classified the patients into four groups by these cut-off values of BMI and VFA as follows: BMI<25 and VFA<100 (OB(−)VA(−)), BMI≥25 and VFA<100 (OB(+)VA(−)), BMI<25 and VFA≥100 (OB(−)VA(+)), and BMI≥25 and VFA≥100 (OB(+)VA(+); figure 1).",1,0,0,0
PMC4360821,"Brachial-ankle pulse wave velocity (baPWV) was measured using a volume-plethysmographic apparatus (BP-203RPE II form PWV/ABI, Omron Healthcare Co., Kyoto, Japan), with subjects in the supine position after at least 5 min of rest.24
25",0,0,0,1
PMC4360821,The baPWV was calculated as reported previously.,0,0,1,0
PMC4360821,26,0,0,0,0
PMC4360821,We simultaneously measured baPWV on the right and left sides and the averaged values from each individual were subjected to statistical analysis.,0,0,0,0
PMC4360821,This study complies with the principles laid down in the Declaration of Helsinki.,0,0,0,0
PMC4360821,Figure 1The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes.,0,0,0,0
PMC4360821,"OB(−)VA(−), patients with VFA<100 cm2 and BMI<25.0 kg/m2; OB(+)VA(−), those with VFA<100 cm2 and BMI≥25 kg/m2; OB(−)VA(+), those with VFA≥100 cm2 and BMI<25 kg/m2; OB(+)VA(+), those with VFA≥100 cm2 and BMI≥25 kg/m2.Statistical analysisStatistical analyses were performed using programs available in the SPSS V.21.0 statistical package (SPSS Inc., Chicago, Illinois, USA).",0,0,0,0
PMC4360821,Data are presented as the mean±SD or geometric mean with 95% CI as appropriate according to data distribution.,0,0,0,0
PMC4360821,"Glucose, aspartate aminotransferase, alanine aminotransferase, triglycerides, C reactive protein (CRP), brain-type natriuretic peptide, and urinary albumin and C-peptide excretion were logarithmically transformed because of skewed distributions.",0,0,0,0
PMC4360821,Categorical variables are presented as a percentage.,0,0,0,0
PMC4360821,Differences among the 4 groups were tested with a one-way analysis of variance (continuous variables) or χ2 test (categorical variables) followed by Tukey-Kramer methods for the post hoc analysis.,0,0,0,0
PMC4360821,Linear regression analysis with a stepwise procedure was used to assess the cross-sectional association of each manifestation of abdominal (VFA) and entire body weight (BMI) with baPWV.,0,0,0,0
PMC4360821,"The following covariates were incorporated in the analysis; age, gender, duration of diabetes, history of CVD, presence of proliferative diabetic retinopathy, smoking status, systolic blood pressure, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, HbA1c, urinary albumin, eGFR, and the use of oral hypoglycemic agents, the use of calcium-channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, and antiplatelet agents.",0,0,0,0
PMC4360821,Differences were considered to be statistically significant at a p value less than 0.05.,0,0,0,0
PMC4210062,"Materials and MethodsThe present study was carried out at the outpatient department of medicine of Kasturba Medical College Hospital, Mangalore, India.",0,0,0,0
PMC4210062,"This study was undertaken after the approval by the institutional ethical committee in accordance with the ethical standards laid down in the Declaration of Helsinki, and obtaining consent from the study participants.",0,0,0,0
PMC4210062,A total of 122 patients with type 2 diabetes mellitus and 94 non‐diabetic healthy subjects who were willing to participate were enrolled into the present study.,0,1,0,0
PMC4210062,"Patients with diabetes mellitus were selected based on established diabetes mellitus, according to American Diabetes Association criteria.",0,1,0,0
PMC4210062,Exclusion criteria were diabetic patients with: (i) any comorbid state or medication known to affect HRV; (ii) heart disease in which regular sinus arrhythmia was lost; (iii) known neuropathy of other etiology; and (iv) smokers and alcohol consumers.,0,1,0,0
PMC4210062,All the participants were underwent a clinical examination.,0,0,0,0
PMC4210062,The height and weight of all the participants were measured.,0,0,0,1
PMC4210062,The body mass index was calculated using the formula: weight in kilograms (kg) divided by height in meters (m) squared.,0,0,1,0
PMC4210062,A 12‐lead electrocardiogram was carried out in all the participants.,0,0,0,0
PMC4210062,The San Antonio Consensus report states that at least one measurement should be carried out in five different diagnostic categories for diagnosing somatic neuropathy (PNP).,0,0,0,1
PMC4210062,The use of all categories together leads to a large degree of overdiagnosis.,0,0,0,0
PMC4210062,Manageability in the outpatient clinic is difficult because of the large number and complexity of the tests that have to be carried out11.,0,0,0,0
PMC4210062,"Therefore, PNP was diagnosed based on neurological examination of the peripheral somatic nervous system.",0,0,0,0
PMC4210062,The diverse pattern of clinical manifestations of PNP compelled us to adopt the neurological scoring system to define PNP based on neurological examination findings and symptoms of PNP.,0,0,0,0
PMC4210062,"However, to diagnose PNP, a minimum of four scores on neurological examination was a prerequisite.",0,0,0,0
PMC4210062,Cases with isolated signs or symptoms were excluded from the study (as a case of doubt).,0,1,0,0
PMC4210062,Neurological examination included the following.,0,0,0,0
PMC4210062,"Reflexes: biceps, quadriceps, Achilles.",0,0,0,0
PMC4210062,"Reflexes were graded as normal = 0, sluggish = 1 and absent = 2. Sensation: tested both in lower and upper limbs.",0,0,0,0
PMC4210062,"Sensation included vibration, pain, temperature and touch.",0,0,0,0
PMC4210062,"Sensory test response was scored as: normal = 0, impaired = 1 and severely impaired = 2. Muscle power: examined both in upper and lower limbs.",0,0,0,0
PMC4210062,"From normal to severally abnormal were graded as grade V = 0, grade IV = 1, grade III = 2, grade II = 3, grade I = 4, grade 0 = 5. Each PNP symptom was given one score.",0,0,0,0
PMC4210062,Fasting and postprandial blood sugars were measured in all the participants.,0,0,0,1
PMC4210062,Glycated hemoglobin (HbA1c) could be measured in 37 diabetics in the diaphragmatic breathing group and 37 diabetics in the conventional deep breathing group (a total of 74 diabetics) owing to financial constraints.,0,0,0,1
PMC4210062,Blood pressure was recorded in all the participants.,0,0,0,1
PMC4210062,Two readings were taken 5 min apart in the sitting position.,0,0,0,1
PMC4210062,The mean of the two was recorded as blood pressure.,0,0,0,0
PMC4210062,"Systolic and diastolic blood pressure were also recorded in the supine position, and then in the standing position with an interval of at least 2 min between positions.",0,0,0,1
PMC4210062,A sustained drop in systolic (>20 mmHg) or diastolic (>10 mmHg) blood pressure after standing for at least 2 min was considered as having orthostatic hypotension12.,1,0,0,0
PMC4210062,The diabetic patients were divided into groups of 61 for diaphragmatic breathing (DPB) and 61 for the deep breathing test (DBT).,0,0,0,0
PMC4210062,Non‐diabetic healthy participants were divided into groups of 47 for DPB and 47 for DBT.,0,0,0,0
PMC4210062,Consecutive alternate eligible diabetic patients and non‐diabetic healthy participants were allocated to the DPB and DBT groups at the time of entry into the study.,0,0,0,0
PMC4210062,"Furthermore, type 2 diabetics in the DPB and DBT groups were divided into three subgroups.",0,0,0,0
PMC4210062,"Group A were essentially with hypertension, but essentially free from PNP.",0,0,0,0
PMC4210062,"Group B were essentially with PNP, but essentially free from cardiovascular disease including hypertension.",0,0,0,0
PMC4210062,Group C were free from clinical evidence of any diabetes‐related complications.,0,0,0,0
PMC4210062,The National Glycohemoglobin Standardization Program (NGSP) and Japanese Diabetes Society (JDS) allow grading of glycemic control based on HbA1c values13.,0,0,0,0
PMC4210062,"Owing to a relatively smaller sample size, a correlation between HRV parameters and HBA1c was considered (instead of dividing them into four subgroups: excellent, good, fair and poor).",0,0,0,0
PMC4210062,"Study ProtocolThe following HRV parameters were quantified during DPB and the DBT from lead II electrocardiogram tracing of 60 s:
Expiratory:inspiratory ratio (E:I ratio).Standard deviation of all the N–N intervals (SDNN).",0,0,0,0
PMC4210062,Root mean square of successive N–N interval difference (r‐MSSD).,0,0,0,0
PMC4210062,Procedure Followed for DBTThis test was carried out in the morning when the participants were completely relaxed.,0,0,0,0
PMC4210062,"Before beginning the test, the participants were taught to breathe, at six breaths per min: 5 s for each inhalation and 5 s for each exhalation.",0,0,0,1
PMC4210062,The examiner raised his hand to signal the start of each inhalation and lowered to signal the start of each exhalation.,0,0,0,1
PMC4210062,Lead II electrocardiogram was then recorded continuously at a speed of 25 mm/s for 60 s while the participants breathed as instructed (Cardiart 108T/MK‐VII; BPL Ltd.,0,0,0,1
PMC4210062,"Bangalore, Karnataka, India).",0,0,0,0
PMC4210062,Procedure Followed for DPBThis was carried out in the morning when the participants were completely relaxed.,0,0,0,0
PMC4210062,This method was adopted from Kisner et al.5 with certain modifications.,0,0,0,1
PMC4210062,"The modification being, in addition to the breathing pattern, relaxation of the mind and concentration on the act of breathing were emphasized.",0,0,0,0
PMC4210062,The participants were taught to carry out this act of breathing at six respiratory cycles per min: 5 s for each inhalation and 5 s for each exhalation.,0,0,0,0
PMC4210062,"In the beginning, the participants were asked to rest for 5 min in the supine position.",0,0,0,0
PMC4210062,"Next, the participants were asked to place their right hand on their chest and left hand below the anterior costal margin.",0,0,0,0
PMC4210062,"Participants were asked to breathe in slowly and deeply through the nose, with the shoulders relaxed and upper chest still, allowing the abdomen to rise.",0,0,0,0
PMC4210062,The participants were told to slowly let all the air out using controlled expiration.,0,0,0,0
PMC4210062,"The participants' left hand would rise during inspiration and fall during expiration, whereas the right hand remained still.",0,0,0,0
PMC4210062,Precautions were taken to avoid hyperventilation.,0,0,0,0
PMC4210062,Lead I electrocardiogram was then recorded continuously at a speed of 25 mm/s for 60 s while the participants breathed as instructed (Cardiart 108T/MK‐VII; BPL Ltd.,0,0,0,0
PMC4210062,Bangalore).,0,0,0,0
PMC4210062,Assessment of E:I RatioThe R–R intervals were measured accurately from a lead II electrocardiogram recorded during the deep breathing test and diaphragmatic breathing separately.,0,0,0,0
PMC4210062,The longest interval during expiration and the shortest R‐R interval during inspiration was expressed as E:I ratio)14.Assessment of SDNNAll the R–R intervals recorded during DPB and the DBT from the lead II electrocardiogram were measured accurately and fed into a computer separately.,0,0,0,0
PMC4210062,"SDNN was then estimated with appropriate statistical functions using Microsoft Windows XP Professional (Microsoft Corporation, Redmond, WA, USA).",0,0,0,1
PMC4210062,The steps followed in computing SDNN were: (i) the mean of the entire set of R–R intervals was calculated; (ii) from each of the duration of R–R interval mean R–R interval was deducted; (iii) each R–R interval was squared; (iv) all the squared R–R intervals were summed; (v) squared R–R intervals were divided by 1–sample size; and (vi) the square root of the number obtained in step (v) was estimated.,0,0,0,0
PMC4210062,Assessment of r‐MSSDAll the R–R intervals recorded during diaphragmatic breathing and conventional deep breathing from lead II electrocardiogram were measured accurately and fed into a computer separately.,0,0,0,0
PMC4210062,r‐MSSD was then estimated with appropriate statistical functions using Microsoft Windows XP Professional (Microsoft Corporation).,0,0,0,0
PMC4210062,Steps followed in computing r‐MSSD.Step #1:,0,0,0,0
PMC4210062,The difference between the RR waveform and the delayed waveform was obtained.,0,0,0,0
PMC4210062,Step #2:,0,0,0,0
PMC4210062,The differences between the R–R intervals were squared.,0,0,0,0
PMC4210062,Step #3: sum of the squared differences were calculated.,0,0,0,0
PMC4210062,Step #4:,0,0,0,0
PMC4210062,The mean of the sum squared differences between the adjacent normal R–R intervals were derived.,0,0,0,0
PMC4210062,Step # 5:,0,0,0,0
PMC4210062,The square root of the mean of the sum squared differences between adjacent normal R–R intervals was derived.,0,0,0,0
PMC4210062,Step # 6:,0,0,0,0
PMC4210062,The square root of the mean of the sum squared differences between the adjacent normal R–R intervals in the record was divided by the number of R–R intervals within a given time minus one R–R interval.,0,0,0,0
PMC4210062,Standard deviation/r‐MSSD,0,0,0,0
PMC4210062,"EstimationFrom Standard deviation and r‐MSSD, Standard deviation/r‐MSSD was calculated.",0,0,0,0
PMC4210062,Statistical AnalysesStatistical analysis was carried out suitably by using Student's unpaired t‐test and Pearson's correlation coefficient test.,0,0,0,0
PMC4210062,The level of significance was determined by two‐tailed test.,0,0,0,0
PMC4210062,Statistical significance was taken to be as a P‐value <0.05.,0,0,0,0
PMC5337055,"MethodsPatients’ populationIn this cross-sectional study, 65 consecutive patients with HF who were scheduled for CRT at our university hospital, from september 2011 to september 2012, were enrolled.",0,0,0,0
PMC5337055,"The inclusion criteria were drug-refractory NYHA class III or IV HF, depressed left ventricular ejection fraction (LVEF) ≤35%, and prolonged QRS duration (≥120 ms).",0,1,0,0
PMC5337055,"Patients were excluded if they were right bundle branch block, non-sinus rhythms, or had CRT insertion within the last 3 months.",0,1,0,0
PMC5337055,The etiology of HF was considered ischemic in the presence of significant coronary artery disease (more than fifthy percent stenosis in at least one of the major coronary arteries) and/or previous revascularization or a history of myocardial infarction.,1,0,0,0
PMC5337055,"All patients were on angiotensin converting enzyme or angiotensin receptor blocker, beta-blockers and low dose of spironolactone before and after CRT implantation; if the patients were symptomatic, diuretic was added to medication.",0,0,0,0
PMC5337055,The study protocol was accepted by our local Ethical Committee.,0,0,0,0
PMC5337055,Written informed consent was obtained from all patients.,0,0,0,0
PMC5337055,Study protocolElectrocardiographyPatients’ resting 12-lead ECGs (0.5,0,0,0,0
PMC5337055,"Hz to 150 Hz, 25 mm/s, 10 mm/mV) were analyzed for fQRS complexes by an expert electrophysiologist who was blinded to the aims of the study and the results of the CRT.",0,0,0,0
PMC5337055,"In wide-complexes QRS, fQRS was defined by the presence of >2 notches on the R wave or the S wave and had to be present in ≥2 contiguous corresponding to a major myocardial segment (Fig. 1) (17).",1,0,0,0
PMC5337055,"The presence of fQRS in two or more contiguous anterior leads (V1, to V5), two or more lateral leads (I, aVL and V6), and in two or more inferior leads (II, III and aVF), and the presence of fQRS in V1 and V2 corresponded to the posterior myocardial segments were recorded.",0,0,0,0
PMC5337055,Figure 1Electrocardiography showing fragmented QRS complexCRT device implantationCRT device implantations were performed by electrophysi-ologists.,0,0,0,0
PMC5337055,Right atrial and right ventricular leads were implanted using a transvenous approach.,0,0,0,0
PMC5337055,LV leads were inserted by a transvenous approach through the coronary sinus into a cardiac vein in the majority of patients.,0,0,0,0
PMC5337055,"In two patients, when the transvenous lead failed to be placed due to procedural difficulty, a minimally invasive epicardial lead was placed by a cardiothoracic surgeon.",0,0,0,0
PMC5337055,"LV lead locationElectrophysiologists performed a pre-implantation coronary venous angiogram in at least 2 orthogonal views (left anterior oblique and right anterior oblique, 20° to 40°), stored post implantation fluoroscopic images in the same views, and obtained post procedural chest x-rays (anteroposterior and lateral views) before the patients was discharged.",0,0,0,0
PMC5337055,A detailed evaluation of the pre-implantation venogram and post implantation LV lead images was made to locate the final position of the LV lead.,0,0,0,0
PMC5337055,"EchocardiographyAll patients underwent transthoracic echocardiography (VIVID S6; General Electronic Company, Wauwatosa, WI, USA) by cardiologists who were blinded to the current study before and 3-6 month after the CRT implantation.",0,0,0,0
PMC5337055,"Left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) were recorded, and LVEF was calculated from the conventional apical two-and four-chamber images using the biplane Simpson’s technique.",0,0,0,0
PMC5337055,All the echocardiographic measurements after CRT implantation were made with the device in active pacing mode.,0,0,0,0
PMC5337055,"The response to CRT was defined as ≥15% decrease in LVESV at follow-up.Statistical analysisData were analyzed using a statistical software program (SPSS version 18.0; SPSS Inc, USA).",0,0,0,0
PMC5337055,Continues data were presented as mean±SD and were tested for normal distribution via the Kolmogorov-Smirnov (K-S) test.,0,0,0,0
PMC5337055,A comparison between clinical and echocardiographic variables before and after CRT was performed by paired sample t test.,0,0,0,0
PMC5337055,Categorical variables were compared by the chi-square test.,0,0,0,0
PMC5337055,Multivariate logistic regression analysis in backward-LR method was used for identifying variables to be predictive of the response to CRT.,0,0,0,0
PMC5337055,"The sensitivity, specificity, positive predictive value and negative predictive value were calculated.",0,0,0,0
PMC5337055,A p value <0.05 was considered significant.,0,0,0,0
PMC4212563,"MethodsData sourceData were extracted from the Children's Mercy Hospital Type 1 diabetes in Pediatrics database (CMH T1P database), which contains demographic, clinical, and laboratory data extracted from the electronic health records of patients with T1DM seen at CMH (Kansas City, Missouri, USA) and nine rural outreach locations since June 1, 1993.Inclusion/exclusion criteria for data sourceThe primary criterion for inclusion in the T1P database was a verifiable diagnosis of T1DM.",0,1,0,0
PMC4212563,"First, individuals with presumed T1DM were identified by an informatics query of billing records (N=4095).",0,0,0,0
PMC4212563,"Next, study personnel reviewed the most recent diabetes clinic documentation to confirm the clinical diagnosis of T1DM and to evaluate for additional medical conditions.",0,0,0,0
PMC4212563,Patients were considered to have T1DM based on the diagnosis noted by the provider in the record.,0,0,0,0
PMC4212563,"Overall, 583 patients did not have a verifiable diagnosis of T1DM (N=3512 included).",0,0,0,0
PMC4212563,"Exclusion criteria for the CMH T1P database included (1) diagnosis of type 2 diabetes mellitus, confirmed monogenic diabetes, cystic fibrosis-related diabetes, or iatrogenic diabetes; (2) chronic medical conditions that might result in a major change in glycemia (eg, systemic steroid treatment) or measurement of glycated hemoglobin (HbA1c; eg, chronic anemia or hemoglobinopathy); and (3) the presence of chromosomal or other genetic disorders (other than Down syndrome or Turner syndrome).",0,1,0,0
PMC4212563,"In total, 89 individuals were excluded by these criteria, leaving 3423 individuals in the T1P database.",0,0,0,0
PMC4212563,"Data collection for data source and study cohortTo create the T1P database, HbA1c data, race, and gender self-reported by the family were obtained by an informatics query of the electronic health record (EHR).",0,0,0,0
PMC4212563,"Race was specified in the EHR as white, black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, Multi-racial, or Other.",0,0,0,0
PMC4212563,Ethnicity was specified as Hispanic or non-Hispanic.,0,0,0,0
PMC4212563,Age at onset of T1DM was obtained by trained study personnel via chart review.,0,0,0,0
PMC4212563,"When the date of diagnosis was not clearly documented, study personnel defined the diagnosis date as the date after which three criteria were met: (A) initiation of insulin therapy was documented, (B) HbA1c was screened and reported to be >6%, and (C) serum autoantibodies (anti-GAD, ICA512/IA2, and/or insulin autoantibodies) screened positive for T1DM.",1,0,0,0
PMC4212563,Patients not meeting the above criteria were considered to have an unknown date of diagnosis.,0,0,0,0
PMC4212563,"After selection of the final cohort included for the T1P database, a random sample of 100 charts was reviewed to ensure accuracy of all extracted data, which revealed 100% accuracy.",0,0,0,0
PMC4212563,"For the present study, patients were excluded if the date of T1DM onset was unknown (n=425), or if patients had either of the following: no HbA1c during the first 3 months (n=378) or no HbA1c during months 4–12 after diagnosis (n=402).",0,1,0,0
PMC4212563,"In total, 2218 participants were evaluable by these criteria; 29 239 HbA1c assessments were available in total (figure 1).",0,0,0,0
PMC4212563,"In order to ensure that only data representing near-complete HbA1c trajectory curves were included in this analysis, all HbA1c values recorded for a particular patient after a monitoring gap of >12 months were excluded from the present analysis (ie, the patients were included, but data after the monitoring gap were excluded).",0,1,0,0
PMC4212563,This criterion led to the exclusion of only 1135 HbA1c values (2%).,0,0,0,0
PMC4212563,"Figure 1Flow diagram of patients meeting inclusion/exclusion criteria for the present analysis (CMH, Children's Mercy Hospital; DM, diabetes mellitus; T1D, type 1 diabetes; HbA1c, glycated hemoglobin).",0,0,0,0
PMC4212563,"Variable definitionsIndependent variables included patient age at diagnosis, race, gender, and diagnostic era.",0,0,0,0
PMC4212563,"Age at diagnosis was also treated as a categorical variable and stratified into the following groups: 0–4, 5–9, and ≥10 years.",1,0,0,0
PMC4212563,"Diagnosis era was also defined as a categorical variable, using the following strata: pre-2000, 2000–2003, and 2004–2009, to coincide with the diabetes center's evolving policy to use split-regimen dosing, multiple daily injections, or continuous subcutaneous insulin infusion, respectively, as first-line therapy.",1,0,0,0
PMC4212563,The dependent variable was the HbA1c trajectory over the 5-year period after diagnosis.,0,0,0,0
PMC4212563,The trajectory of intraparticipant HbA1c values for each age group was constructed using third order polynomials and utilizing all available HbA1c values obtained more than 1 month following initiation of insulin therapy.,0,0,0,0
PMC4212563,HbA1c during the study period was measured in the CMH endocrine laboratory using methodologies that evolved from 1993 to 2009.,0,0,0,0
PMC4212563,"Initially, the Quik Sep manual ion exchange column was utilized, followed by the introduction of the BioRad diaStat (HPLC) in 1999, the BioRad Variant II (HPLC) in 2001, the Primus PDQ (Boronate Affinity) in 2004, and the Tosoh G8 (HPLC) in 2008.",0,0,0,0
PMC4212563,The point-of-care In2it (Boronate Affinity) was introduced in 2009 as an adjunct method of measurement (contemporary with the Tosh G8 HPLC) at certain CMH clinic locations geographically separated from the endocrinology laboratory at CMH.,0,0,0,0
PMC4212563,All instruments used from 1999 onward were certified by the National Glycohemoglobin Standardization Program (NGSP) as having documented traceability to the Diabetes Control and Complications Trial (DCCT) Reference Method.Statistical analysisBaseline characteristics were compared across the diagnostic age categories.,0,0,0,0
PMC4212563,Categorical variables were examined as frequencies and compared using χ2 or Fisher's exact test.,0,0,0,0
PMC4212563,Continuous variables were examined as means (±SDs) and compared using one-way analysis of variance.,0,0,0,0
PMC4212563,The p<0.05 was defined as the limit of statistical significance.,0,0,0,0
PMC4212563,"Results are reported as means (±SDs) or mean (upper, lower 95% confidence limits) unless otherwise specified.",0,0,0,0
PMC4212563,"Within-patient HbA1c trajectories were modeled using hierarchical linear models, including a random intercept by patients and fixed linear and polynomial coefficients.",0,0,0,0
PMC4212563,Mean trajectories were estimated within prespecified patient subgroups.,0,0,0,0
PMC4212563,"Trajectories were statistically compared using multiple-DF likelihood ratio tests, jointly testing all four cubic polynomial terms, and trajectory shapes were compared by jointly testing the linear, quadratic, and cubic terms.",0,0,0,0
PMC4212563,"After examining HbA1c trajectories, we noted an inflection point at approximately 1.5 years postdiagnosis.",0,0,0,0
PMC4212563,Post hoc analysis was performed to characterize the HbA1c rate of rise over time (HbA1c slope) during the first 1.5 years after diagnosis.,0,0,0,0
PMC4212563,"Intraparticipant HbA1c slope was determined using linear regression and utilizing all available HbA1c values during the first 1.5 years postdiagnosis, with the exception of HbA1c values obtained prior to initiation of insulin therapy (ie, at or preceding diagnosis).",0,0,0,0
PMC4212563,"We next performed a series of stratified analyses to determine whether HbA1c trajectories differed by gender, race, or diagnosis era after controlling for the age of diagnosis.",0,0,0,0
PMC4212563,"In these analyses, intraparticipant HbA1c trajectories were calculated and compared across diagnostic age subgroups within each stratum for gender, race, and diagnosis era using the statistical methods described above.",0,0,0,0
PMC4212563,Formal interaction tests were conducted for each of these factors with age at diagnosis.,0,0,0,0
PMC4212563,"Finally, the association between age at diagnosis and HbA1c trajectories was examined within strata based on the first HbA1c level after the initiation of insulin therapy (<7%, 7–9%, or >9% (<53, 53–75, or >75 mmol/mol), respectively), to account for differences in initial glycemic control.",0,0,0,0
PMC4212563,"Analyses were performed using SAS, V.9.3 (SAS Institute, Cary, North Carolina, USA).",0,0,0,0
PMC5336805,MethodsPatients and definitionsThe study was a cross-sectional study.,0,0,0,0
PMC5336805,The study participants were consecutive patients on warfarin therapy for more than 3 months who presented to the outpatient department of cardiology at Kocaeli Derince Training and Research Hospital.,0,1,0,0
PMC5336805,Patients who had AF or MHV or both were included in the study.,0,1,0,0
PMC5336805,Patients who had ACS or underwent percutaneous coronary intervention (PCI) or a revascularization procedure involving the peripheral arteries in the preceding year were excluded.,0,1,0,0
PMC5336805,"Because the vast majority of patients attend their routine follow-up once a month, a data collection time of 3 months was considered adequate for a single-center study.",0,0,0,1
PMC5336805,"Medical history, concomitant diseases, and treatment data were obtained through patient interviews or from hospital records.",0,0,0,0
PMC5336805,Major bleeding was defined as intracranial bleeding or any bleeding requiring transfusion under warfarin therapy.,1,0,0,0
PMC5336805,Other types of bleeding under warfarin therapy were classified as minor bleeding.,1,0,0,0
PMC5336805,Cerebrovascular accident (CVA) was defined as transient or permanent neurologic deficit of thromboembolic etiology.,1,0,0,0
PMC5336805,Coronary artery disease (CAD) was defined as documented history of myocardial infarction or the presence of more than 50% diameter stenosis of a coronary artery on coronary angiography.,1,0,0,0
PMC5336805,"Peripheral artery disease (PAD) was defined as angiographically or noninvasively (with ultrasound, computed tomography, magnetic resonance imaging) documented critical stenosis in the carotid, renal, or upper or lower extremity arteries.",1,0,0,0
PMC5336805,Vascular disease was defined as disease of either the coronary or peripheral arteries.,1,0,0,0
PMC5336805,Blood samples for international normalized ratio (INR) were drawn as a part of routine control.,0,0,0,0
PMC5336805,"Therapeutic INR ranges were 2.0-3.0 for patients with AF and aortic valve replacement (AVR) and 2.5-3.5 for patients with mitral valve replacement (MVR) and AVR plus AF, as described by the guidelines (6-10).",0,0,0,0
PMC5336805,Echocardiography was performed for patients without recent assessment.,0,0,0,0
PMC5336805,Left ventricular (LV) systolic dysfunction was accepted as an ejection fraction less than 40%.,0,0,0,0
PMC5336805,"CHADS-VASc [Congestive heart failure, Hypertension, Age>75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65-74 years, Sex category (female)] and HAS-BLED [Hypertension, Abnormal liver/kidney function (1 point each), Stroke, Bleeding history, Labile INR, Elderly (>65 years), Drugs/alcohol (1 point each)] scores were calculated at the time of the interview.",0,0,0,0
PMC5336805,"Although the HAS-BLED score was described for AF, it was also used in MHV replacement to estimate bleeding risk (11).",0,0,0,0
PMC5336805,"This study was approved by the local Ethics Committee (Clinical Research Ethics Committee of the Faculty of Medicine of Kocaeli University, number: KOÜ KAEK 2013/20).",0,0,0,0
PMC5336805,Patients who did not give written informed consent were not included in the study.,0,1,0,0
PMC5336805,Statistical analysisContinuous variables were presented as means ± standard deviations and compared using the student t-test.,0,0,0,0
PMC5336805,INR values and duration of warfarin therapy did not show normal distribution and were presented as median (25-75 percentiles) and compared using the Mann-Whitney U test.,0,0,0,0
PMC5336805,Categorical variables were presented as numbers (percentages) and compared using the chi square or Fisher’s exact test.,0,0,0,0
PMC5336805,A two-sided p value of <0.05 was considered statistically significant.,0,0,0,0
PMC5336805,Logistic regression analysis (LRA) was performed to determine independent correlates of bleeding episodes and warfarin–aspirin combination.,0,0,0,0
PMC5336805,"A stepwise model with backward selection method was used, and p values of <0.050 and of >0.100 were selected for inclusion to and exclusion from the next step, respectively.",0,0,0,0
PMC5336805,Results were tabulated as odds ratio (OR) and 95% confidence intervals (CI).,0,0,0,0
PMC5336805,"Statistical Package for the Social Sciences (SPSS for Windows, Version 11.0, SPSS Inc., Chicago, IL, USA) was used for the statistical analysis.",0,0,0,0
PMC3335898,"METHODSIn this prospective case-control study, we recruited 642 type 2 diabetic patients presenting at two outpatient clinics of the Akhavan Hospital in Kashan, Iran: 173 with a diagnosis of opium abuse (cases) and 469 without this diagnosis (controls).",0,0,0,0
PMC3335898,We obtained clinical and demographic information about all participants through a detailed questionnaire.,0,0,0,0
PMC3335898,"Opium use status was ascertained by self report; however, because of variation in opium quality and difficulty in uniform measurement across all study patients, the quantity of opium intake was not estimated.",0,0,0,0
PMC3335898,"However, all opium abusers reported having regularly used opium for at least 12 months prior to admission (as indicated by the question, ""Has the client continued to use opium despite recurrent problems aggravated by the substance use within the last 12-month period?"") [15].",1,0,0,0
PMC3335898,Data on the frequency and duration of opium intake was missing or incomplete in some cases.,0,0,0,0
PMC3335898,"Depressive symptomalogy and severity were assessed through administration of the Beck Depression Inventory (BDI) [16], and patients scoring over 16 were considered to be depressed.",1,0,0,0
PMC3335898,"A corresponding diagnosis was made based on the Diagnostic and Statistical Manual of Mental Disorders-IV, Text Revision, 2000 (DSM-IV TR) criteria [17].",1,0,0,0
PMC3335898,"To distinguish opium-induced major depressive disorder (MDD) from independent MDD, patients with a history of depression before beginning opium use, such as those who had used antidepressants or been hospitalized due to depression, were excluded.",0,1,0,0
PMC3335898,Patients were considered to have hypertension if they were currently using antihypertensive medications or if they had blood pressure readings above 140/90 mm,1,0,0,0
PMC3335898,Hg on two different occasions.,1,0,0,0
PMC3335898,Hypercholesterolemia was defined as having one or more serum cholesterol level readings above 6.2 mmol/L (240 mg/dL) [18].,1,0,0,0
PMC3335898,"Blood glucose control was assessed by measuring HbA1c levels, and values above 7% were considered uncontrolled [19].",1,0,0,1
PMC3335898,"The study protocol was approved by the ethics committee of Kashan University of Medical Sciences (Kashan, Iran).",0,0,0,0
PMC3335898,Informed consent was obtained from the patients before enrollment.,0,0,0,0
PMC3335898,"Statistical analysisIn a case-control study, cases and controls ideally match on all characteristics except the variable of interest.",0,0,0,0
PMC3335898,"In order to consider the confounding effects of unmatched characteristics, we treated them as covariates in a multiple logistic regression analysis.",0,0,0,0
PMC3335898,"Variables with P values less than 0.2 for differences between the two groups were considered to be covariates: these included age, marital status, literacy, hypertension, and hyperlipidemia.",0,0,0,0
PMC3335898,Results were reported as mean±standard deviation for quantitative variables and percentages for categorical variables.,0,0,0,0
PMC3335898,The groups were compared using the Student's t-test for continuous variables and the chi-square test (or Fisher's exact test as appropriate) for categorical variables.,0,0,0,0
PMC3335898,Odds ratios (OR) and 95% confidence intervals (CI) for OR were calculated.,0,0,0,0
PMC3335898,"To decrease the effects of probable confounders, adjusted ORs were estimated when appropriate.",0,0,0,0
PMC3335898,Results for which P values were 0.05 or less were considered statistically significant.,0,0,0,0
PMC3335898,"All the statistical analyses were performed using SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA).",0,0,0,0
PMC6612327,MethodsThis multicenter observational study focused on LH identification at insulin self-injection sites in a large series of dialyzed DM patients.,0,0,0,0
PMC6612327,"The dialysis units (DUs) contributing to the study as the Nefrocenter Research Network (Campania Region, Southern Italy) followed standardized procedures within the frame of a shared care pathway and used the same software for data recording.",0,0,0,0
PMC6612327,Enrolment CriteriaAll DM outpatients over 17 years old on multiple daily insulin (MDI) regimen for at least 1 year referred to our DUs were consecutively enrolled.,0,1,0,0
PMC6612327,"Exclusion CriteriaExclusion criteria were neoplastic diseases, advanced liver disease, and steroid treatment.",0,1,0,0
PMC6612327,"Study ProtocolThe protocol was designed according to the Helsinki declaration and approved by the Ethics Committee of Vanvitelli University, Naples, Italy (Trial registration number 126-11.01.2019).",0,0,0,0
PMC6612327,All patients provided informed consent to personal data utilization for research purposes and completed a validated questionnaire-based interview with the help of specifically trained nurses [20–23] by also indicating all sites used for insulin injection.,0,0,0,0
PMC6612327,"After that, medical investigators checked those sites for the presence of skin lesions according to a structured protocol and, in order to ensure subsequent analysis under strictly anonymous conditions, filled in a web-based clinical record form (eCRF) identifying patients by a unique ID key and uploading to a database matching clinical data with questionnaire answers.",0,0,0,0
PMC6612327,"Recorded parameters were demographics; diabetes duration; daily insulin shot number and dose; ice-cold insulin utilization; pen/syringe injection use; needle features (length/gauge) and reuse rate; size, rotation rate and relative distance of injection sites; glycemic variability and eventually occurring injection into LH lesions; unexplained hypoglycemic events as previously described [20].",0,0,0,0
PMC6612327,"Specific Details
HYPO was defined according to American Diabetes Association (ADA) statements [3], i.e., the occurrence of one or more symptoms of hypoglycemia (including palpitations, tiredness, sweating, hunger, dizziness, and tremor) and a confirmed blood glucose (BG) reading ≤ 70 mg/dL.",1,0,0,0
PMC6612327,"Frequent unexplained hypoglycemia was defined as having HYPO at least once a week in the absence of any identified precipitating event including changes in insulin dosage, diet composition, or amount of physical activity.",1,0,0,0
PMC6612327,"HYPOs were further defined as severe (SH; BG < 50 mg/dL) and non-severe (NSH; 50 > BG < 70 mg/dL) [23–26].GV was investigated by a validated questionnaire already used in previous studies [11, 27, 28] and, as a result of the lack of universally accepted criteria, was defined as unpredictable and unexplained shifts from < 60 mg/dL to > 250 mg/dL occurring one or more times on the same day or on different days within 1 week during the previous month [11, 27, 28].",1,0,0,0
PMC6612327,"Since a large glycemic variability is typically observed between days on and off dialysis, the average of the widest glycemic variations occurring on three dialysis days and three dialysis-free days within 1 week was considered.",0,0,0,0
PMC6612327,"The evaluation–validation of HYPOs and GV was based on the analysis of patients’ self-monitored blood glucose (SMBG) recordings using a twice-a-day “staggered” protocol as previously described [12], and, according to a specific pre-study training, of any additional glucose checks performed in case of sudden HYPO symptoms.",0,0,0,0
PMC6612327,"This highly flexible method was chosen as it is strongly supported by specialists owing to its easier and immediate interpretation and it is easily accepted by patients, thus ensuring the strictest possible adherence to given instructions [29].LipohypertrophyTwo trained physicians for each dialysis unit separately identified LH at all sites utilized by insulin-treated patients and, in case of any discrepancy, did it again until final agreement.",0,0,0,0
PMC6612327,"The LH identification procedure referred to a structured observation and palpation method [30, 31] taking into account further suggestions derived from previously published experience [32].",0,0,0,0
PMC6612327,"Briefly, the method consisted of the inspection of each area of interest through direct and tangential light against a dark background and of careful palpation implying slow circular and vertical, progressively deeper finger tip movements followed by repeated horizontal attempts on the same spot.",0,0,0,0
PMC6612327,In the present study only LH lesions were considered.,0,0,0,0
PMC6612327,Statistical AnalysisPredictors of LH were identified by sequentially examining data with SPSS version 20.,0,0,0,0
PMC6612327,A p value less than 0.05 was considered as statistically significant.,0,0,0,0
PMC6612327,"Contingency tables showed no low expected counts (< 5 for 20% of cells) for categorical variables, confirming Pearson’s chi-square test as reliable.",0,0,0,0
PMC6612327,Mann–Whitney U test and Pearson chi-square test were first performed to assess whether or not variables under investigation displayed any different mean levels/percentage distribution in patients with LH (LH+) as compared to those without LH (LH−).,0,0,0,0
PMC6612327,Then all variables were entered into unadjusted odds ratio analysis according to univariate binary logistic regression function and significant ones were then removed one at a time from subsequent stepwise backward multivariate logistic regression analysis as suited to no longer significant elements.,0,0,0,0
PMC6612327,"After calibration and discrimination ability assessment by Hosmer–Lemeshow goodness of fit test (HLGOF) and receiver operating characteristic (ROC) analysis, respectively, adjusted odds ratios were reported as estimated in the refitted final model.",0,0,0,0
PMC3675672,"2Method2.1SubjectsTwenty stable subjects with MR, identified from the echocardiography laboratory of Imperial College Healthcare NHS Trust, underwent transthoracic echocardiography.",0,1,0,0
PMC3675672,"Inclusion criteria were the presence of mild, moderate or severe MR as judged by a conventional clinical echocardiogram and a recognisable PISA in the 4-chamber apical view.",0,1,0,0
PMC3675672,"Patients were excluded if they had moderate or severe disease of tricuspid or pulmonary valves (3 patients), any aortic valve disease graded mild or higher, a prosthetic aortic valve (2) or atrial fibrillation (4).",0,1,0,0
PMC3675672,The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee and written informed consent was obtained.2.2EchocardiographyEchocardiographic data were acquired with the patient in the left lateral decubitus position using a Philips iE33 echocardiography system.,0,0,0,0
PMC3675672,"Continuous wave (CW) Doppler, colour Doppler and colour M-mode images were acquired with simultaneous ECG, and stored digitally.",0,0,0,1
PMC3675672,"Images were acquired in the apical view, using a 30°colour Doppler sector.",0,0,0,1
PMC3675672,CW Doppler velocity across the mitral valve was acquired co-axially with the regurgitant jet; the peak velocity was then measured.,0,0,0,1
PMC3675672,"2.3Proximal isovelocity surface area methodCurrently, conventional PISA is the recommended method for MR quantification [1].",0,0,0,1
PMC3675672,The PISA method is based on the continuity principle that flow converges toward the regurgitant orifice approximately symmetrically from all directions (at least near the orifice).,0,0,0,0
PMC3675672,"Progressively closer to the orifice, blood must accelerate because the surface area of the notional hemisphere through which it passes becomes progressively smaller, while flow rate (in ml/min), equalling velocity × area, is conserved because blood is incompressible.",0,0,0,0
PMC3675672,"The downwards aliasing velocity is typically chosen for Vr (velocity at distance r from the orifice), because it can be read directly from the colour bar on the scanner.",0,0,0,0
PMC3675672,The radius r is the distance from the orifice to the onset of aliasing.,1,0,0,0
PMC3675672,Velocity at the orifice (Vo) is determined separately by continuous wave Doppler.,0,0,0,0
PMC3675672,The orifice area (Ao) is then calculated (Fig. 1).,0,0,0,0
PMC3675672,The flow convergence region was visualized by colour Doppler velocity mapping.,0,0,0,0
PMC3675672,"The aliasing velocity was kept at 31.9 cm/s, suitable for PISA.",0,0,0,0
PMC3675672,Quadruplicate loops of 2 beats each were acquired (acquisition time = 5 s).,0,0,0,0
PMC3675672,"Three operators spent an average of 15 s measuring the radius for each conventional PISA EROA measurement, blinded to each others’ findings.",0,0,0,0
PMC3675672,"The operators were required to select the frame from which to take the measurements, as well as to choose the exact location of the orifice from where to measure r, and calculate EROA.",0,0,0,0
PMC3675672,The 4 EROAs took a total of ~ 80 s for acquisition and analysis.2.4AQURO methodIt is not essential to measure the radius of a shell to calculate EROA with the flow convergence concept.,0,0,0,0
PMC3675672,The flow convergence pattern contains valuable information that could help calculate the EROA.,0,0,0,0
PMC3675672,The rate of increase of velocity with distance can replace the separate measurement of velocity and distance.,0,0,0,0
PMC3675672,"Although this entails making more measurements, the whole method can be automated.",0,0,0,0
PMC3675672,"The origin of this method is a rewriting [12] of the conventional PISA mathematical equation so that, in the case of hemispheric isovelocity surfaces, the relationship between Vo/Vr and r is linear with a slope 2π/Ao, where Vo is the peak velocity at the regurgitant orifice (obtained from CW Doppler measurements), and Vr is the profile of velocity measurements obtained at distances r from the orifice.",0,0,0,0
PMC3675672,The EROA can be calculated directly from this slope (Fig. 2).,0,0,0,0
PMC3675672,"Just as for conventional PISA, the flow convergence region was imaged by colour Doppler flow mapping.",0,0,0,0
PMC3675672,The beam was positioned along the centreline of the regurgitant orifice.,0,0,0,0
PMC3675672,Flow velocities were acquired as colour M-Mode images.,0,0,0,0
PMC3675672,For each AQURO measurement we used an average of 20 s of data (to create a fair comparison with PISA).,0,0,0,0
PMC3675672,Typically this time was spent acquiring 10 still frames of 2–3 beats each.,0,0,0,0
PMC3675672,"Quadruplicate AQURO measurements (a total of 40 still frames per patient) were acquired with 55 cm/s aliasing velocity, which is the optimal velocity for AQURO analysis.",0,0,0,0
PMC3675672,Software then automatically calculated EROA beat-by-beat.,0,0,0,0
PMC3675672,The program first identifies regurgitant areas for each image (Fig. 3a).,0,0,0,0
PMC3675672,Because of the movement of the mitral valve though systole it then shears the image to allow averaging of flow velocities at equivalent distances across the sequential lines of the colour M-mode image (Fig. 3b).,0,0,0,0
PMC3675672,It then calculates the rate at which velocity declines with increasing distance from the orifice along each scan line.,0,0,0,0
PMC3675672,"The program converts colour pixel data to velocities using the colour scale bar, and then analyses all vertical scan lines of each beat.",0,0,0,0
PMC3675672,It plots Vo/Vr against r for series of time points (Fig. 3c).,0,0,0,0
PMC3675672,The analysis distance in the r direction is fixed at 1 cm (chosen after pilot data analysis).,0,0,0,0
PMC3675672,The shape of the relationship between Vo/Vr and r is expected to be linear near the valve.,0,0,0,0
PMC3675672,"The program calculates the slopes of scan lines where this relationship is linear, rejecting scan lines where linearity is poor because they most likely reflect noisy instants or instants at the very beginning or end of systole; the number of scan lines actually used per beat was 28 ± 15.",0,0,0,0
PMC3675672,"The software then calculates the average of the slopes of those lines, and hence the EROA, defined as 2π/slope2 (Fig. 3d).",0,0,1,0
PMC3675672,The entire process is repeated for each beat and for all 10 colour M-Mode images in a single AQURO measurement.,0,0,0,0
PMC3675672,The average of all these individual 2π/slope2 values is taken to be the single AQURO EROA from the 20 s of acquired data (typically 20–25 beats).2.5Statistical analysisThe intraclass correlation coefficient (ICC) was used to analyse the quadruplicate measurements (conventional PISA and AQURO).,0,0,0,0
PMC3675672,It quantifies whether measurements differ between patients because of true difference between patients or random measurement noise (Fig. 4).,0,0,0,0
PMC3675672,"The ICC value lies between 0 (all noise, no signal) and 1 (all signal, no noise).",0,0,0,0
PMC3675672,"We assessed agreement between replicate measurements for both the PISA and AQURO methods using Bland-Altman analysis [13] giving the mean difference and standard deviation of difference (SDD, a measurement of their disagreement).",0,0,0,0
PMC3675672,We chose to evaluate 3 replicate measures for each of the two methods.,0,0,0,0
PMC3675672,For PISA we therefore compared data from 1 pre-specified video loop from each observer.,0,0,0,0
PMC3675672,For AQURO we compared the EROA data from 3 separate pre-specified sets of data.,0,0,0,0
PMC3675672,"Interobserver variability for conventional PISA was tested, by 3 operators independently measuring the same video loops.",0,0,0,0
PMC5446380,MethodsData from the ELEMENT-1 and ELEMENT-2 studies were analyzed.,0,0,0,0
PMC5446380,Both trials were registered at Clinical Trials.gov (NCT01421147 and NCT01421459).,0,0,0,0
PMC5446380,"Detailed study methods and results for the primary endpoints for both studies have been previously described [5, 6].",0,0,0,0
PMC5446380,"Briefly, ELEMENT-1 was a 52-week (24-week treatment period plus 28-week extension period), open-label study of patients with T1D being treated with basal and bolus insulin [5].",0,0,0,0
PMC5446380,"ELEMENT-2 was a 24-week, double-blind study of patients with T2D who were insulin-naïve or previously treated with IGlar [6].",0,0,0,0
PMC5446380,"In both studies, patients were randomized to receive an LY IGlar or IGlar dose that was equivalent to their prestudy insulin dose except for patients with T2D who were insulin-naïve and started with 10 units of LY IGlar or IGlar.",0,0,0,0
PMC5446380,"The LY IGlar or IGlar dose was titrated on the basis of daily blood glucose levels [5, 6].",0,0,0,0
PMC5446380,"The primary efficacy outcome in both studies was to demonstrate the non-inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar as measured by change in HbA1c from baseline to 24 weeks [5, 6].",0,0,0,0
PMC5446380,"Both of these studies were done in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki [12], and written informed consent was obtained from all patients [5, 6].Antibody determination methods have been described in greater detail previously [5–7].",0,0,0,0
PMC5446380,"Briefly, samples used in this study for antibody determination were those collected before randomization (baseline) and at study endpoint.",0,0,0,0
PMC5446380,Insulin antibodies were quantified as percent binding using a classic radioimmunoassay format.,0,0,0,0
PMC5446380,"The anti-LY IGlar antibody assay has cross-reactivity to IGlar and human insulin; hence, antibodies to LY IGlar and IGlar were measured using the same assay [5–7].",0,0,0,0
PMC5446380,"Insulin antibody testing was conducted by Millipore (St. Charles, MO, USA).",0,0,0,0
PMC5446380,"In each study, patients in the upper quartile of maximum antibody percent binding (UQMAPB) were determined as follows: among all patients with postbaseline insulin antibodies, the maximum postbaseline insulin antibody level (percent binding) per patient was identified.",0,0,0,0
PMC5446380,Patients whose maximum postbaseline percent binding belonging to the highest 25% of the maximum values observed comprised the UQMAPB.,0,0,0,0
PMC5446380,Patients in the lower 75% and patients who did not have any detectable antibodies postbaseline comprised those patients not in the UQMAPB.,0,0,0,0
PMC5446380,Postbaseline maximum antibody percent binding (MAPB) levels and the proportions of patients who exhibited IARs in the UQMAPB with either treatment were evaluated to compare the IAR profiles of LY IGlar and IGlar.,0,0,0,0
PMC5446380,"Separate analyses for each study also compared LY IGlar to IGlar for clinical outcomes [changes in glycated hemoglobin (HbA1c) (%), basal insulin dose (U/kg/day), weight (kg), incidence of adverse events, and incidence of total hypoglycemia] among patients who did or did not exhibit IARs in the UQMAPB.",0,0,0,0
PMC5446380,The potential differential treatment effects of UQMAPB status on clinical and safety outcomes were also assessed by interaction tests.,0,0,0,0
PMC5446380,Hypoglycemia was defined in accordance with American Diabetes Association [13] and European Medicine Agency [14] guidelines as having a blood glucose no greater than 3.9 mmol/L (70 mg/dL) or signs or symptoms attributable to low blood glucose levels.,1,0,0,0
PMC5446380,"Analyses were also performed with hypoglycemia defined as having a blood glucose of less than 3.0 mmol/L (54 mg/dL), a cutoff that had been recommended in the past [15].Statistical AnalysisThe analysis population was comprised of all randomized patients who took at least one dose of study drug (full analysis set) and also had a baseline and at least one postbaseline insulin antibody level assessment.",1,1,0,0
PMC5446380,Fisher’s exact test was used to analyze binary data.,0,0,0,0
PMC5446380,"Relationships between UQMAPB status (UQMAPB or not UQMAPB) and continuous outcomes were analyzed by an analysis of covariance model with adjustments for design factors—with baseline HbA1c serving as a covariate; and country, time of basal insulin injection (daytime vs. evening/bedtime), sulfonylurea use (ELEMENT-2 only), treatment, UQMAPB status, and treatment-by-UQMAPB interaction as fixed effects.",0,0,0,0
PMC5446380,Relationships between UQMAPB status and categorical outcomes for adverse events were analyzed.,0,0,0,0
PMC5446380,The Cochran–Mantel–Haenszel test was used for between-treatment comparisons of odds ratios within UQMAPB status subgroups.,0,0,0,0
PMC5446380,The Breslow–Day test was used to assess the homogeneity of odds ratios for the interaction between treatment and UQMAPB status.,0,0,0,0
PMC5446380,"Data were analyzed using SAS version 9.1.3 (SAS Drug Development, Cary, NC, USA).",0,0,0,0
PMC4336407,"MethodsStudy populationThe study population was identified from a hospital electronic diabetes register which recorded clinical details of patients with T1D and T2D who attended clinics at the Northern General Hospital and Royal Hallamshire Hospital in Sheffield, UK.",0,0,0,0
PMC4336407,Clinical data were routinely entered into the database each time the patients were seen in these clinics.,0,0,0,0
PMC4336407,This diabetic population was referred by general practitioners predominantly to improve poor diabetes control and for optimization of risk factor management.,0,0,0,0
PMC4336407,Other reasons include those on hospital follow-up for chronic diabetes-related complications and newly diagnosed diabetes identified from hospital admissions.,0,0,0,0
PMC4336407,Definition of study populationYoung-onset T2D was defined as age of diagnosis below 40 years as stipulated in the National Institute for Health and Care Excellence (NICE) guideline.9,1,0,0,0
PMC4336407,"Since the youngest age of diagnosis for T2D was 15 years, the age of diabetes onset between 15 and 39 years was chosen to define this cohort.",0,1,0,0
PMC4336407,Patients with T1D with a similar age of diagnosis were used as a comparator.,0,1,0,0
PMC4336407,This is to minimize the bias associated with difference in the age of diabetes onset.,0,0,0,0
PMC4336407,"T2D was defined as those whose diabetes was controlled by oral hypoglycemic agents without the need for continuous insulin therapy within the first year of diagnosis and/or with negative autoantibody status (glutamic acid decarboxylase, islet cell antibody, and islet-antigen-2).",1,0,0,0
PMC4336407,T1D was defined by the absolute requirement for insulin therapy within 1 year of diagnosis and/or with positive autoantibody status.,1,0,0,0
PMC4336407,"Those with diabetes etiology due to maturity onset diabetes of the young, gestational diabetes and secondary diabetes were excluded.",0,1,0,0
PMC4336407,Data collectionThis was a cross-sectional study focused on the hospital diabetes population.,0,0,0,0
PMC4336407,Data were extracted from the diabetes register in 2009 as part of the service evaluation exercise.,0,0,0,0
PMC4336407,The most recent data obtained from the last clinic visit were used for analysis.,0,0,0,0
PMC4336407,Patients with incomplete data were excluded.,0,1,0,0
PMC4336407,"For each patient, complete data on clinical characteristics, laboratory tests (glycated hemoglobin (HbA1c), full lipid profile (total cholesterol, high-density lipoprotein (HDL), and triglyceride), and kidney function) and diabetes-related complications pertaining to microvascular disease (retinopathy and peripheral neuropathy) and cardiovascular disease (CVD; ischemic heart disease, peripheral vascular disease, and stroke) were collected.",1,0,0,0
PMC4336407,These medical conditions were entered into the database using the International Classification of Diseases 10 and Read codes.,0,0,0,0
PMC4336407,"At the time of data extraction, microalbuminuria was not routinely screened in patients with T2D; hence, these data were not included in the study analysis.",0,1,0,0
PMC4336407,"However, screening for other microvascular complications (retinopathy and neuropathy) was routinely performed in all patients.",0,0,0,1
PMC4336407,"Apart from age of onset, comparing the outcomes of T1D and T2D is often confounded by the differences in disease duration.",0,0,0,0
PMC4336407,"To minimize this bias and to assess the impact of diabetes duration, study subjects were stratified into three categories of diabetes duration, namely, <10, 10–20, and >20 years.",1,0,0,0
PMC4336407,Clinical characteristics and the diabetes complication burden were analyzed in each group.,0,0,0,0
PMC4336407,Retinopathy was detected from digital photography which was performed as part of the city-wide diabetes eye screening program.,0,0,0,0
PMC4336407,"Peripheral neuropathy was detected by clinical examination (monofilament test, vibration sense), nerve conduction test, or presence of sensory symptoms.",0,0,0,1
PMC4336407,"Ischemic heart disease was defined as myocardial infarction (ST and non-ST elevation), stable and unstable angina and/or coronary intervention.",1,0,0,0
PMC4336407,"Peripheral vascular disease was defined as a history of leg amputation for ischemia, peripheral revascularization, or ankle-brachial index <0.9.",1,0,0,0
PMC4336407,Stroke was defined as ischemic stroke proven on a CT scan or history of transient ischemic attack.,1,0,0,0
PMC4336407,Hypertension was defined as blood pressure >140/80 mm Hg or >130/80 mm,1,0,0,0
PMC4336407,Hg with diabetic complications or on antihypertensive treatment while dyslipidemia was defined as fasting triglyceride >1.7 mmol/L and/or HDL <1.03 mmol/L for male or <1.29 mmol/L for female or on specific treatment for this condition.,1,0,0,0
PMC4336407,"Overweight and obesity were defined by body mass index (BMI) greater than 25 kg/m2.Statistical analysisAll statistical analyses were performed using the Statistical Package for Social Science V.16.0 for Windows (SPSS Inc, Chicago, Illinois, USA).",1,0,0,1
PMC4336407,"Continuous data were expressed as mean±SD, while categorical data were expressed as percentage.",0,0,0,0
PMC4336407,The normality of continuous data distribution was assessed with the Kolmogorov-Smirnov test to determine the appropriate method for parametric or non-parametric statistical analysis.,0,0,0,0
PMC4336407,"Continuous data were analyzed by Student's t test or the Mann Whitney U test, while the χ2 test was used to compare categorical variables between two groups.",0,0,0,0
PMC4336407,The χ2 value for the trend was used to determine the significance of trends in frequency across different groups.,0,0,0,0
PMC4336407,"Logistic regression analysis was conducted to estimate the odds of diabetes complications associated with the type of diabetes (type 2 vs 1), controlled for variables found to be significant in the univariate analysis.",0,0,0,0
PMC4336407,"The independent variables used were age, sex, HbA1c, creatinine, diabetes duration, hypertension, dyslipidemia, and BMI>25 kg/m2.",0,0,0,0
PMC4336407,A p value of <0.05 was considered significant.,0,0,0,0
PMC5253194,MATERIALS AND METHODSParticipants and studied variablesThe study was conducted by the hypertension research center affiliated to Cardiovascular Research Institute (a WHO collaborating center in the EMR) from July to October 2014.,0,0,0,0
PMC5253194,"In order to find potential volunteers from community, we used a wide range of materials from flyers and brochures to posters.",0,0,0,0
PMC5253194,A total of 140 healthy participants volunteered to take part in this cross-sectional study.,0,0,0,0
PMC5253194,"Eligibility requirements included willingness to participate in the study, age 18 years and older, normal BP defined as systolic BP below 140 mmHg and diastolic BP below 90 mmHg based on 3 screening visits of 1 wk apart.",1,1,0,0
PMC5253194,"The exclusion criteria was history of hypertension; history of special diet including low salt diets; history of taking antihypertensive medications and diuretics for any reason, oral contraceptives and nonsteroidal anti-inflammatory drugs; any history of myocardial infarction, heart failure, cerebrovascular accidents and renal failure.",0,1,0,0
PMC5253194,Written informed consents were obtained from each participant and the study protocol was approved by the ethical committee of Cardiovascular Research Institute.,0,0,0,0
PMC5253194,"A questionnaire was used at the baseline observation by trained staff to collect information on demographic characteristics as well as family history of hypertension, coronary artery disease, and lifestyle habits including regular physical activity, dietary pattern and smoking status.",0,0,0,0
PMC5253194,The Hospital Anxiety and Depression Scale questionnaire was also used to determine the score of anxiety and depression.,1,0,0,0
PMC5253194,"This scale consists of seven items for anxiety and seven items for depression, with scores ranging from 0 to 21.",0,0,0,0
PMC5253194,The higher scores demonstrate more intensity in anxiety or depression level.,0,0,0,0
PMC5253194,"Scores higher than 7, in both domains indicate that participants are likely to be depressed or suffer from anxiety[22,23].",1,0,0,0
PMC5253194,"Anthropometric measurements of weight, height, waist and hip circumferences were obtained during baseline examination with the individual in minimal clothing.",0,0,0,1
PMC5253194,The WHO STEPS Surveillance Manual (The WHO STEP wise Approach to Chronic Disease Risk Factor Surveillance) was used for measuring waist and hip circumference[24].,0,0,0,1
PMC5253194,Body mass index (BMI) was calculated as weight (in kilograms) over height squared (in meters).,0,0,1,0
PMC5253194,"Venous blood samples after fasting for at least 8 h were taken for measurement of fasting blood sugar (FBS), serum blood urea nitrogen (BUN), creatinine (Cr), uric acid (UA), sodium (Na), potassium (K) levels, and lipid profile including low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and total cholesterol (TC).",0,0,0,1
PMC5253194,Plasma measurements were assessed using commercially available kits (Parsazmoun).,0,0,0,1
PMC5253194,BP was measured by trained staff for each participant using an automated mercury sphygmomanometer with the individual in sitting position and 5 min of rest.,0,0,0,1
PMC5253194,"All the participants were asked to avoid consumption of alcohol, tea, or coffee, physical exercise or smoking for at least one hour prior to admission.",0,0,0,1
PMC5253194,Mean arterial pressure (MAP) was calculated as [(2 × diastolic) + systolic]/3 and reported for each measurement.,0,0,1,0
PMC5253194,"We considered the following definitions for cardiovascular risk factors: Current smoking of at least one cigarette per day; lack of regular physical activity (less than 30 min a day, five days a week); raised blood glucose (FBS > 126 mg/dL); elevated blood cholesterol [TC > 200 mg/dL, TG > 150 mg/dL, LDL > 130 mg/dL, HDL below 40 mg/dL (male) and less than 50 mg/dL (female)]; and being overweight or obese (BMI > 25 kg/m2, waist circumference > 92 cm in males and > 88 cm in females)[25].",1,0,0,0
PMC5253194,Study designThe study was conducted in two days.,0,0,0,0
PMC5253194,"On the first day of the study, individuals were admitted at 8 AM and were put on a low calorie and low sodium diet (10 mmol/d).",0,0,0,0
PMC5253194,"At this time, venous blood samples were obtained, anthropometric measurements were calculated, and the questionnaires were filled out from participants by trained staff.",0,0,0,0
PMC5253194,"Two hours after the admission, three measurements of BP were obtained with five minutes intervals and the mean of them was recorded as the baseline BP.",0,0,0,1
PMC5253194,"After obtaining the baseline BP, 2 L of normal saline was administered intravenously over 4 h (500 mL/h).",0,0,0,1
PMC5253194,"Two hours after normal saline infusion, BP was obtained and post-saline MAP was calculated.",0,0,0,1
PMC5253194,Then participants were discharged and were asked to return back to the clinic the next morning.,0,0,0,0
PMC5253194,"To ensure compliance to the study protocol, individuals were required to eat pre-packaged foods that were prepared according to the protocol including low-carbohydrate, low-fat, and low-sodium diet (10 mmol/d) and were instructed to avoid any foods that were not provided by the study staff.",0,0,0,1
PMC5253194,Participants were also followed up over the night by telephone to evaluate any potential side effects and to ensure their adherence to the study dietary protocol.,0,0,0,0
PMC5253194,"On the following day, participants were admitted again at 8 AM and BPs were obtained.",0,0,0,0
PMC5253194,"Sodium and volume depletion was then induced by a low sodium diet (10 mmol/d) and administration of three doses of oral furosemide (40 mg each dose, at 10 AM, 2 PM and 6 PM).",0,0,0,0
PMC5253194,"Two hours after completion of the last dose of furosemide, BP was measured according to the study protocol.",0,0,0,0
PMC5253194,The MAP after sodium and volume depletion was compared with the post-saline MAP.Individuals who demonstrated a decrease in MAP ≥,1,0,0,0
PMC5253194,10 mmHg were defined as “salt sensitive”.,1,0,0,0
PMC5253194,Those with MAP decrease < 10 mmHg were categorized as “salt insensitive” including both the salt resistant (ΔMAP < 6 mmHg) and intermediate (ΔMAP 6-10 mmHg) with respect to sodium sensitivity.,1,0,0,0
PMC5253194,"Statistical analysisAll data were analyzed by SPSS, version 15 (SPSS Inc, Chicago, IL, United States).",0,0,0,0
PMC5253194,"Respectively, a P value ≤ 0.05 and P value ≤ 0.1 were considered as statistically and marginally significant for all analyses.",0,0,0,0
PMC5253194,Student’s t test for continuous variables and χ2 test for discrete variables were used.,0,0,0,0
PMC5253194,Man-Whitney test was applied where appropriate.,0,0,0,0
PMC5253194,"Multiple Logistic Regression model was carried out to examine the association between demographic, anthropometric, psychological characteristics and laboratory studies of those with the salt sensitivity.",0,0,0,0
PMC5253194,Odds ratios (ORs) were reported with the corresponding 95%CI.,0,0,0,0
PMC5253194,Repeated measure ANOVA was used for comparing the means of systolic BP in different times.,0,0,0,0
PMC5253194,The dependent variable was salt sensitivity.,0,0,0,0
PMC5253194,"Independent variables included demographic, anthropometric, psychosocial characteristics, laboratory studies, and cardiovascular risk factors of those adjusted based on age and sex.",0,0,0,0
PMC5253194,The statistical methods of the study were reviewed by biomedical statistician.,0,0,0,0
PMC6848580,MethodsStudy,0,0,0,0
PMC6848580,"PopulationsThis study used data collected from two population-based cross-sectional surveys: the Shanghai Survey of Eastern China, collected during June 2016 and December 2017; and the Västerbotten Intervention Program (VIP) (Västerbotten County, northern Sweden), collected from 2014 to 2017.",0,0,0,0
PMC6848580,The Shanghai Survey is a part of national population cohort study conducted in eastern China that aimed to establish a large-scale regional cohort database for NCDs.,0,0,0,0
PMC6848580,We adopted a multistage stratified clustered sampling method to recruit participants.,0,0,0,0
PMC6848580,"At stage one, four communities (Zhongshan, Xinqiao, Sheshan and Maogang) were selected on the basis of geographic region, economic status and willingness to participate.",0,1,0,0
PMC6848580,"At stage two, one-third of the committees/villages were randomly selected from each community.",0,0,0,0
PMC6848580,"At stage three, we selected adults aged 35–64 years who had lived in Shanghai for more than 5 years, with a final sample of 25,356 participants.",0,1,0,0
PMC6848580,"After exclusion of individuals who lacked data in any of the variables (5.1%, n = 1301), 24,055 individuals were used in the final analysis.",0,1,0,0
PMC6848580,The VIP is a long-term cardiovascular disease (CVD) prevention programme conducted in northern Sweden with the aim of reducing mortality from CVD and diabetes.,0,0,0,0
PMC6848580,The VIP is integrated into ordinary primary care routines.,0,0,0,0
PMC6848580,"All residents who turn 40, 50 or 60 years old in Västerbotten County are invited for a health examination at their primary health centre.",0,0,0,0
PMC6848580,"During 2014–2017, 25,511 participants were enrolled.",0,0,0,0
PMC6848580,"After the exclusion of individuals who lacked data in any of the variables (8.4%, n = 2134), 23,377 individuals were used in the final analyses.",0,1,0,0
PMC6848580,"Using the state-issued ‘unique person numbers’, Statistics Sweden linked the VIP data with the population register data on socioeconomic indicators.",0,0,0,0
PMC6848580,"The anonymous linked dataset is hosted by the Department of Epidemiology and Global Health, Umeå University in the Edwin database.",0,0,0,0
PMC6848580,"Ethical ApprovalThe Shanghai Survey protocol was approved by the ethical review committee of the School of Public Health, Fudan University (IRB approval number 2016-04-0586).",0,0,0,0
PMC6848580,"In Sweden, the use of the Edwin database for this research has been approved by the Regional Ethical Committee at Umeå University (EPN 14-06-05 (Dnr 2014 196-32 M)).",0,0,0,0
PMC6848580,Written informed consent was obtained from all study participants prior to the study.,0,0,0,0
PMC6848580,"Data CollectionQuestionnairesThe Shanghai Survey used an electronic standardized questionnaire that contained questions on demographics (sex, age, marital status, education level), health-related behaviours (smoking, drinking, physical activity), and family history of chronic diseases.",0,0,0,0
PMC6848580,"Individuals were categorised by age as 35–44, 45–54 or 55–64 years old.",1,0,0,0
PMC6848580,"Smoking status was “never smoked”, “ex-smoker” or “current smoker” based on responses to the questions “Have you ever smoked at least one cigarette every day for more than 6 months?” and “What is your current smoking status?”",1,0,0,0
PMC6848580,Alcohol consumption was determined on the basis of the response to the question “Have you consumed alcohol at least three times a week for more than 6 months?”,1,0,0,0
PMC6848580,"Physical activity was classified as “high”, “moderate” or “low” on the basis of responses to the International Physical Activity Questionnaire Short Form [13].",1,0,0,0
PMC6848580,"The VIP study used a standardized questionnaire that collected information on lifestyle behaviours such as smoking, drinking and physical activity, history of chronic diseases and use of medicines, and sociodemographic factors.",0,0,0,0
PMC6848580,"The VIP participants were categorised by age as 40, 50 or 60 years old.",0,0,0,1
PMC6848580,"Smoking status was “never smoked”, “ex-smoker” or “current smoker” based on responses to the question “Do you currently smoke?”",1,0,0,0
PMC6848580,We defined ex-smokers as those who had previously smoked daily/occasionally and current smokers as those who currently smoked intermittently or daily.,1,0,0,0
PMC6848580,Alcohol consumption levels were ascertained on the basis of participants’ responses to the question “How often do you drink alcohol?” and divided between “no” (for ‘never’ and ‘once a month or less’) and “yes” (at least twice a month).,0,0,0,1
PMC6848580,"Physical activity was classified as “high”, “moderate” or “low” on the basis of responses to questions regarding the work commute, recreational time and physical exercise, as previously described [14].",0,0,0,1
PMC6848580,"Both surveys classified marital status as “currently married” (married and cohabiting) or “currently unmarried” (unmarried, widowed or divorced).",0,0,0,1
PMC6848580,"Education level was categorised as “low” (completion of 9 years of compulsory education), “medium” (completion of 12 years of education) or “high” (graduation from a university).",0,0,0,1
PMC6848580,"A family history of chronic diseases was determined by asking whether any family member suffered from conditions such as cardiovascular diseases, diabetes mellitus or hypertension.",0,0,0,1
PMC6848580,Anthropometric MeasurementsHeight and weight were measured while participants were barefoot and wearing light clothing.,0,0,0,1
PMC6848580,Height was accurate to 0.1 cm and weight was accurate to 0.1 kg. BMI (kg/m2) was then calculated.,0,0,1,0
PMC6848580,The Shanghai Survey used the criteria proposed by the Working Group on Obesity in China (WGOC) [15] to define “overweight” as a BMI of 24–27.9 kg/m2 and “obese” as a BMI of 28 kg/m2 or more.,1,0,0,0
PMC6848580,The VIP survey used the World Health Organization (WHO) recommendations for categorising BMI as “overweight” (25.0–29.9 kg/m2) and “obese” (30 kg/m2 or more) [16].,1,0,0,0
PMC6848580,Blood Pressure MeasurementThe Shanghai Survey measured blood pressures using a digital sphygmomanometer on the right arm while the participant was seated having rested for 5 min.,0,0,0,1
PMC6848580,Three measurements were taken and the mean values were recorded.,0,0,0,1
PMC6848580,Hypertension was defined as a resting systolic blood pressure (SBP) of 140 mmHg or more and/or a diastolic blood pressure (DBP) of 90 mmHg or more.,1,0,0,0
PMC6848580,The VIP measured blood pressure using a manual sphygmomanometer on the right mid-arm at the level of the heart while the participant was seated.,0,0,0,1
PMC6848580,"Respondents were asked to rest for at least 5 min before two measurements were taken, and the average of those two measurements was recorded.",0,0,0,1
PMC6848580,The participants were also asked if they had used any blood pressure-lowering medications in the 14 days prior to being measured.,0,0,0,1
PMC6848580,"Hypertension was defined as a resting SBP of 140 mmHg or more and/or a DBP of 90 mmHg or more, and/or the use of medications for hypertension during the preceding 14 days.",1,0,0,0
PMC6848580,Blood Sampling and MeasurementsBlood samples were collected in the morning after an overnight fast.,0,0,0,1
PMC6848580,The Shanghai Survey stored samples at − 80 °C for no more than 6 h prior to them being transported to the Shanghai Dian Diagnostics Co. Ltd. for analysis.,0,0,0,0
PMC6848580,"Glycated haemoglobin (HbA1c) was measured using high pressure liquid chromatography (TOSOH G8, automatic haemoglobin A1c analyser).",0,0,0,1
PMC6848580,"The VIP survey determined fasting blood glucose (FPG) and 2-h plasma glucose (2hPG) measured in a 75-g oral glucose tolerance test from capillary plasma samples using a Reflotron benchtop analyser (Boehringer Mannheim GmbH, Mannheim, Germany).",0,0,0,1
PMC6848580,The Shanghai Survey determined serum total cholesterol (TC) using enzyme colorimetry (Roche COBAS C501 automatic biochemical analyser) and defined hypercholesterolaemia as total serum cholesterol of 6.2 mmol/L or more [17].,1,0,0,0
PMC6848580,The VIP used a Reflotron benchtop analyser (Roche Diagnostics) and defined hypercholesterolaemia using the same threshold (serum cholesterol of 6.2 mmol/L or more) and/or the use of a lipid-lowering medication during the preceding 14 days.,1,0,0,0
PMC6848580,Main OutcomeThe main outcome measurement was the presence of prediabetes or T2DM.,0,0,0,0
PMC6848580,T2DM was defined on the basis of a combination of a self-reported questionnaire (“Have you been diagnosed by a healthcare professional as having T2DM?”) and blood measurement (HbA1c as a diagnostic tool in the Shanghai Survey; FPG and 2hPG as the diagnostic tools in the VIP).,1,0,0,0
PMC6848580,Participants with T2DM were then classified as having a diagnosis of T2DM from a doctor or as having undiagnosed T2DM if they had no diagnosis from a doctor but an abnormal blood test.,1,0,0,0
PMC6848580,The Shanghai Study used an HbA1c cut-off value from the American Diabetes Association (ADA) [18] and the WHO criteria [19].,1,0,0,0
PMC6848580,"The VIP only used the WHO criteria, because only capillary blood samples were available.",1,0,0,0
PMC6848580,"Prediabetes was defined as the absence of T2DM, but the presence of an abnormal blood measurement based on the ADA and WHO criteria.",1,0,0,0
PMC6848580,Table S1 in the supplementary material summarises the diagnostic criteria used in the Shanghai and VIP surveys.,0,0,0,0
PMC6848580,Statistical AnalysisThe descriptive statistics of categorical variables were presented as frequency and percentage.,0,0,0,0
PMC6848580,"To enable a comparison between the two populations, we calculated the age- and education-adjusted prevalence of prediabetes and T2DM.",0,0,1,0
PMC6848580,"Multinomial logistic regression models with enter selection method were used to examine any association between sociodemographic, lifestyle and biological factors and the prevalence of prediabetes or T2DM, by sex, for the Chinese and Swedish populations.",0,0,0,0
PMC6848580,"The dependent variable was categorised into three groups of ‘normal blood glucose’ (as per the reference category), ‘prediabetes’ and ‘T2DM’.",0,0,0,0
PMC6848580,The associations between the independent variables and prediabetes and T2DM were presented using adjusted odds ratios (OR) and 95% confidence intervals (CI).,0,0,0,0
PMC6848580,"Following the logistic regression analysis, we conducted post-estimation analyses to estimate the predicted probabilities of T2DM in different age groups for individuals with different levels of BMIs (as a continuous scale).",0,0,0,0
PMC6848580,All the analyses were stratified by sex.,0,0,0,0
PMC6848580,"Data analyses were performed using Stata Version 15.1 (StataCorp, College Station, Texas, USA).",0,0,0,0
PMC6848580,Statistical significance was set at p < 0.05 for the two-sided test.,0,0,0,0
PMC6280270,"MethodsWe included 358 patients who underwent elective CTO PCI between January 2012 and August 2017 (179 patients via the radial approach and 179 patients via the femoral approach) in the Department of Cardiology, Bezmialem Vakıf University.",0,0,0,0
PMC6280270,This study had a retrospective design as the included cases were collected from our CTO database.,0,0,0,0
PMC6280270,"We matched patients with similar lesion characteristics: if we included a LAD CTO for the femoral arm, we searched for a radial case with similar or equal lesion characteristics.",0,0,0,0
PMC6280270,"According to this screening method, cross-over cases were not considered for our study from the beginning.",0,0,0,0
PMC6280270,"Multiple experienced operators were involved in this study, and most of the coronary procedures were done through the radial approach (>90%).",0,0,0,0
PMC6280270,Every patient’s intervention was conducted by an experienced operator who had at least 3 years of experience using the radial approach.,0,0,0,0
PMC6280270,Operators generally used the right radial artery for intervention and the left radial artery for bilateral injection (90%).,0,0,0,0
PMC6280270,"Similarly, in the femoral group, operators most often used the right femoral artery for intervention and the left femoral artery for bilateral injection (91%).",0,0,0,0
PMC6280270,CTO was defined as thrombolysis in myocardial infarction (TIMI) grade 0 flow with an estimated duration of occlusion of >3 months.,1,0,0,0
PMC6280270,Indications for revascularization were angina or equivalent and/or evidence of myocardial ischemia.,1,0,0,0
PMC6280270,"Patients were anticoagulated with unfractionated heparin with an initial bolus of 70-100 U/kg, with subsequent boluses targeted to an activated clotting time of >300s throughout the intervention.",0,0,0,1
PMC6280270,There was no restriction with respect to the lesion or occlusion length.,0,0,0,0
PMC6280270,Postdilatation was mandatory to ensure optimal stent expansion and strut apposition.,0,0,0,0
PMC6280270,Dual antiplatelet therapy with acetylsalicylic acid 100 mg per day and clopidogrel 75 mg per day or ticagrelor 90 mg twice daily was prescribed for at least 12 months.,0,0,0,0
PMC6280270,Every patient signed an informed consent for the procedure and subsequent anonymous follow-up data analysis for clinical research purposes.,0,0,0,0
PMC6280270,Patient selectionPatients from 18 to 80 years with one or more CTOs presenting with angina symptoms or equivalent and/or reversible ischemia were included.,0,1,0,0
PMC6280270,"The main exclusion criteria were MI within 30 days in the territory of the target CTO or within 3 days in another territory, renal failure with serum creatinine level >3 mg/dL, other comorbid conditions with life expectancy <2 years, contraindications to aspirin or clopidogrel therapy, and women with child bearing potential.",0,1,0,0
PMC6280270,"Angiographic success was defined as a visual estimated residual in-stent diameter stenosis <30%, with TIMI flow grade 3 without occlusion of a significant side branch, flow limiting dissection, distal embolization, or angiographic evidence of thrombus.",1,0,0,0
PMC6280270,"Procedural success was defined as the composite endpoint of angiographic success without associated in-hospital major clinical complications [e.g., death, MI, stroke, coronary perforation with tamponade, bleeding requiring transfusion emergency coronary artery bypass graft surgery (CABG)].",1,0,0,0
PMC6280270,"Periprocedural MI was defined as an elevation of cardiac biomarkers (creatine kinase-myocardial band ×5 times the upper limits of normal, Troponin ×5 times the upper limit of normal).",1,0,0,0
PMC6280270,"Clinical endpoint parametersClinical endpoints that were analyzed included the composite of all-cause death, cardiac death, and major adverse cardiovascular and cerebrovascular events (MACCEs) including nonfatal target vessel MI, coronary perforation, contrast-induced nephropathy (CIN), bleeding at the vascular access site requiring transfusion, cardiac tamponade requiring pericardiocentesis, and stroke as a result of the procedure.",0,0,0,0
PMC6280270,"Follow-up MI was diagnosed based on the rise of cardiac troponins above the 99th percentile upper reference limit with at least one of the following observations: symptoms of ischemia; changes in electrocardiogram, i.e., new or presumed new significant ST-T changes or new left bundle branch block or development of pathological Q-waves; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; or identification of an intracoronary thrombus by angiography.",1,0,0,0
PMC6280270,Statistical analysisAll continuous variables were tested for normality using Kolmogorov-Smirnov test.,0,0,0,0
PMC6280270,"Data are presented as percentages, mean±standard deviation (SD), or median (interquartile range).",0,0,0,0
PMC6280270,Chi-square analysis was used for comparing categorical variables between the groups.,0,0,0,0
PMC6280270,Differences in continuous variables were tested with a student t-test or Mann-Whitney U test for parametric and nonmetric variables respectively.,0,0,0,0
PMC6280270,"Statistical analysis was performed using SPSS version 2.0 (SPPS Inc., Chicago, IL, USA).",0,0,0,0
PMC6531521,"MethodsSubjectsThe SPIRITS-J study was conducted as an investigator-initiated, multicenter, cohort study at Juntendo University Hospital, its associated hospitals, and primary care clinics.",0,0,0,0
PMC6531521,"At first, the SPIRITS-J study was planned to evaluate the efficacy and safety of 6-month sitagliptin add-on therapy in Japanese patients with type 2 diabetes treated by diet and exercise, oral hypoglycemic agents (OHAs), and/or insulin therapy.",0,0,0,0
PMC6531521,Details of participants in this study were described previously [23].,0,0,0,0
PMC6531521,"After the following 6-month intervention period with sitagliptin, the extended cohort study was planned to investigate the long-term clinical outcomes including all-cause mortality and microvascular and macrovascular complications prospectively until September 30, 2015.",0,0,0,0
PMC6531521,The pharmacological approach including continuation of sitagliptin was left to the attending physician’s discretion during the follow-up period.,0,0,0,0
PMC6531521,"We excluded patients with a history of diabetic ketoacidosis or hyperosmolar non-ketonic coma within 6 months, serious infections, renal dysfunction (serum creatinine ≥ 13.26 μmol/dL), and pregnant or breast-feeding women.",0,1,0,0
PMC6531521,The ethics committees of the participating hospitals approved the study protocol and informed consent was obtained from each subject.,0,0,0,0
PMC6531521,"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.",0,0,0,0
PMC6531521,This study was registered as the clinical trial UMIN 000004121.,0,0,0,0
PMC6531521,The name of the institutional review board that approved this study is the Juntendo Clinical Research and Trial Center at Juntendo University Hospital.,0,0,0,0
PMC6531521,"Data Collection and Biochemical TestsBaseline demographic data were collected for all patients enrolled in this study including age, sex, body mass index (BMI), diabetes duration, diabetes-related complications, medical history, systolic and diastolic blood pressure, lipid profile, random blood glucose, glycated hemoglobin (HbA1c), serum creatinine, ingredient of medication for dyslipidemia, hypertension, diabetes, and other related diseases.",0,0,0,0
PMC6531521,Blood test results were obtained from the medical records.,0,0,0,0
PMC6531521,Glucose and HbA1c were measured with standard techniques.,0,0,0,0
PMC6531521,The value of HbA1c (%) was estimated as the National Glycohemoglobin Standardization Program (NGSP) equivalent value (%) calculated by the formula HbA1c (%) = [HbA1c (Japan Diabetes Society) (%) + 0.4%] [24].,0,0,1,0
PMC6531521,The estimated glomerular filtration rate (eGFR) was calculated by the following formula: eGFR (mL/min/1.73 m2) = 194 × Age − 0.287 ×,0,0,1,0
PMC6531521,Serum creatinine − 0.1094 (× 0.739 for women) [25].,0,0,1,0
PMC6531521,"The clinical characteristics data including body weight, blood sample data, and ingredient of medication were collected during the follow-up period at 1 year (12 ± 3 months), 2 year (24 ± 3 months), and 3 year (36 ± 3 months) visits which were scheduled according to routine clinical practice.",0,0,0,0
PMC6531521,"Clinical Outcomes and AssessmentsThe primary clinical outcome was a composite of myocardial infarction (MI), stroke, and all-cause mortality.",1,0,0,0
PMC6531521,"Secondary clinical outcomes were new-onset or progression of microvascular complications including retinopathy, nephropathy, and neuropathy, atrial fibrillation, revascularizations (coronary artery bypass surgery, percutaneous coronary interventions, peripheral artery angioplasty, and carotid artery stenting), peripheral artery disease, heart failure requiring admission, and hypoglycemia.",1,0,0,0
PMC6531521,"To diagnose acute MI, transient elevation of biochemical markers based on myocardial necrosis was needed in addition to symptoms or electrocardiographic findings which suggested the existence of myocardial ischemia [26].",0,0,0,0
PMC6531521,"Stroke was defined as confirmation of abnormal findings by computed tomography, magnetic resonance imaging, or autopsy and consisted of focal or global neurological deficits.",1,0,0,0
PMC6531521,Stroke events were classified according to World Health Organization (WHO) criteria [27].,1,0,0,0
PMC6531521,No cases of asymptomatic lesions detected by brain imaging were included.,0,1,0,0
PMC6531521,Only first-ever cardiovascular events during the observational period were counted in the analysis.,0,1,0,0
PMC6531521,Information about clinical outcomes was collected through an annual report from each physician.,0,0,0,1
PMC6531521,The cause of death conformed to the certificate of death.,0,0,0,0
PMC6531521,Adjudication of all clinical outcomes was performed by central committees composed of experts in each complication.,0,0,0,0
PMC6531521,"New-onset or progression of microvascular complication was defined as follows: retinopathy was progression from absence of retinopathy to non-proliferative retinopathy or proliferative retinopathy, progression from non-proliferative retinopathy to proliferative retinopathy, or loss of vision caused by retinopathy.",1,0,0,0
PMC6531521,"Nephropathy was progression from normoalbuminuria to macroalbuminuria, or progression from microalbuminuria to macroalbuminuria, increase in serum creatinine concentration by at least twice the study baseline, or end-stage renal failure.",1,0,0,0
PMC6531521,Neuropathy was peripheral nerve disorder independent from spinal canal stenosis or neurological diseases.,1,0,0,0
PMC6531521,Severe hypoglycemia is defined as having low blood glucose level that requires assistance from another person to treat.,1,0,0,0
PMC6531521,All adverse events were collected by the attending physicians at every patient visit.,0,0,0,1
PMC6531521,We assessed the predictive value of clinical risk factors for primary clinical outcomes.,0,0,0,0
PMC6531521,Statistical AnalysisResults are expressed as mean ± standard deviation (SD) or percentage.,0,0,0,0
PMC6531521,Differences between baseline data and any observation points were examined for statistical significance using the Student’s t test.,0,0,0,0
PMC6531521,"Categorical variables were compared using a Chi-square test, and presented as absolute frequencies with percentages.",0,0,0,0
PMC6531521,"For the primary event incidence, each participant contributed person-time from the observation start date until date of non-fatal MI, non-fatal stroke, and all-cause death, or end of follow-up, whichever occurred first.",0,0,0,0
PMC6531521,"For mortality, person-time was accumulated until date of death from any cause or end of follow-up.",0,0,0,0
PMC6531521,Hazard ratios (HRs) and 95% confidential intervals (CIs) were estimated by Cox proportional hazards modeling.,0,0,0,0
PMC6531521,"In multivariable-adjusted analyses, we adjusted for age, sex, history of coronary artery disease, hypertension (yes/no), cigarette smoking (never, current), LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, HbA1c, BMI, eGFR, history of retinopathy, or neuropathy, or nephropathy, and hypoglycemia.",0,0,0,0
PMC6531521,"All analyses were performed using SAS ver. 9.2 (SAS Institute Inc., Cary, NC, USA).",0,0,0,0
PMC5779136,MethodsStudy populationWe retrospectively evaluated 412 patients who underwent 24 hour HM due to complaints of palpitation in our hospital between August 2012 and February 2013.,0,1,0,0
PMC5779136,"To exclude possible coronary artery disease (CAD), we did not evaluate and include the patients with complaints of chest pain and dyspnea.",0,1,0,0
PMC5779136,Patients with positive noninvasive stress tests were also not done.,0,0,0,0
PMC5779136,"Among the evaluated 412 patients, 62 patients with missing ECGs, 26 patients with ischemic cardiomyopathy, 18 patients with bundle branch block, 11 patients with moderate to severe valvular disease, 8 patients with nonischemic cardiomyopathy, 4 patients with pacemaker activity, and 1 patient with hypertrophic cardiomyopathy were excluded from study.",0,1,0,0
PMC5779136,"Finally, 282 patients were included in the study.",0,0,0,0
PMC5779136,"Firstly, the patients were divided into 2 groups with respect to the presence of fQRS, and then, patients were divided into 3 groups with respect to frequency of PVCs, with groups 1, 2, and 3 representing seldom PVCs (<120 PVCs/day), moderate-frequency PVCs (120-720 PVCs/day), and frequent PVCs (>720 PVCs/day), respectively (18).",1,0,0,0
PMC5779136,Patients’ medical history and baseline characteristics were extracted from the medical recordings.,0,0,0,0
PMC5779136,"Hypertension (HTN), diabetes mellitus (DM), smoking, and family history of coronary artery disease (CAD) were noted.",0,0,0,0
PMC5779136,Body mass index (BMI) was calculated by using the standard formula [weight (kilogram)/square of height (meter)].,0,0,1,0
PMC5779136,"Baseline laboratory findings, including fasting plasma glucose (FPG), creatinine, potassium, hemoglobin (Hgb), leukocytes, thyroid-stimulating hormone (TSH), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and total cholesterol levels, were noted from the laboratory recordings obtained prior to HM.",0,0,0,0
PMC5779136,Glomerular filtration rate (eGFR) was measured using the standard Cockcroft-Gault formula.,0,0,0,1
PMC5779136,"Echocardiographic recordings (all of them were done with a Vivid 7, General Electric Vingmed, Horten, Norway) were evaluated, and ejection fraction (EF) (by Simpson method), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), interventricular septum (IVS) thickness in diastole, posterior wall (PW) thickness in diastole, and left atrium (LA) diameter in apical for chamber dimensions were noted.",0,0,0,0
PMC5779136,All echocardiographies in our institution were performed according to previous guidelines of the American Society of Echocardiography (19).,0,0,0,1
PMC5779136,ElectrocardiographyA 12-lead surface ECG was obtained from all patients before connecting the Holter device to the patient.,0,0,0,0
PMC5779136,"The 12-lead ECGs (Nihon-KohdenCardiofax ECG1350K, Tokyo, Japan, filter range 0.5",0,0,0,0
PMC5779136,"Hz to 150 Hz, AC filter 60 Hz, 25 mm/s, 10 mm/mV) were analyzed by 2 independent cardiologists who were blinded to the Holter data.",0,0,0,0
PMC5779136,"fQRS was defined as the presence of different RSR’ patterns (QRS duration <120 ms), which included an additional R wave (R’ prime) or notching of the R wave or S wave, or the presence of more than one R’ prime without typical bundle branch block in two contiguous leads corresponding to a major coronary artery territory (12-14).",1,0,0,0
PMC5779136,"ECGs were evaluated with the naked eye by two cardiologists, who were blinded to the Holter results for the presence of fQRS without using any magnification.",0,0,0,1
PMC5779136,The inter-observer concordance rate for determining fQRS was 98.5% between the two readers.,0,0,0,0
PMC5779136,"In cases of disagreement, the final decision was made mutually.",0,0,0,0
PMC5779136,"Holter monitoring and interpretationHolter devices (Universal resting 12-lead Holter dms 300-4A, mtm multitechmed gmbh, Schwarzwaldstrasse, Germany) were applied to the patient by our clinic's nurse; the patient came back after 24 hours, and the nurse took off the device and uploaded the recordings to the Holter archive.",0,0,0,0
PMC5779136,"Two independent cardiologists evaluated the recordings for PVCs, and the number of PVCs was recorded.",0,0,0,0
PMC5779136,"Statistical analysisAll statistical studies were carried out with the SPSS program (version 15.0, SPSS, Chicago, İllinois, USA).",0,0,0,0
PMC5779136,"Quantitative variables were expressed as the mean value±SD, and qualitative variables were expressed as percentages (%).",0,0,0,0
PMC5779136,All measurements were evaluated with the Kolmogorov-Smirnov test.,0,0,0,0
PMC5779136,"A comparison between two groups, according to the presence of fQRS, was performed using the student t-test.",0,0,0,0
PMC5779136,"A comparison between three groups, according to the number of PVCs, was performed using one-way ANOVA and Tukey test for post-hoc analysis.",0,0,0,0
PMC5779136,Categorical variables were compared by the likelihood ratio χ2 test or Fisher's exact test.,0,0,0,0
PMC5779136,"Multinomial logistic regression analysis, which included variables with p<0.1, was performed to identify independent predictors of PVC frequency.",0,0,0,0
PMC5779136,"Age ≥65, increased left atrium diameter (≥35 mm), increased interventricular septum diameter (≥11 mm), male gender, DM, HT, family history, beta-blocker usage, and presence of fQRS were entered into the model.",1,0,0,0
PMC5779136,A p value <0.05 was considered statistically significant.,0,0,0,0
PMC4627540,"Materials and MethodsParticipantsA total of 1,183 pregnant women with no previous diabetes were enrolled in the study during December 2010 through July 2011 at the Japanese Red Cross Medical Center.",0,1,0,0
PMC4627540,"Exclusion criteria included: a fasting blood glucose >126 mg/dL, glycated hemoglobin (HbA1c) >6.5%, a blood glucose measurement of >200 mg/dL 2-h after an OGTT.",0,1,0,0
PMC4627540,The present study was carried out in accordance with the Declaration of Helsinki.,0,0,0,0
PMC4627540,Informed consent was obtained from all participants.,0,0,0,0
PMC4627540,GCT and OGTTStandard 1-h 50-g GCTs were carried out between weeks 20 and 28 of gestation.,0,0,0,1
PMC4627540,Participants with a 1-h blood glucose >130 mg/dL were considered GCT(+) in this cohort.,1,0,0,0
PMC4627540,"The blood glucose threshold of 130 mg/dL, instead of 140 mg/dL set by the Japan Assessment of GDM Screening Trial Group, was used for this cohort because of the relatively older age (average 34 years) of the participants.",1,0,0,0
PMC4627540,Informed consent was obtained at 16–20 weeks of gestation.,0,0,0,0
PMC4627540,The GCT(+) women also underwent a 10–12-h fasting 75-g OGTT.,0,0,0,0
PMC4627540,"Venous blood samples were drawn at 0, 0.5, 1 and 2 h for biochemical analyses.",0,0,0,0
PMC4627540,"As specified by the International Association of Diabetes and Pregnancy Study Groups1 and the American Diabetes Association criteria10 for GDM diagnostic threshold, GDM was defined as a plasma glucose concentration equal or higher than one of the three following measurements at screening: baseline 92 mg/dL, 1-h post OGTT 180 mg/dL and 2-h post OGTT 153 mg/dL.Biochemical AnalysesHeight and weight were routinely recorded, and body mass index was calculated to estimate overall adiposity.",1,0,0,0
PMC4627540,Blood samples collected for the GCT and OGTT were centrifuged at 800 g for 6 min.,0,0,0,1
PMC4627540,Specimens were aliquoted and stored at −80°C before being assayed.,0,0,0,1
PMC4627540,"Glucose was quantified using a glucose oxidase kit with a GA 1170 auto-analyzer (ARKRAY Inc., Kyoto, Japan).",0,0,0,1
PMC4627540,"Total cholesterol (TC), TG, HDL-C and LDL-C were quantified using enzymatic colorimetric methods according to manufacturers' protocols (Cholestest CHO; Sekisui Medical Co. Ltd., Tokyo, Japan).",0,0,0,0
PMC4627540,"Insulin and ApoB-48 were measured by using a chemiluminescent enzyme-immunoassay system (Lumipulse Presto-II, Lumipulse ƒ system, respectively; Fujirebio Inc., Tokyo, Japan)11, and ApoA-I, ApoB and ApoC-III were determined by turbidometric immunoassay kits according to the manufacturer's recommendations (Sekisui Medical Inc., Tokyo, Japan).",0,0,0,1
PMC4627540,The C-reactive protein (CRP) was measured using the Nanopia CRP kit provided by Sekisui Medical Co. Ltd.,0,0,0,1
PMC4627540,The various lipid and lipoprotein concentrations were measured in fasting samples.,0,0,0,1
PMC4627540,"Insulin sensitivity as a measure of basal insulin sensitivity during an OGTT was estimated using the homeostasis model assessment of insulin resistance, calculated as (fasting glucose [mg/dL]) × (fasting insulin [μU/mL]) / 40512.",0,0,1,1
PMC4627540,"The early insulin response during an OGTT was estimated as the insulinogenic index: (Δinsulin [30–0 min]/Δglucose [30–0 min])13.Statistical AnalysisIn the univariate analyses, t-tests with unequal variances were used to examine different means between the two groups compared.",0,0,1,0
PMC4627540,All statistical tests were two-sided.,0,0,0,0
PMC4627540,P-values < 0.05 were considered statistically significant.,0,0,0,0
PMC4627540,"For the multivariate analysis, logistic regression analyses were carried out between the data for GDM(+) and GDM(−).",0,0,0,0
PMC4627540,The dependent variable was denoted as ‘1’ for GDM(+) and ‘0’ for GDM(−).,0,0,0,0
PMC4627540,Significant factors from the univariate analyses with a large enough sample size were used for multivariate analyses.,0,0,0,0
PMC4627540,"For the model selection, we used Akaike's Information Criteria14.",0,0,0,0
PMC4627540,"The statistical procedures were carried out using open source free software of Statistical Language R (University of Auckland, Auckland, New Zealand)15.",0,0,0,0
PMC4627540,"All the data are presented as mean ± standard error (SE), unless otherwise indicated.",0,0,0,0
PMC4627540,The statistical analysis was extended to define receiver operating characteristic curves for the lipid markers asking their predictive value.,0,0,0,0
PMC4627540,"We examined the receiver operating characteristic curves for the seven lipid markers, respectively.",0,0,0,0
PMC4627540,"Then, we calculated the area under the curve for the receiver operating characteristic of each lipid marker.",0,0,0,0
PMC5497286,2Materials and methods2.1Study populationData of 15 SSc patients who underwent skin tissue biopsy were available for analysis.,0,0,0,0
PMC5497286,They were divided into PH (n = 6) and non-PH groups (n = 9) according to the estimated pulmonary arterial pressure measured by ultrasound echocardiography (UCG).,0,0,0,1
PMC5497286,PH was defined as tricuspid valve regurgitation pressure gradient (TRPG) of more than 40 mm Hg.,1,0,0,0
PMC5497286,"The echocardiographic findings of all study participants using Aplio XG (Toshiba, Tokyo, Japan) ultrasound systems were evaluated by two independent investigators who were blinded to the clinical data.",0,0,0,1
PMC5497286,The clinical and laboratory data reported in this study were obtained at the time of skin sampling.,0,0,0,0
PMC5497286,"The study protocol was approved by the Human Ethics Review Committee of Kumamoto University and a signed consent form was obtained from each subject.2.2miRNA isolation, PCR array and real-time PCRThe miRNA was isolated from human skin tissue using the miRNeasy FFPE kit (Qiagen, Hilden, Germany).",0,0,0,0
PMC5497286,"For PCR array, the miRNAs were reverse transcribed into first-strand cDNA using an RT2 miRNA First-Strand Kit (Qiagen).",0,0,0,1
PMC5497286,"The cDNA was mixed with QuantiTast SYBR Green PCR Master Mix, and the mixture was added into 384-well RT2 miRNA PCR Array that included primer pairs for 1066 human miRNAs (Qiagen).",0,0,0,1
PMC5497286,"For real-time PCR, the primers and templates were mixed with SYBR Advantage Quantitative PCR Premix (Clontech, Mountain View, CA).",0,0,0,1
PMC5497286,"The DNA was amplified for 40 cycles of denaturation for 5 s at 95 °C and annealing for 20 s at 60 °C on C1000 Thermal Cycler (CFX384, Bio-Rad Laboratories, Hercules, CA).",0,0,0,1
PMC5497286,The transcript levels were normalized to those of U6 in the same sample.2.3Statistical analysisData of two groups were compared for statistical significance by the Student t test.,0,0,0,1
PMC5497286,Correlations were assessed by Pearson's correlation coefficient.,0,0,0,0
PMC5497286,A p value of < 0.05 denoted the presence of a statistically significant difference.,0,0,0,0
PMC3178704,"METHODSParticipantsThirty (15 male and 15 female) overweight, but otherwise healthy adolescents (as determined by their annual school physical examination), were recruited from the same grade (mean age of 13.10 years) in a middle school in Seoul, South Korea.",0,0,0,0
PMC3178704,Identifying an individual as being overweight (body mass index [BMI] >85th percentile) was assessed by using age- and gender-specific BMI reference charts for Korean children and adolescents between 2 to 19 years of age [26].,1,0,0,0
PMC3178704,Two of the enrolled female students had a BMI between the 85th and 75th percentile but were included in this study because there were only 13 girls that had met the criteria for being overweight in the school at the time of the screening procedure.,0,1,0,0
PMC3178704,"These two female students were separated and assigned in to the diet only group and the resistance exercise group, respectively.",0,0,0,0
PMC3178704,This study was approved by an Institutional Ethics Review Board at the Boramae Medical Center.,0,0,0,0
PMC3178704,Informed written consents were obtained from the parents of the enrolled children and assent from the children were also obtained.,0,0,0,0
PMC3178704,Participants were excluded if they were taking medication or were smokers.,0,1,0,0
PMC3178704,"Participants who had been diagnosed with a condition that is known to influence body composition or insulin/glucose metabolism, had an orthopedic condition that would limit their ability to perform exercise, or had participated in a structured exercise, nutrition, or weight loss program in the past six months, were also excluded.",0,1,0,0
PMC3178704,"Study protocolThe participants were first divided by sex, and were then randomly assigned to one of the three treatment groups with random number table, which were the diet only (DO), diet with aerobic exercise (AE), and diet with resistance training (RT) group.",0,0,0,0
PMC3178704,"Anthropometric variables (body weight, height and waist circumference), fasting glucose, insulin and 75 g oral glucose tolerance test (OGTT) values were measured prior to and after the 12 weeks of exercise training and diet protocol.",0,0,0,0
PMC3178704,Body weight was measured on a balance scale calibrated to 0.1 kg. Barefoot standing height was measured to the nearest 0.1 cm using a wall-mounted stadiometer.,0,0,0,1
PMC3178704,The same investigator measured waist circumference before and after the study with a Gullick II measuring tape.,0,0,0,1
PMC3178704,"Waist circumference was measured, during expiration, at the narrowest point between the lower rib and the iliac crest.",0,0,0,1
PMC3178704,BMI was calculated as weight in kilograms divided by the square of the height in meters.,0,0,1,0
PMC3178704,Measurements were carried out one week before and after the exercise program.,0,0,0,0
PMC3178704,"Percent body fat and total body muscle mass were measured by using an Inbody 4.0 bioelectrical impedance meter (Biospace Co., Seoul, Korea).",0,0,0,1
PMC3178704,"Visceral, thigh and intramuscular fat areas were measured by computed tomography (CT) with a Somatom Sensation 16 (Siemens Medical Solutions, Forchheim, Germany).",0,0,0,1
PMC3178704,The CT measurement protocol for fat area was similar to that used in a study by Poehlman et al. [15].,0,0,0,1
PMC3178704,Total thigh fat area (TTFA) and intramuscular fat area (IMFA) were measured using a method that has been reported by Goodpaster et al. [27].,0,0,0,1
PMC3178704,The abdominal bioelectrical impedance analysis (BIA) method [28] was also used to evaluate the visceral fat accumulation in each subject.,0,0,0,1
PMC3178704,The insulin sensitivity index was obtained by using the results of the OGTT and Stumvoll's equations [29].Dietary protocolEach study participant received an individualized dietary education program that was provided by a professional nutritionist twice a week throughout the 12 weeks of the study.,0,0,0,1
PMC3178704,"The detailed program is described in Table 1. All three of the groups (DO, AE, and RT) participated in the dietary education program.",0,0,0,0
PMC3178704,"The basic guidelines of the dietary education program were calorie restriction to avoid obesity (at least >1,200 kcal per day to prevent malnutrition), limiting dietary fat intake to improve blood lipid profiles, having low-salt intake to improve hypertension, eating three regular meals a day (breakfast, lunch and dinner) and avoiding snacks as much as possible.",0,0,0,1
PMC3178704,Participants were asked to write daily dietary records and these were reviewed weekly by the nutritionist.,0,0,0,0
PMC3178704,Exercise protocolThe 12-week exercise training program was fully supervised by a trained exercise physiologist from the Department of Physical Education in the College of Education at the Seoul National University.,0,0,0,0
PMC3178704,"In addition to the dietary energy restriction, ten participants in the AE group performed aerobic exercise three days a week.",0,0,0,0
PMC3178704,The students in the AE group were also told to perform gymnastics every day throughout the second and third month of the program.,0,0,0,0
PMC3178704,"Modes of aerobic exercise consisted of jumping rope, walking or running on a treadmill and stationary cycling.",0,0,0,0
PMC3178704,The daily training duration was 40 minutes which included a 5 minute warm-up and a cool down period with stretching.,0,0,0,0
PMC3178704,"The training intensity progressed from 60% to 70% of the maximal oxygen consumption (60%, 1st month; 65%, 2nd month; 70%, 3rd month).",0,0,0,0
PMC3178704,Maximal oxygen consumption was determined during a ramp treadmill test.,0,0,0,1
PMC3178704,"The training volume of each session progressed from 300 to 400 kcal/session (300 kcal, 1st month; 350 kcal, 2nd month; 400 kcal, 3rd month) [30].",0,0,0,1
PMC3178704,Another 10 participants in the RT group performed resistance training three days a week in addition to their dietary energy restriction.,0,0,0,1
PMC3178704,"Training sessions began with a 15 minute warm-up period of jogging, gymnastics, and stretching (5 minutes for each type of exercise).",0,0,0,1
PMC3178704,One repetition maximum (1RM) is defined as the maximum amount of resistance that can be moved through the full range of motion of an exercise for no more than one repetition.,1,0,0,0
PMC3178704,The 1RM was calculated by using the formula derived by Kuramoto and Payne [31] and resistance training was performed at approximately 60% of 1RM.,0,0,1,0
PMC3178704,"The resistance training program consisted of one set of each of the following ten exercises: squats, leg extension, lying leg curls, military press, leg press, lateral pulldowns, bench press, crunch, leg raise, and dead lift.",0,0,0,1
PMC3178704,These exercises provided a total body resistance training program for all of the major muscle groups of the body.,0,0,0,0
PMC3178704,Each subject was given a target load range and they were asked to attempt to keep each set (n=2 to 3) within the target range by adjusting the load to allow the prescribed number (n=10 to 12) of repetitions.,0,0,0,0
PMC3178704,"The curriculum was personalized to match the skill level of each of the participants and was progressive in nature, by increasing the number of sets, repetitions, and the amount of resistance used as the participant's technique and strength improved.",0,0,0,0
PMC3178704,Resting periods were 1 to 1.5 minutes between sets.,0,0,0,1
PMC3178704,"Each training session lasted approximately 60 minutes, which included a final 5 minute cooling down period of stretching.",0,0,0,1
PMC3178704,"Biochemical analysisA standard OGTT was performed in the overweight children by using 1.75 g/kg of a maximum flavored solution containing 75 g of glucose (Glu-Orange; Lotte Pharm, Seoul, Korea).",0,0,0,1
PMC3178704,"Samples were drawn at 0, 30, 60, 90, and 120 minutes after the OGTT and the levels of glucose and insulin were measured.",0,0,0,1
PMC3178704,"Serum insulin levels (µU/mL) were measured using an insulin immunoradiometric assay kit (Biosource Europe S.A., Nivelles, Belgium), which had a cross-reactivity with proinsulin of 0.3%.",0,0,0,1
PMC3178704,"The reported intra-assay variation was 1.6% to 6.2% and the interassay variation was 6.1% to 6.5%.Statistical analysisData were analyzed using the PASW Statistics version 18.0 for Windows (SPSS Inc., Chicago, IL, USA).",0,0,0,1
PMC3178704,Values are presented as mean±standard deviation.,0,0,0,0
PMC3178704,For all statistical analyses a P value of less than 0.05 (two-sided) was considered to be statistically significant.,0,0,0,0
PMC3178704,"The study was powered to detect up to a 25% differences in insulin sensitivity by using a conservative estimate of the standard deviation of the insulin sensitivity index, and using a power of 80%.",0,0,0,0
PMC3178704,Statistical significance was tested using the one-way ANOVA with Bonferroni correction in order to evaluate group differences at baseline.,0,0,0,0
PMC3178704,Changes in variables following the exercise program were compared with baseline values by using the repeated measures ANOVA for each of the three groups.,0,0,0,0
PMC3178704,One-way ANOVA with Bonferroni correction was applied to evaluate the main effects and interactions on all of the dependent variables in each of the three groups by time (prior to and after the 12-week program).,0,0,0,0
PMC3178704,Differences in the inter-group analysis were tested with the ANCOVA and the post-hoc analysis was performed by using the Tukey method for multiple comparison tests.,0,0,0,0
PMC3178704,"All values were adjusted for baseline age, sex, and BMI in the inter-group analysis.",0,0,0,0
PMC5630559,"MethodsStudy PopulationThis cross-sectional, observational study was conducted at a tertiary-level armed forces hospital between January 2015 and December 2016.",0,0,0,0
PMC5630559,All patients with a known diagnosis of CP (aged 18–70) of any duration undergoing follow-up at our hospital were included in the study.,0,1,0,0
PMC5630559,"We excluded patients with known systemic disorders (chronic liver disease, chronic kidney disease, thyroid disease) and long-term intake of drugs that could affect the body fat (glucocorticoids and thyroxine).",0,1,0,0
PMC5630559,We excluded patients with CP who had steatorrhea and signs of malabsorption.,0,1,0,0
PMC5630559,The patients were divided into two groups based on the etiology for the comparison: group 1 (alcoholic CP) and group 2 (tropical CP).,0,0,0,0
PMC5630559,"The local ethics committee approved the trial protocol and the study, being cross-sectional and observational in nature, precluded the registration with any known database from our country.",0,0,0,0
PMC5630559,"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.",0,0,0,0
PMC5630559,Informed consent was obtained from all patients for being included in the study.,0,0,0,0
PMC5630559,Study MeasuresA detailed history regarding the CP profile was obtained from all the participants.,0,0,0,0
PMC5630559,A general physical examination was conducted that include measurements which are relevant for the identification of abdominal obesity.,0,0,0,1
PMC5630559,Abdominal circumference (AC) was measured as the narrowest circumference between the lower costal margin and the iliac crest in centimeters.,0,0,0,1
PMC5630559,A fasting venous blood sample after an overnight fast for more than 12 h was collected from each participant at 0800 hours.,0,0,0,0
PMC5630559,The serum was analyzed for hematological and biochemical parameters.,0,0,0,0
PMC5630559,The intra- and interassay coefficient of variation for all the tests is less than 6% in our laboratory.,0,0,0,0
PMC5630559,Body fat percentage and visceral fat were determined in the fasting state at the same time of the day by both methods using BIA and DEXA sequentially.,0,0,0,1
PMC5630559,The subjects did not exercise or consume caffeine or alcohol prior to the measurement of body fat percentage.,0,0,0,1
PMC5630559,"BIA was performed using an Omron HBF-701 instrument (Omron Corporation, Shimogo-ku, Kyoto, Japan) and DEXA was performed using a Hologic QDR 2000 (Hologic ®, Bedford, MA 01730, USA).",0,0,0,1
PMC5630559,"The machine calculates the percentage fat, estimated VAT in grams, and other important body composition parameters [13].",0,0,0,0
PMC5630559,Study,0,0,0,0
PMC5630559,DefinitionsDiabetes and prediabetes were defined as per the American Diabetes Association (ADA) guidelines [14].,1,0,0,0
PMC5630559,Pancreatogenic diabetes was classically diagnosed as per the criteria proposed by Ewald and Bretzel [15].,1,0,0,0
PMC5630559,"However, we excluded patients with exocrine deficiency and patients with onset of diabetes prior to the diagnosis of CP.",0,1,0,0
PMC5630559,Hence the spectrum of diabetes evaluated in our study is a combination of T2DM and pancreatogenic diabetes.,0,0,0,0
PMC5630559,CP was diagnosed on the basis of clinical and imaging criteria [16].,1,0,0,0
PMC5630559,"Alcoholic CP was diagnosed in a patient with alcohol consumption of more than 14 units per week for 5 years prior to the onset of CP. Tropical CP (TCP) was diagnosed in patients with no identifiable cause along with normal radiological appearance of gall bladder and normal gamma-glutamyl transpeptidase (GGT).StatisticsData are presented as mean ± SD, and a comparison between the groups was done using nonparametric (Mann–Whitney U test) and Fisher’s exact tests.",1,0,0,0
PMC5630559,Spearman’s correlation test was used for correlation between numerical variables and a P value of less than 0.05 was considered significant.,0,0,0,0
PMC5630559,"The statistical analysis and graph generation were done using the Graph Pad Prism Software, Version 6 (Graph Pad Software, San Diego, CA, USA).",0,0,0,0
PMC4865392,"MethodsAs part of the EMPOWR protocol, a pilot study was conducted to develop, implement, and evaluate an education intervention for Hispanic women at risk for GDM within the existing CP model.",0,0,0,0
PMC4865392,"This study was approved by the University of Kentucky Institutional Review Board, and each patient signed an approved consent form to enter the program.",0,0,0,0
PMC4865392,"SettingParticipants receiving services at a university-affiliated, high-risk prenatal clinic directed by the university’s Department of Maternal-Fetal Medicine were included in the pilot study.",0,0,0,0
PMC4865392,"The prenatal clinic provides care for women who are pregnant with a condition that puts the mother, fetus, or both at a higher-than-normal risk for pregnancy-related complications.",0,0,0,0
PMC4865392,"Women who are likely to have a high-risk pregnancy include those who have preexisting diabetes or GDM and those who have had any complications such as preeclampsia, GDM, preterm labor, or early delivery in previous pregnancies.",0,0,0,0
PMC4865392,Four obstetricians/perinatologists who specialize in high-risk maternal-fetal medicine serve as providers for the clinic.,0,0,0,0
PMC4865392,An advanced-practice registered nurse who is also a certified nurse midwife provides prenatal care and is a trained facilitator for the CP program.,0,0,0,0
PMC4865392,The nurse is also certified as an oral interpreter and is fluent in English and Spanish.,0,0,0,0
PMC4865392,PopulationInclusion criteria included participants in the EMPOWR study who 1) were at <20 weeks’ gestation upon entry to the group (required for entry to the CP program); 2) gave informed consent to participate; 3) were of Hispanic descent; and 4) attended at least 5 of the 10 CP sessions.,0,1,0,0
PMC4865392,Forty-one women were eligible for inclusion in the pilot study.,0,0,0,0
PMC4865392,"Because GDM is typically diagnosed at 24–28 weeks’ gestation, the pilot study intervention targeted Hispanic women who were referred to the CP group as being high risk for GDM.All patients in the intervention group (n = 15) received basic education from a nurse educator about risk factors for GDM, general nutrition, and safe exercise based on current American College of Obstetricians and Gynecologists (ACOG) recommendations (11).",0,0,0,0
PMC4865392,Only the women in the group who were diagnosed with GDM received the full DSME curriculum with counseling provided by a registered dietitian (for medical nutrition therapy [MNT]) and by a nurse educator.,0,0,0,0
PMC4865392,"For women diagnosed with GDM, topics including nutrition, exercise, breastfeeding, labor and delivery, and postpartum care were discussed in more detail relative to GDM.",0,0,0,0
PMC4865392,Self-monitoring of blood glucose records were downloaded at each session and discussed.,0,0,0,0
PMC4865392,"The curriculum content for patients at risk for GDM and those diagnosed with GDM in the CP model aligned with the American Diabetes Association’s National Standards for Diabetes Self-Management Education and Support (Table 1) (9).TABLE 1.Curriculum Content Based on the American Diabetes Association’s National Standards for Diabetes Self-Management Education and Supporta: Patients at Risk for GDM or Diagnosed With GDM in the CP ModelSession Number (Gestational Week)CP CurriculumbAt Risk for GDM/With GDM Curriculumc1 (16)Introduction to centering, nutrition, weightDisease Process (GDM risk factors)Nutrition/Lifestyle (food diary, nutrition facts label, fast food/healthier choices)Physical Activity/Lifestyle (physical activity in pregnancy)2 (20)Body changes, common discomforts, HANDS3 (24)Relaxation, dental issues, breastfeedingMonitoring/Interpreting Blood Glucose(screening for GDM [1-hour, 50-g glucose load test])4 (28)Contraception, domestic violence, preterm laborNutrition/Lifestyle (MNT)Physical Activity/Lifestyle (effects on blood glucose)Monitoring Blood Glucose (SMBG)5 (30)Birth center tourMonitoring/Interpreting Blood Glucose (upload/review of SMBG records)6 (32)Labor and delivery, when to go to hospital, pain relief options, preeclampsiaReducing Risks (labor and delivery/GDM)Monitoring/Interpreting Blood Glucose (upload/review of SMBG records)7 (34)Infant care, car seat/crib safetyMonitoring/Interpreting Blood Glucose (upload/review of SMBG records)Monitoring/Interpreting Other Parameters (U/S and fetal weight)8 (36)Postpartum emotional adjustments, postpartum care, breastfeedingPersonal Strategies to Promote Health (breastfeeding after delivery, GDM)Personal Strategies to Promote Health (GDM with future pregnancies, type 2 diabetes risk)Monitoring/Interpreting Blood Glucose (upload/review of SMBG records)9 (38)Newborn safety, preparing for labor, stages of labor videoMonitoring/Interpreting Blood Glucose (upload/review of SMBG records)10 (40)Disease Process/Psychosocial Issues (GDM with future pregnancies, type 2 diabetes risk)Monitoring/Interpreting Blood Glucose (PP screening, upload/review of SMBG records)Using Medications/Prevention of Acute Complicationsd (prescribed drugs, hypoglycemia)aRef.",1,0,0,0
PMC4865392,"9, Standard #6.",0,0,0,0
PMC4865392,bAll patients enter the program before 20 weeks’ gestation.,0,0,0,0
PMC4865392,cItalicized topics are aligned with ADA curriculum.,0,0,0,0
PMC4865392,dUsing Medications/Prevention of Acute Complications may be used at any time point if medication therapy is a necessary part of treatment.,0,0,0,0
PMC4865392,"ADA, American Diabetes Association; HANDS, Health Access Nurturing Development Services; PP, postpartum; SMBG, self-monitoring of blood glucose; U/S, ultrasonography.",0,0,0,0
PMC4865392,The control group (n = 26) comprised Hispanic women at higher risk for GDM who entered the CP program during identical months of the previous calendar year.,0,0,0,0
PMC4865392,"High-risk women in the control group did not receive the basic education from the nurse educator about risk factors for GDM, general nutrition, and safe exercise.",0,0,0,0
PMC4865392,Women diagnosed with GDM in the control group were referred for GDM-related services and did not return to their respective CP groups.,0,0,0,0
PMC4865392,Hispanic women who were smokers were excluded from this evaluation because of the association between smoking and low birth weights (12).,0,1,0,0
PMC4865392,Smoking status was determined based on preset urine cotinine limits.,1,0,0,0
PMC4865392,A urine cotinine level of <99 ng/mL was used to classify women who did not smoke during pregnancy; women with cotinine levels ≥100 ng/mL were classified as smokers (13).,1,0,0,0
PMC4865392,One patient in the control group had a cotinine level >100 ng/mL and was excluded from this analysis; no women in the intervention group were confirmed as smokers.,0,1,0,0
PMC4865392,"Hispanic women in the program spoke Spanish as a primary language; therefore, an interpreter certified in oral interpretation was present during all patient-provider interactions, including DSME.Data CollectionData were collected at three time points: maternal demographic characteristics and history of GDM were collected at baseline (first prenatal visit); birth outcomes data were collected via retrospective chart review after delivery; and patient satisfaction data were collected from women who had completed at least five sessions by session 7, 8, or 9. Demographic data reported were age, BMI, married/partnered status, and history of GDM/macrosomia at baseline (first prenatal visit).",0,0,0,1
PMC4865392,"Outcomes MeasuresBirth outcomes, including neonatal birth weight, mode of delivery, and gestational age were collected for all study participants via retrospective chart review.",0,0,0,0
PMC4865392,Neonatal birth weight was reported in grams; mode of delivery was characterized as cesarean section versus spontaneous vaginal delivery; and gestational age was reported in weeks from estimated date of delivery.,0,0,0,0
PMC4865392,"A macrosomic neonate was defined as >4,000 g (14,15).Patient satisfaction rates were evaluated in the intervention group.",1,0,0,0
PMC4865392,"A satisfaction survey in which participants rated 12 discussion topics as either “not helpful,” “somewhat helpful,” “very helpful,” or “not discussed” was administered.",0,0,0,0
PMC4865392,"Four questions regarding the group setting dynamics and preparation for labor and delivery were assessed with possible ratings of “disagree,” “not sure,” and “agree.”",0,0,0,0
PMC4865392,"Finally, a measurement of overall experience with the CP group care setting was assessed using a 1–5 scale rating, with 1 being the worst and 5 being the best.",0,0,0,0
PMC4865392,Qualitative feedback was also solicited.,0,0,0,0
PMC4865392,Comments written in Spanish were translated by an interpreter certified in written interpretation.,0,0,0,0
PMC4865392,"For the EMPOWR protocol, study data were collected and managed using REDCap (Research Electronic Data Capture) tools hosted at the University of Kentucky (16).",0,0,0,0
PMC4865392,"REDCap is a secure, web-based application designed to support data capture for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.",1,0,0,0
PMC4865392,"Statistical AnalysisDescriptive statistics, including means and standard deviations (SDs) or frequency distributions, as appropriate, were used to summarize study variables.",0,0,0,0
PMC4865392,"For between-group comparisons (intervention vs. control), a two-sample t test analysis evaluated differences in maternal age, maternal BMI, maternal weeks of gestation at birth, and neonatal birth weight.",0,0,0,0
PMC4865392,"Because of the small sample sizes, a Fisher’s exact test was used to determine associations between group (intervention or control) and partnered status, history of GDM/macrosomia, and mode of delivery.",0,0,0,0
PMC4865392,Data were also analyzed for women with GDM and women without GDM within the intervention and control groups.,0,0,0,0
PMC4865392,Frequency distributions were used to summarize patient satisfaction.,0,0,0,0
PMC4865392,Significance was set at P <0.05 for all results.,0,0,0,0
PMC4865392,"SPSS version 22.0 (SPSS Corp., Chicago, Ill.) was used for analysis.",0,0,0,0
PMC5368488,"MethodsPatient populationThis study was undertaken in Radiology Department of Hacettepe University, Faculty of Medicine.",0,0,0,0
PMC5368488,Our study was approved by the local Ethics Committee and conducted in accordance with the Declaration of Helsinki.,0,0,0,0
PMC5368488,"Between December 2011 and February 2012, 200 consecutive patients were accepted into the study.",0,0,0,0
PMC5368488,Patients were randomly assigned to each group.,0,0,0,0
PMC5368488,The indication for CTA was suspected CAD.,1,0,0,0
PMC5368488,Patients’ clinical data and information were gathered prospectively.,0,0,0,0
PMC5368488,"Exclusion criteria for the study were a history of coronary artery bypass graft, coronary artery stent, cardiac pacemaker, known allergy to iodinated contrast agents, history of renal parenchymal disease or failure, arrhythmia, and pregnancy.",0,1,0,0
PMC5368488,Each group was divided into three subgroups by the patients’,0,0,0,0
PMC5368488,"HR (prospective triggering group ≤60, 61-67, ≥68 beats per minute [bpm] and retrospective gating group ≤71, 72-80, ≥81 bpm).",1,0,0,0
PMC5368488,Some patients HR exceeded 70 bpm in the prospective group during scanning.,0,0,0,0
PMC5368488,"Pre-scanning medicationIn patients with an HR above 70 bpm, IV 5 mg β-blocker (metoprolol) was applied 5 minutes before the prospectively ECG-triggered CTA.",0,0,0,1
PMC5368488,No β-blocker was applied before retrospectively ECG-gated CTA.,0,0,0,1
PMC5368488,"Prior to scanning, patients received one sublingual dose of nitroglycerin aerosol spray.",0,0,0,1
PMC5368488,"There was no contraindication to β-blockers (such as diabetes mellitus, heart failure) or to nitroglycerin aerosol spray (such as usage of vasodilators).",0,0,0,0
PMC5368488,"Also, there were no side effects/complications concerning the premedication procedure.",0,0,0,0
PMC5368488,"CT technique, scan protocol, and post-processing of the imagesAll coronary CTAs were performed with a first-generation DSCT scanner (SOMATOM Definition, Siemens Healthcare, Forchheim, Germany).",0,0,0,0
PMC5368488,"A pilot view of the thorax was obtained, and the scanning was performed from 2 cm below the level of the carina to the diaphragm, in a cranio-caudal direction.",0,0,0,1
PMC5368488,"ECG lines were placed in their standard positions, and this was followed by the placement of an 18-gauge needle in the antecubital vein.",0,0,0,1
PMC5368488,"Then, 80 mL non-ionic contrast agent (Ultravist 370 mg/mL; Bayer Schering Pharma, Berlin, Germany) at a flow rate of 5 mL/sec was administered intravenously and followed by a 50-mL saline flush at 5 mL/sec with an automatic injector (Ulrich, Germany).",0,0,0,1
PMC5368488,The volume of the contrast agent was regardless of the patient’s weight.,0,0,0,0
PMC5368488,"The bolus was tracked by using an automated bolus triggering technique in the ascending aorta (CARE Bolus; Siemens Healthcare, Forchheim, Germany).",0,0,0,1
PMC5368488,"The examination was automatically started 7 seconds after the triggering threshold (100 Hounsfield unit [HU]) was reached.CT images were acquired with a detector collimation of 2 × 32 × 0, 6 mm, and a gantry rotation time of 0.33 seconds.",0,0,0,1
PMC5368488,"Tube voltage was set at 100 kVp for patients who had a body mass index (BMI) <25 (only one patient’s BMI was <25, so we excluded the dose-length product [DLP] and attenuation values of this patient) and 120 kVp for ≥25 BMI.",0,1,0,0
PMC5368488,"In the prospective triggering group, the step-and-shoot method was used, as the x-ray tube was on only in 70% of the R-R interval (without padding).",0,0,0,0
PMC5368488,"In the retrospective gating group, the ECG tube current modulation technique was used, as the tube current (mA) was changed during the examination for each body part.",0,0,0,0
PMC5368488,"In 30%-80% of the R-R intervals, the maximum effective mA was set, and during the rest of the R-R interval, the mA was lowered to 20% of the effective dose.",0,0,0,0
PMC5368488,"For both groups, acquired images from raw data were reconstructed with a slice thickness of 0.75 mm with traditional filtered back projection and soft-tissue kernel (B26f).",0,0,0,0
PMC5368488,"Images were sent directly to the workstation for post-processing and evaluation (Leonardo, Siemens AG, Healthcare Sector, Forchheim, Germany).",0,0,0,0
PMC5368488,"In the retrospective gating group, the best reconstruction phase was selected and sent to the workstation.",0,0,0,0
PMC5368488,"The post-processing procedure included maximum intensity projection (MIP), multiplanar reformation (MPR), and volume rendering (VR).",0,0,0,1
PMC5368488,"Image analysis, evaluation method, and radiation dose assessmentImages were evaluated by two radiologists (double blinded) who had at least 8 years of experience in cardiac CTA.",0,0,0,0
PMC5368488,The observers had no information about the patients and the CTA algorithms.,0,0,0,0
PMC5368488,The image interpretation was performed 3 to 5 weeks after the coronary CTA.,0,0,0,1
PMC5368488,The segments that had a diameter of 1.0 mm or higher were interpreted according to the American Heart Association guidelines (15).,1,0,0,0
PMC5368488,The observers evaluated each coronary artery segment and rated scores for the quality of the images by using a 5-point Likert scale.,1,0,0,0
PMC5368488,"The Likert scale was defined as 1: poor image quality, poor vessel wall definition; 2: adequate, decreased image quality with poor vessel wall definition; 3: good vessel wall definition and image quality; 4: very good, good attenuation of vessel lumen and delineation of contours, coronary wall definition; and 5: excellent, excellent attenuation of the vessel lumen and clear delineation of the vessel walls and excellent image quality.",1,0,0,0
PMC5368488,"Additionally, the observers measured the attenuation values of the coronary artery segments.",0,0,0,1
PMC5368488,"The DLP values, which can be found on the CT scanner panel, were recorded for each examination in both groups.",0,0,0,0
PMC5368488,"The effective radiation dose (RD: in millisieverts; mSv) was calculated using the equation that is used traditionally (RD= DLP x k, k=0.017).Statistical analysisFor the statistical analysis, the Stata (v.9.0 Stata Corporation, Texas, USA) and SPSS (v.15.0 for Windows;",0,0,1,0
PMC5368488,"Chicago, IL, USA) statistical software programs were used.",0,0,0,0
PMC5368488,"Numerical quantitative data variables were summarized as mean, ± standard deviation, and median [maximum-minimum].",0,0,0,0
PMC5368488,Frequencies-percentages were used for categorical variables.,0,0,0,0
PMC5368488,The interobserver correlation between the two radiologists was evaluated with κ statistics (weighted kappa).,0,0,1,0
PMC5368488,"The correlation was classified as moderate (κ=0.41-0.60), good (κ=0.61-0.80), and very good (κ=0.81- 1.00).",1,0,0,0
PMC5368488,The image quality scores for each HR group were evaluated with the Kruskal-Wallis test.,0,0,0,0
PMC5368488,Pairwise comparisons were done by Bonferroni-adjusted Mann-Whitney U test.,0,0,0,0
PMC5368488,The numerical variable differences between the two groups (prospective triggering and retrospective gating) were calculated using t-test and Mann-Whitney U test.,0,0,0,0
PMC5368488,A value of p<0.05 was considered a statistically significant difference.,0,0,0,0
PMC6407671,Data analysisDiabetes mellitus is defined as having an FPG concentration of >7.0 mmol/L and/or a PG concentration of >11.1 mmol/L 2 hours after 75 g oral glucose load or the taking of current medication for diabetes.,1,0,0,0
PMC6407671,Prediabetes refers to IGT and impaired fasting glucose (IFG).,1,0,0,0
PMC6407671,IGT refers to 2-hour PG level of 140 mg/dL (7.8 mmol/L) but <200 mg/dL (11.1 mmol/L).,1,0,0,0
PMC6407671,"IFG refers to an FPG level of 110 mg/dL (6.1 mmol/L) but <126 mg/dL (7.0 mmol/L). (5) Definitions are as follows:
Central obesity in terms of abnormal waist: waist circumference ≥90 cm for males and ≥80 cm for females were defined as abnormal waist circumference.",1,0,0,0
PMC6407671,"17,18High triglycerides level: triglycerides ≥150 mg/dL (≥1.7 mmol/L), or the taking of treatment for this lipid abnormality16:Reduced high-density lipoprotein (HDL)-cholesterol: HDL-cholesterol <40 mg/dL (<1.03 mmol/L) for males and <50 mg/dL (<1.29 mmol/L) for females, or the taking of treatment for this lipid abnormality.",1,0,0,0
PMC6407671,"High BP: systolic BP ≥130 or diastolic BP ≥85 mmHg, or treatment of previously diagnosed hypertension.17,18Complex sampling designs (stratified sampling, cluster sampling, and unequal sampling weights) were controlled at every step of data analysis using “svy” (survey) commands in the statistical software Stata Version 13.0.",1,0,0,0
PMC6407671,The prevalence of diabetes and prediabetes was presented as percentages with a 95% CI for both sexes and four age groups.,0,0,0,0
PMC6407671,Multinomial logistic regression was carried out to determine the independent effect of each of the risk factors on diabetes and prediabetes.,0,0,0,0
PMC6407671,"Selection of the variables for inclusion as well as the modeling procedure was done according to the guidelines prescribed by David W. Hosmer and Stanley Lemeshow.6Initially, 13 variables (age, sex, urban–rural residence, household annual income, smoking rate, intake of alcohol, intake of fruit and vegetables, physical activity, central obesity, hypertension, total blood cholesterol, fasting triglycerides, and HDL) were included and modeled, using backward selection and a 0.05 significance level.",0,0,0,0
PMC6407671,"In the final model, only five variables (sex, age, urban–rural residence, central obesity, and high triglycerides) remained: the other eight variables were omitted due to their statistical insignificance and minor contribution to the model.",0,0,0,0
PMC6712222,"METHODSEthicsThe present study's protocol was approved by the Institutional Review Board of Samsung Medical Center (SMC) in Seoul, Republic of Korea and was performed according to the Declaration of Helsinki.",0,0,0,0
PMC6712222,"All participants were provided with written informed consent forms and signed them voluntarily (IRB File No. SMC 2012-08-074-002).Study designThis study was a single center, open-label, single-arm pilot trial without sample size calculation.",0,0,0,0
PMC6712222,"Glycemic indexes and fecal microbiota were analyzed before and after the administration of a commercially available dietary fiber supplement, AGIO (a mixture of 3.9 g of plantago seed and 0.13 g of ispaghula husk in one package; Bukwang Pharmaceutical Co. Ltd., Seoul, Korea) for 4 weeks.",0,0,0,1
PMC6712222,All participants were given three packages of the fiber supplement per day.,0,0,0,1
PMC6712222,"After 4 weeks of fiber supplement intake, participants stopped consumption for the next 4 weeks to evaluate restoration.",0,0,0,1
PMC6712222,They were asked to write in diet diaries three times a week to estimate dietary fiber intake from everyday meals.,0,0,0,0
PMC6712222,"Mixed-meal tolerance test (MMTT; consisting of 62% carbohydrate, 20% fat, and 18% protein) and fecal sampling were performed at each visit to compare the effects of fiber supplement consumption on incretin levels and microbiota, respectively (Fig. 1).Study outcomesThe primary outcome of this study was the effect of fiber supplement use on insulin secretion and insulin sensitivity.",0,0,0,1
PMC6712222,"Secondary outcomes were the changes of incretin levels (i.e., gastric inhibitory polypeptide [GIP], glucagon-like peptide-1 and -2 [GLP-1 and GLP-2], peptide YY [PYY]), systemic inflammatory status as represented by lipopolysaccharide (LPS) level, and microbiota composition.",0,0,0,0
PMC6712222,"Study populationThis study enrolled patients with T2DM who visited the Diabetes Center at SMC, Seoul, Republic of Korea in 2014.",0,0,0,0
PMC6712222,Eligible participants were required to be older than 50 years of age and meet the following three conditions: (1) have a presence of at least two components of the National Cholesterol Education Program Third Adult Treatment Panel (NCEP-ATP III) criteria for metabolic syndrome; (2) have a glycosylated hemoglobin (HbA1c) value of 7.0% to 9.0%; and (3) be taking combination therapy of metformin and sulfonylurea for at least the previous 6 months.,1,1,0,0
PMC6712222,"Conversely, patients who met at least one of following criteria were excluded: (1) using insulin, alpha-glucosidase inhibitors, meglitinides, thiazolidinediones, or incretin agents such as dipeptidyl peptidase-4 inhibitors or GLP-1 receptor agonists; (2) experienced acute complications of T2DM in last 6 months; (3) having significant cardiovascular disease; (4) having a treatment history of oral or intravenous antibiotic agent usage within the last 12 months; (5) having taken supplementary fiber agents within the last 6 months; and (6) having a fasting C-peptide level of <1.0 ng/mL.For subgroup analysis, two groups were defined by the differences in area under the curve (AUC) of glucose during MMTT between the first and second visits.",0,1,0,0
PMC6712222,"The first and last tertiles of the change ratio of AUC were defined as ‘responders’ and ‘nonresponders,’ respectively.",1,0,0,0
PMC6712222,"Clinical and biochemical measurementsWe collected past medical history, family history, and current smoking and alcohol consumption status via medical record review and individualized questionnaires.",0,0,0,0
PMC6712222,"During the participants' three visits (at weeks 0, 4, and 8), venous blood sampling was done after at least 8 hours of overnight fasting and analyzed at a certified central laboratory at SMC.",0,0,0,1
PMC6712222,"Fasting plasma glucose (FPG) level was determined by the hexokinase method using the GLU kit (Roche Diagnostics, Basel, Switzerland) on a Roche Modular DP analyzer (Roche Diagnostics).",0,0,0,1
PMC6712222,"Fasting plasma insulin values were derived from an immunoradiometric assay (DIAsource Co., Louvain-la-Neuve, Belgium).",0,0,0,1
PMC6712222,LPS was checked before each MMTT.,0,0,0,1
PMC6712222,"During MMTT, venous blood was drawn at 0, 30, 60 , 90, and 120 minutes for glucose, C-peptide, insulin, and incretins.",0,0,0,1
PMC6712222,"Serum was isolated and stored at −80℃, then sent to an outside laboratory (BIOINFRA Inc., Seoul, Korea).",0,0,0,1
PMC6712222,"Glucagon, total GIP, active GLP-1, and total PYY were measured using a Millipore Human Metabolic Hormone Magnetic Bead Panel (Merck Millipore, Darmstadt, Germany) on a Luminex 200 system (Luminex Corp., Austin, TX, USA).",0,0,0,1
PMC6712222,"GLP-2 and LPS were detected by use of a Millipore enzyme-linked immunosorbent assay (ELISA) kit (Merck Millipore) and a Cloud-Cone Corporation ELISA kit (Cloud-Clone Corp., Houston, TX, USA), respectively, using the Emax analyzer (Promega Corp., Madison, WI, USA).Insulin secretion was evaluated with the insulinogenic index (IGI) derived from the MMTT data, while insulin sensitivity was determined by the quantitative insulin sensitivity check index (QUICKI) and Matsuda index (MI).",0,0,0,1
PMC6712222,Disposition index values were also evaluated [222324].Microbiota analysisMicrobiota analysis was conducted to reveal the changes of abundance and composition according to each visit and to compare that of ‘responders’ and ‘nonresponders.’,0,0,0,0
PMC6712222,Fecal samples were collected at each visit and stored at −80℃.,0,0,0,1
PMC6712222,"DNA extraction and 16S ribosomal RNA gene-based pyrosequencing by the methods described previously [25] were conducted at ChunLab Inc. (Seoul, Korea).",0,0,0,1
PMC6712222,"Chimeric sequences were detected using UCHIME [26] and the EzTaxon-e database [27], and the latter was used to assign each read taxonomically.",0,0,0,1
PMC6712222,The linear discriminant analysis of the effect size (LEfSe) algorithm [28] was used to estimate taxonomic composition and to identify differences between paired comparisons.,0,0,0,1
PMC6712222,Statistical analysesContinuous variables were presented as medians and interquartile ranges.,0,0,0,0
PMC6712222,"The Mann-Whitney U test, Wilcoxon signed-rank test, and chi-square test were used to compare laboratory and clinical variables.",0,0,0,0
PMC6712222,Values of P<0.05 were considered to be statistically significant.,0,0,0,0
PMC6712222,Multiple comparisons were corrected with Bonferroni's method.,0,0,0,0
PMC6712222,"Statistical analyses were performed using the SPSS version 24.0 for Windows software (IBM Corp., Armonk, NY, USA).",0,0,0,0
PMC6712222,"Based on the relative abundance analysis using LEfSe from the results of the Kruskal-Wallis and Wilcoxon tests, P<0.05 was considered to indicate statistical significance, and the threshold on the logarithmic linear discriminant analysis (LDA) score was deemed to be 2.0.",0,0,0,0
PMC6861008,Research design and methods​Study designA cohort study consisting of a prospective intervention cohort and a historical reference cohort in a real-world setting.,0,0,0,0
PMC6861008,The intervention consisted of a motivational interviewing to improve adherence to healthy eating in addition to routine care and was offered to all pregnant women with type 2 diabetes.,0,1,0,0
PMC6861008,The reference cohort received routine care only.,0,0,0,0
PMC6861008,The goals for glycemic control and gestational weight gain were the same in the two cohorts as was the routine obstetrical control and management.,0,0,0,0
PMC6861008,The focus of the motivational interviewing was to encourage the women to follow the recommended diabetes diet21 and to comply to local gestational weight gain recommendations.,0,0,0,0
PMC6861008,22 Gestational weight gain (kg) and LGA infants (birth weight >90th percentile) were the main outcomes.,0,0,0,0
PMC6861008,​Study populationAll consecutive women with type 2 diabetes from a geographically well-defined region of approximately 4 million inhabitants were invited to participate from August 2015 to February 2018.,0,0,0,0
PMC6861008,The inclusion criteria were: singleton pregnancy before 20 weeks in women aged ≥18 years.,0,1,0,0
PMC6861008,"All women were followed at either Center for Pregnant Women with Diabetes, Rigshospitalet or Department of Obstetrics and Endocrinology, Odense University Hospital.",0,0,0,0
PMC6861008,"The women were registered as having type 2 diabetes, if the diagnosis was present at referral.",0,0,0,0
PMC6861008,Women diagnosed with type 2 diabetes in early pregnancy with HbA1c ≥6.5% (48 mmol/mol) were also included (the intervention cohort: n=4 and the reference cohort: n=3).,0,1,0,0
PMC6861008,"Exclusion criteria were very few: previous bariatric surgery (n=3) and for ethical reasons, insufficient Danish language skills (n=40).",0,1,0,0
PMC6861008,The reference cohort consisted of all pregnant women with type 2 diabetes treated at the centers in the period February 2013 to August 2015 and matched the same inclusion and exclusion criteria as the intervention cohort.,0,0,0,0
PMC6861008,"If a woman had more than one pregnancy in the study period, the pregnancy in which she underwent intervention was the pregnancy included (n=9).",0,0,0,0
PMC6861008,Data for the reference cohort were registered prospectively but collected retrospectively.,0,0,0,0
PMC6861008,"​The lifestyle intervention with motivational interviewingAll women received individual one-to-one sessions with a lifestyle coach at each pregnancy visit at the centers, preferably every 2 weeks.",0,0,0,0
PMC6861008,"The lifestyle coaching was based on principles of patient empowerment and cognitive behavioral techniques, inspired by motivational interviewing.",0,0,0,0
PMC6861008,17,0,0,0,0
PMC6861008,An individual action plan for improving dietary behavior was made during the first session and evaluated and tailored in subsequent sessions.,0,0,0,0
PMC6861008,"At each visit the following dietary objectives were presented for the patient, of which one was to be achieved or maintained until the next session: (1) watch portion size—focus on the amount of carbohydrates in each meal; (2) eat mainly carbohydrates of low glycemic index (for example, more vegetables or whole grain products); (3) reduce the intake of carbohydrate of high glycemic index (for example, less or no takeaway food, less or no cakes, candy, snacks, chips, ice cream, sugary beverage).",0,0,0,0
PMC6861008,"Furthermore, the women were motivated to watch daily weight changes.",0,0,0,0
PMC6861008,"The lifestyle coaches were midwives, who had received special training in the motivational interviewing with focus on lifestyle changes as a part of the DALI study.20 During the DALI study, the midwives had regular assessment of their skills in the use of the motivational interviewing and had years of practical experience.",0,0,0,0
PMC6861008,The first session of the motivational interviewing lasted 45 min.,0,0,0,0
PMC6861008,"To minimize the time consumption for the patients and the caregivers, the sessions of motivational interviewing were thereafter sought combined with routine diabetes care within the time frame of one appointment, if possible.",0,0,0,0
PMC6861008,Women living a long distance from the clinic could convert a minor part of the one-to-one contacts to telephone calls with the lifestyle coaches.,0,0,0,0
PMC6861008,"Women in the intervention cohort were judged to be compliant to the intervention, if attending at least 80% of the visits.",0,0,0,0
PMC6861008,"​The routine diabetes care for both cohortsAt the first pregnancy visit, the women received a one-to-one consultation with a nurse, a registered dietitian and a diabetologist.",0,0,0,0
PMC6861008,"Thereafter, the women were seen by a diabetes caregiver preferably every 2 weeks throughout pregnancy.",0,0,0,0
PMC6861008,The women received information from a dietitian about the recommended diabetes diet21 and education in carbohydrate exchange including an introduction to a local smartphone application with pictures and information on the carbohydrate amounts to aid learning.,0,0,0,0
PMC6861008,"The goals were: (1) adequate nutrient intake to support a healthy pregnancy; (2) carbohydrates mainly deriving from low glycemic index sources; and (3) a total daily energy intake of approximately 1673 kcal (7000 kJ) including 175 g carbohydrates in total (43 E%) with approximately 150 g deriving from the major carbohydrate sources (bread, potatoes, rice, pasta, fruits, and dairy products).",1,0,0,0
PMC6861008,The women were encouraged to be physically active for at least 30 min/day if this was not medically contraindicated.,0,0,0,0
PMC6861008,"The goals for gestational weight gain followed the Copenhagen guidelines22 for pregnant women with diabetes according to pre-pregnancy BMI, that is, pre-pregnancy BMI<25 kg/m2: aiming for 100 g/week in the first half of pregnancy and thereafter 400 g/week with a total weight gain of 10–15 kg. BMI 25–29.9 kg/m2: aiming for 100 g/week in the first half of pregnancy and thereafter 300 g/week, with a total weight gain of 5–8 kg.",1,0,0,0
PMC6861008,"BMI≥30 kg/m2: aiming for 0 g/week in the first half of pregnancy and thereafter 200 g/week, with a total weight gain of 0–5 kg.",1,0,0,0
PMC6861008,"Self-monitored plasma glucose measurements were recommended seven times daily, aiming for preprandial plasma glucose values between 4 and 6 mmol/L and 90 min postprandial values between 4 and 8 mmol/L.",1,0,0,0
PMC6861008,The aim for HbA1c was <6.7% (50 mmol/mol) in the first half of pregnancy and <5.8% (40 mmol/mol) in the second half of pregnancy.,1,0,0,0
PMC6861008,Before pregnancy most women were treated with diet alone or in a combination with oral antidiabetic drugs and/or glucagon-like peptide-1 (GLP-1) analogs.,0,0,0,0
PMC6861008,"At first pregnancy visit, the treatment with oral antidiabetic drugs and/or GLP-1 analogs was discontinued and not used during pregnancy.",0,0,0,0
PMC6861008,"Therefore, insulin treatment was often initiated or tailored.",0,0,0,0
PMC6861008,"At each pregnancy visit, HbA1c and weight were measured, and a dipstick of sterile urine was screened for proteinuria and ketonuria.",0,0,0,1
PMC6861008,"The daily insulin dose, the occurrence of mild hypoglycemia in the previous week and the median of each time point in the 7-point plasma glucose profile for 5 days were noted.",0,0,0,0
PMC6861008,These data were used for reinforcement of dietary advice and insulin dose adjustments.,0,0,0,0
PMC6861008,"​Procedure and data collectionFor both cohorts, maternal clinical data were collected at first pregnancy visit (early pregnancy visit) and at 35–37 weeks (late pregnancy visit).",0,0,0,0
PMC6861008,"The women’s self-reported weight and height before pregnancy, age at inclusion, duration of diabetes, gestational age at first visit, parity, ethnicity and smoking were noted.",0,0,0,0
PMC6861008,The women were weighted on calibrated electronic scales without shoes or heavy clothes to the nearest 0.1 kg.,0,0,0,0
PMC6861008,Gestational weight gain was defined as the difference between measured weights at the early and the late pregnancy visits.,1,0,0,0
PMC6861008,"Within the three BMI classes (normal weight (BMI<25 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI≥30 kg/m2)) gestational weight gain was categorized as follows based on the Institute of Medicine (IOM) 2009 recommendation23: insufficient (<11.5, <7.0 and<5.0 kg for the BMI classes, respectively), appropriate (11.5–16.0, 7.0–11.5 and 5.0–9.0 kg) and excessive (>16, >11.5 and >9 kg).HbA1c was analyzed immediately by a DCA 2000 analyzer by a latex immunoagglutination inhibition method (DCA 200; Bayer, Mishawaka, IN).",1,0,0,0
PMC6861008,Delta-HbA1c was defined as the difference between the HbA1c measurements at the early and the late pregnancy visits.,1,0,0,0
PMC6861008,The urine was analyzed by Siemens CLINITEK Status+Analyzer.,0,0,0,0
PMC6861008,The occurrence of ketonuria was noted if the concentration of ketone bodies was ≥4.0 mmol/L.,1,0,0,0
PMC6861008,Diabetic retinopathy was assessed by retinal photoscreening and evaluated by an ophthalmologist.,0,0,0,0
PMC6861008,"Diabetic nephropathy was defined as albumin-creatinine ratio ≥300 mg/g at the early pregnancy visit, based on two urine samples.",1,0,0,1
PMC6861008,The data on maternal neck and ankle circumference and subcutaneous skinfolds were collected for the intervention cohort at the early and the late pregnancy visits.,0,0,0,0
PMC6861008,"Neck circumference was obtained in a standing relaxed position in the midway of the neck, between mid-cervical spine and mid-anterior neck to within 1 mm.",0,0,0,0
PMC6861008,Ankle circumference was measured 5 cm above the lateral malleolus at both ankles as a pragmatic estimate for the development of peripheral edema.,0,0,0,0
PMC6861008,"Skinfold thickness at four areas (biceps, triceps, suprailiac and subscapular) was measured to the nearest millimeters with a Harpenden caliper24 and given as a sum of skinfolds.",0,0,0,0
PMC6861008,"Furthermore, the women answered two questions in a questionnaire: ‘How motivated are you for achieving good glycemic control during pregnancy’ and ‘How motivated are you for achieving appropriate gestational weight gain during pregnancy’ on a Likert scale from 1 to 10.",0,0,0,0
PMC6861008,A score ≥8 on the Likert scale was considered as very motivated.,0,0,0,0
PMC6861008,The coaches were motivated for using the motivational interviewing but were not asked about their own motivation.,0,0,0,0
PMC6861008,"The following data on pregnancy outcome were retrieved from the medical records: gestational age at delivery, preterm delivery (before 37 completed weeks), cesarean section (elective and emergency), shoulder dystocia and the sex of the infant.",0,0,0,0
PMC6861008,"Weight, length, and abdominal and head circumference of the infant were measured shortly after birth.",0,0,0,0
PMC6861008,Birth weight z-score was calculated by local growth curves adjusted for gestational age and infant sex.,0,0,0,0
PMC6861008,"25 LGA and small for gestational age (SGA) were defined as birth weight >90th and <10th percentiles, respectively.",1,0,0,0
PMC6861008,"As only half of the population was of Northern European origin, the prevalence of LGA and SGA infants was calculated by two different methods: first, by traditional Nordic growth curves25 adjusted for gestational age and infant sex; second, by using customized birth weight centiles (gestation-related optional weight, GROW26) adjusted for maternal height, weight, ethnic origin, parity, gestational age and infant sex.",0,0,0,0
PMC6861008,"Perinatal mortality (offspring death after 20 gestational weeks or within the first 7 days of life), major congenital malformations (leading to death, causing a substantial future handicap or requiring surgery), neonatal hypoglycemia (defined as a plasma glucose value below 2.2 mmol/L, measured within 4 hours of life27), jaundice (requiring phototherapy), and transient tachypnea (requiring continuous positive airway pressure for more than 60 min) were noted.",1,0,0,0
PMC6861008,"Perinatal morbidity was defined as the occurrence of at least one of the following complications: major congenital malformation, neonatal hypoglycemia, jaundice or transient tachypnea.",1,0,0,0
PMC6861008,"In addition, the infants in the intervention cohort had skinfold measurements of triceps, quadriceps, suprailiac and subscapular region measured to the nearest millimeter and performed with a Harpenden skinfold caliper24 within 48 hours after birth.",0,0,0,0
PMC6861008,"​Statistical analysesContinuous data with normal distribution are reported as mean±SD, continuous data with skewed distribution as median (IQR) and categorical data as number (%).",0,0,0,0
PMC6861008,"Comparison between the cohorts was performed by Student’s t-test, Mann-Whitney U test, χ2 test or Fisher’s exact test where appropriate.",0,0,0,0
PMC6861008,"To control for the following covariates from the early pregnancy visit: nulliparity, smoking, pre-pregnancy BMI and HbA1c (%), an analysis of covariance was used for comparison of gestational weight gain and birth weight z-score between the cohorts.",0,0,0,0
PMC6861008,Statistical analyses were performed with IBM SPSS Statistics V.22.,0,0,0,0
PMC6861008,"Statistically significant differences were defined as a two-sided p<0.05.A priori, we performed a simple power analysis.",0,0,0,0
PMC6861008,"Based on our previous study,5 we assumed a prevalence of LGA of 20% and 35% in the two cohorts and with a power of 80%, 135 women were needed in each cohort to detect a significant difference.",0,0,0,0
PMC2660489,"Laboratory methodsAll of the analytical measurements were performed at the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA) as described previously (12,13).",0,0,0,0
PMC2660489,"Pertinent to the current analyses, creatinine concentrations in the serum and urine were measured by a variation of the Jaffe method and urine albumin concentration was measured by a fluoroimmunoassay.",0,0,0,0
PMC2660489,Albuminuria was assessed using a spot urine test of albumin and creatinine.,0,0,0,0
PMC2660489,"The ACR was used to define categories of albuminuria: normal (<30 mg/g creatinine), microalbuminuria (30-<300 mg/g creatinine), and macroalbuminuria (≥300 mg/g creatinine).",1,0,0,0
PMC2660489,"In this report, the term “elevated ACR” indicates the combined categories of microalbuminuria and macroalbuminuria.",1,0,0,0
PMC5329743,"MATERIALS AND METHODSAfter fasting from caffeine for at least 24 h and food for at least 8 h prior, eleven healthy non-smoker medical students (9 males), average age 24.5 years (range 23-27 years), average BMI 22.8, received an electrocardiogram (ECG), blood pressure and pulse check, and underwent baseline testing (BL) of endothelial function using the technique of endothelium-dependent flow-mediated dilatation (FMD) with high-resolution ultrasound according to recommended guidelines of the University of Wisconsin Atherosclerosis Imaging Research Program Core Laboratory by a single registered vascular ultrasonographer who was certified by the University of Wisconsin Atherosclerosis Imaging Research Program Core Laboratory[12].",1,0,0,0
PMC5329743,"After resting supine for 10-min in a temperature-controlled room, a blood pressure cuff was placed on the widest part of proximal right forearm approximately 1 cm distal to the antecubital fossa.",0,0,0,1
PMC5329743,"Using a 10 MHz resolution linear array vascular ultrasound transducer with a Philips iE33 ultrasound machine, the brachial artery was located above the elbow and scanned in longitudinal sections.",0,0,0,1
PMC5329743,"After recording baseline B-mode digital images of the brachial artery and spectral Doppler images of flow, the forearm cuff was inflated to 250 mmHg for 5 min to induce reactive hyperemia.",0,0,0,1
PMC5329743,"Immediately after deflation, spectral Doppler images are obtained to verify hyperemia.",0,0,0,1
PMC5329743,FMD of the brachial artery was measured 60 and 90 s after cuff deflation.,0,0,0,0
PMC5329743,The relative FMD (%) was calculated as the ratio between the largest post-cuff release and the baseline diameter.,0,0,1,0
PMC5329743,"Each image was checked for quality control, and each artery diameter was measured from the media to media points by two experts, 3 measurements at the QRS complex, repeated on 3 separate beats, and then averaged.",0,0,0,1
PMC5329743,"The subjects then drank an energy beverage (EB), a 24-oz can of Monster Energy Drink® in approximately 1 min.",0,0,0,0
PMC5329743,"The contents of this can include 54 g Sucrose, glucose, sucralose, maltodextrin, Sodium 360 mg Sodium Citrate Sodium Chloride, Caffeine 240 mg, Taurine 2000 mg, Niacin 40 mg 200% RDA Niacinamide, Pyridoxine 4 mg 200% RDA, Cyanocobalamin (B12) 12 mcg 200% RDA, Riboflavin (B2) 3.4 mg 200% RDA, Ginseng Extract 400 mg, Glucuronolactone, Inositol (B8), Guarana Extract, and L-Carnitine all listed as a part of a 5000 mg “Energy Blend”, and Sodium Benzoate.",0,0,0,0
PMC5329743,The subjects had FMD repeated at 90 min after consumption of the EB.,0,0,0,0
PMC5329743,The subjects were in the supine position for all ECGs and FMD measurements.,0,0,0,1
PMC5329743,Statistical analysisStatistical analyses were performed by John P Higgins and the statistical methods of this study were reviewed by Benjamin Yang using Microsoft Excel 2010 and the Data Analysis ToolPak.,0,0,0,0
PMC5329743,"We used the t-test: Paired Two Sample for Means, and significance was defined as a P-value of 0.05 or less.",0,0,0,0
PMC2453668,"Statistical methodsData analysis was performed with SPSS (version 14.0.0 for Windows; SPSS, Chicago, IL).",0,0,0,0
PMC2453668,"Descriptive information for each of the variables was derived, and distribution was assessed.",0,0,0,0
PMC2453668,Logistic regression modeling was used to assess risk factors for incident retinopathy among those with diabetes.,0,0,0,0
PMC2453668,Only factors identified to be significantly associated with incident retinopathy at model 2 were include in the multivariate model (model 3).,0,0,0,0
PMC2453668,Logistic regression was also used to determine the association of baseline retinopathy with incident diabetes.,0,0,0,0
PMC6204861,Statistical analysisResults are represented as mean ± SEM.,0,0,0,0
PMC6204861,"Two-group analysis was performed using t-test between HG and ctrl, APS-HG and HG, APS-siRNASOD2 and siRNASOD2, and siRNA-SOD2 and ctrl (Stata 14.0).",0,0,0,0
PMC6204861,P-value <0.05 was considered statistically significant.,0,0,0,0
PMC6772182,"2.5Statistical methodsSample size was determined using published data from an 8‐week clinical trial with empagliflozin, an SGLT2 inhibitor, in which the drug decreased HbA1c by 0.4% in people with T1DM.14",0,0,0,0
PMC6772182,"After consideration of study differences and assuming a 0% decrease in the placebo group and a shared SD of 0.7% with an assignment ratio of 2:1, the numbers of participants required to detect a 0.4% difference between groups with a power of 90% were calculated to be 49 and 97 in the placebo and treatment groups, respectively.",0,0,0,0
PMC6772182,We therefore planned to enrol 50 and 100 participants in the respective groups.,0,0,0,0
PMC6772182,The full analysis set (FAS; primary analysis) included all participants who received at least one dose of the study drug during the treatment period and for whom at least one efficacy variable was measured after administration of the study drug.,0,1,0,0
PMC6772182,"The per‐protocol set (PPS) (secondary analysis) consisted of participants included in the FAS who met the inclusion criteria and did not meet any of the exclusion criteria, received the study drug for at least 56 days, had ≥80% compliance and no major protocol deviations.",0,1,0,0
PMC6772182,The safety analysis set included all participants who received at least one dose of the study drug.,0,1,0,0
PMC6772182,Primary and secondary endpoints were examined descriptively and using analysis of covariance (ANCOVA) with variable value at baseline as a covariate to calculate adjusted mean differences (AMDs) compared with placebo and 95% confidence intervals (CIs).,0,0,0,0
PMC6772182,Subgroup analyses for the primary endpoint were performed using stratification according to the subgroups described previously.,0,0,0,0
PMC6772182,The primary endpoint of HbA1c used an unadjusted α‐value of 0.05 to control for type 1 error.,0,0,0,0
PMC6772182,Adjustments for multiplicity were not applied for other endpoints.,0,0,0,0
PMC6772182,The number and percentage of participants with AEs and drug‐related AEs and descriptive statistics were calculated for laboratory test values using the safety analysis set.,0,0,0,0
PMC6772182,A two‐sided significance level of 0.05 was used.,0,0,0,0
PMC6772182,"Data were analysed using SAS Drug Development software (ver. 4.5 or higher; SAS Inc., Cary, North Carolina) and SAS® software (version 9.4 or higher; SAS Inc.).",0,0,0,0
PMC6952721,"Research methodsWe studied 2070 patients consecutively from the “Registre d’Infarctus Maine-Anjou” survey, that prospectively included all patients presenting with a STEMI in a Western region of France, in which the only available 24 h-7 d coronary angiography service was in Angers University Hospital.",0,0,0,0
PMC6952721,"Median age was 64 (interquartile range 53-77) years, 74.3% were male, 41% presented with anterior infarction and 81% underwent primary percutaneous coronary intervention.",0,0,0,0
PMC6952721,Outcomes were gathered during the year following MI. Bleeding Academic Research Consortium (BARC) 3 and 5 bleeding events were used to assess in-hospital bleeding complications.,0,0,0,1
PMC6952721,Cox regression analyses were performed to assess correlates for 1-year mortality.,0,0,0,0
PMC2827492,Statistical methodsThis study was designed to detect a 1% difference in A1C with 80% power using a 0.05-level two-sided test.,0,0,0,0
PMC2827492,Improvement was defined in terms of mean differences at 3 and 6 months as well as differential change over time.,0,0,0,0
PMC2827492,"The primary outcome, A1C, was specified a priori.",0,0,0,0
PMC2827492,"P < 0.05 was considered to be statistically significant, with no adjustment for multiple comparisons.",0,0,0,0
PMC2827492,Our intent-to-treat approach included all randomly assigned participants to the extent possible.,0,0,0,0
PMC2827492,"Data features that mandated special methods were the laboratory reporting of a small number of A1C values exceeding some cut point (truncated values, i.e., reported as >11.5, >11.8, or >12.3%) and a few missing A1C values.",0,0,0,0
PMC2827492,"A modified multiple-imputation approach was used to obtain unbiased estimates, appropriate variances, and valid tests, based on a chained-equations algorithm (21) implemented in STATA SE 9.2 (22).",0,0,0,0
PMC2827492,"Mean A1C, weight, blood pressure, and lipid values were compared for the ACM+HT and CC groups at baseline, 3 months, and 6 months.",0,0,0,0
PMC2827492,The proportions of participants in each group who reached defined clinical target values at each time point were compared using Fisher's exact tests.,0,0,0,0
PMC2827492,"For each continuous outcome, difference scores were computed between each pair of time points (baseline to 3 months, baseline to 6 months, and 3 months to 6 months).",0,0,0,0
PMC2827492,Between-group comparisons of difference scores were obtained by regressing the difference scores for each pair of time points on a dummy variable for treatment group (if necessary to accommodate multiple imputation) or using a t test.,0,0,0,0
PMC2827492,Within-group difference scores were compared with zero using linear regression including only an intercept or a t test (as appropriate).,0,0,0,0
PMC2827492,The interaction of treatment group and insulin status at baseline was assessed.,0,0,0,0
PMC2827492,"In the ACM+HT group, Pearson correlations summarized associations between A1C at 6 months and the frequencies of SMBG and adjustments of insulin.",0,0,0,0